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Abstract
MicroRNAs (miRNAs) are small non-coding ribonucleic acids (RNAs) that extensively
regulate gene expression in metazoan animals, plants and protozoa. Approximately 22
nucleotides in length, miRNAs usually repress gene expression by binding to sequences
with partial complementarity on target messenger RNA (mRNA) transcripts. In mammals,
miRNAs are thought to control the activity of more than 60% of all protein-coding genes
and extensively participate in the regulation of many cellular functions.
With few exceptions, metazoan miRNAs base-pair with their targets imperfectly, fol-
lowing a set of rules that have been formulated by employing experimental and
bioinformatics-based analyses. This limited complementarity makes the task of computa-
tionally identifying miRNA targets very challenging and usually leads to large numbers of,
mostly false, potential targets.
Earlier computational tools have mainly focused on dissecting individual miRNA-target
interactions by relying on sequence-based identification of miRNA-target binding sites or
on mRNA/miRNA expression data analysis. With the goal to gain a systemic understanding
of miRNA-mediated interaction networks, in this research work, we develop IntegraMiR,
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a novel integrative analysis method that can be used to infer certain types of regulatory
loops of dysregulated miRNA/Transcription Factor (TF) interactions which appear at the
transcriptional, post-transcriptional and signaling levels in a statistically over-represented
manner.
To reliably predict miRNA-target interactions from mRNA/miRNA expression data and
construct their networks with a systems perspective, our proposed method collectively uti-
lizes the aforementioned molecular structures identified to be statistically over-represented
in gene regulatory networks, sequence-based miRNA-target predictions obtained from dif-
ferent algorithms, known information about mRNA and miRNA targets of TFs available in
existing databases, available molecular subtyping information, and state-of-the-art statisti-
cal techniques to appropriately constrain the underlying analysis.
To investigate the effectiveness of our proposed procedure, we apply our method on
mRNA/miRNA expression data from prostate tumor and normal samples and detect nu-
merous known and novel miRNA-mediated dysregulated loops and networks in prostate
cancer. In addition, as an application of our work on miRNA/TF-mediated loop and net-
work identification, we utilize the IntegraMiR paradigm and exploit additional publicly
available databases and datasets to infer miRNA-mediated regulatory networks in Autism
Spectrum Disorders, that were of interest to our experimental collaborators at the School
of Medicine.
We demonstrate instances of the results in a number of distinct biological settings,
which are known to play crucial roles in the contexts of prostate cancer and autism spec-
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trum disorders. Our findings show that the proposed computational method can be used to
effectively achieve notable systemic insights into the poorly understood molecular mech-
anisms of miRNA-mediated interactions and dissect their functional roles in cancer in an
effort to pave the way for miRNA-based therapeutics in clinical settings.
To study the dynamics of biomolecular interaction networks, we focused on a protein-
protein interaction network in living cells. Our collaborators at the School of Medicine
planned to synthetically develop and characterize a biomaterial, which was produced by
this protein-protein interaction network, and which would act as a molecular sieve to con-
trol the passage of biomolecules in living cells. And we wanted to computationally model
the formation of this biomolecular sieve, termed a hydrogel, and characterize its properties
that were relevant to the experimental work.
Specifically, we investigate a novel strategy for generating intracellular hydrogels, termed
iPOLYMER for intracellular Production Of Ligand-Yielded Multivalent EnhanceRs. This
particular design not only circumvents invasive approaches, such as microinjection, but
also enables hydrogel formation inside living cells in a rapidly inducible manner.
To overcome difficulties in evaluating gel formation in situ, we developed a physical
computational model for three-component multivalent-multivalent molecular interactions
that led to a rigorous method for computationally implementing iPOLYMER. Our ap-
proach was based on a realistic kinetic Monte Carlo simulation algorithm that produced
sufficiently accurate approximations of stochastic reaction-diffusion dynamics. In partic-
ular, we spatially discretized the well-known continuous-space Doi model of stochastic
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reaction-diffusion, and obtained a physically valid approximation based on the reaction-
diffusion master equation (RDME). This led to a Markov process model that describes the
time evolution of the location of each basic or aggregate molecule at a resolution of one
voxel in the system. We simulated the resulting process by a stochastic kinetic Monte Carlo
algorithm.
In addition, we employed our computational model of iPOLYMER to assess the ef-
fects of various parameters on gel formation and its properties. This presented us and our
experimental collaborators with a deeper understanding of the problem of gel synthesis,
which guided the experimental design and provided further validation of the experimental
findings and conclusions.
In the end, we would like to note that the findings from all three research problems
we tackled here present strong computational evidence that proves to be highly valuable to
experimental biologists in providing reliable predictions and systemic insights which could
help them guide their applied research with an efficient and cost-effective approach.
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For more than the entire past century, classical experimental methodologies have dom-
inated biological research, providing a wealth of information about individual molecular
species in cells and their functions. However, there is an increasing and strong level of
evidence suggesting that an isolated biological function can only rarely be attributed to an
individual biological molecule. Instead, more recently, it is argued that most biological
characteristics are due to complex interactions between the cell’s numerous constituents,
such as proteins, DNA and RNA. Therefore, a major challenge for the biological sciences
in this century is to unravel the structure and the dynamics of these complex intracellular
interactions at a systems level. Systems biology, being an interdisciplinary biology-based
area of research, concentrates on such systemic understanding of the complex interaction
networks in biological systems by utilizing the computational and statistical methodologies
applied to biological and medical data.
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The behavior of most complex systems, including the cellular interaction networks,
originates from the orchestrated interplay of many components that interact with each other
through pairwise interactions. And, in order to understand the function of a cell, it is, in
this way, convenient to conceptualize the cellular activities as systems of interacting el-
ements. For such a systems-level representation, one needs to know: i) the identity of
the components that constitute the biological system of interest, ii) the interactions among
these components, and iii) the dynamic behavior of these molecular entities, meaning how
their abundance or activity changes over time in various conditions [3, 75]. It is noteworthy
that early attempts at systems-level understanding of biology suffered from inadequate data
to be utilized to base the relevant mathematical theories and computational models upon;
however, the emergence of high-throughput technologies and high-precision experimental
techniques brought an abundance of data on system elements and interactions, leading to
a revival of the field of systems biology. In particular, these experimental methods en-
able the measurement of expression levels for thousands of genes and the determination of
thousands of protein-protein interactions in cells.
It is well known that the creation of models of the functions of genes and proteins in
cells is of fundamental and immediate significance to the emerging field of computational
systems biology. Some of the most successful attempts at cell-scale modeling to date have
been based on constructing networks that represent hundreds of experimentally-validated
biochemical interactions, while others have been very successful at inferring statistical
networks from large amounts of high-throughput data. These types of cellular networks
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(metabolic, regulatory, or signaling) can be analyzed, and predictions about biological be-
havior made and tested. Many types of statistical and computational models have been
built and applied to study cellular behavior and in this research work, we focus on two
distinct instances, one from each of the two broad types of models used in computational
systems biology: i) statistical inference models applied to gene regulatory interaction net-
works and ii) biochemical reaction models applied to protein-protein interaction networks.
It is helpful to note that, in both instances of the models we consider here, the interaction
of system elements is modeled by a graph representation which ascribes the graph nodes
(also called vertices) to the molecular species of interest and represents their pairwise rela-
tionships by edges (also called links) connecting pairs of nodes. The nodes of (sub)cellular
systems may be genes, mRNAs, proteins, or other molecules. Directed edges have a speci-
fied source (starting) node and target (end) node and are most suited to represent regulatory
relationships. Non-directed edges are most appropriate for mutual interactions, such as
protein-protein binding or for relationships whose source and target are not yet determined.
It goes without saying that computational models and methods in systems biology are
most useful if they lead to concrete and novel biological predictions that could guide the ex-
perimental biologists in validating the resulting predictions and if they address the pressing
issues in biology and medicine, with the potential to have a high impact in applied research.
As a matter of fact, the three specific research problems we tackle here (which are catego-
rized under the previous two broad modeling paradigms), have been identified as critical,
applied research problems by our collaborators at the Johns Hopkins School of Medicine.
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The first two problems, i.e. integrative identification of microRNA-mediated gene regu-
latory interaction networks in the contexts of: i) prostate cancer, and ii) autism spectrum
disorders, are tackled by the statistical inference models, and the third research problem,
i.e. modeling the dynamics of synthetic protein-protein interaction networks in living cells,
is tackled by the biochemical reaction system modeling techniques. In the following, we
briefly review the biological and computational backgrounds related to these three specific
problems and their significance in biology and medicine. In the first two research problems
we tackle in this work, our focus will be on identifying microRNA-mediated networks in
gene regulatory interactions networks.
1.1 MicroRNA/TF-mediated Networks in
Prostate Cancer
MicroRNAs (miRNAs) have attracted a great deal of attention in biology and medicine.
They are small non-coding ribonucleic acids (RNAs) that extensively regulate gene expres-
sion in metazoan animals, plants and protozoa. Approximately 22 nucleotides in length,
miRNAs usually repress gene expression by binding to sequences with partial complemen-
tarity on target messenger RNA (mRNA) transcripts. In mammals, miRNAs are thought to
control the activity of more than 60% of all protein-coding genes and extensively partici-
pate in the regulation of many cellular functions [37, 114]. It has been hypothesized that
miRNAs interact with transcription factors (TFs) in a coordinated fashion to play key roles
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in regulating signaling and transcriptional pathways and in achieving robust gene regula-
tion.
In our first research work, we propose a novel integrative computational method to infer
certain types of deregulated miRNA-mediated regulatory circuits (motifs) at the transcrip-
tional, post-transcriptional and signaling levels. The first set of motifs that our method
considers are three-node feed-forward loops (FFLs) that have recently attracted a great
deal of attention among systems and experimental biologists. These motifs are excellent
models of coordinated miRNA-mediated and transcriptional regulation, which have been
hypothesized to be prevalent in the human and mouse genomes [155].
In addition to the modulatory and/or reinforcing gene regulatory roles that miRNAs are
known to play in concert with TFs in the context of FFLs, they have been hypothesized to
play key roles in regulating signaling pathways as well. In this respect, although miRNAs
are known to have subtle effects on protein levels of individual targets, their cumulative
influence can significantly affect the outcomes controlled by signaling pathways, given the
multiplicity of their targets and concurrent downregulation of several of these targets. To
take this important aspect into account, our method also considers the basic Type III loop
motif, in which a miRNA targets two gene transcripts, G-1 and G-2, whose proteins could
potentially interact with each other according to a pathway map provided in the KEGG
database (http://www.kegg.jp). See Fig. 2.1.
To reliably predict miRNA-target interactions from mRNA/miRNA expression data,
our method collectively utilizes the aforementioned molecular structures identified to be
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statistically over-represented in gene regulatory networks (FFLs and Type III loops), sequence-
based miRNA-target predictions obtained from several algorithms, known information about
mRNA and miRNA targets of TFs available in existing databases, available molecular sub-
typing information, and state-of-the-art statistical techniques to appropriately constrain the
underlying analysis. In this way, the method exploits almost every aspect of extractable
information in the expression data.
We apply our procedure on mRNA/miRNA expression data from prostate tumor and
normal samples and detect numerous known and novel miRNA-mediated deregulated loops
and networks in prostate cancer. We also demonstrate instances of the results in a number
of distinct biological settings, which are known to play crucial roles in prostate and other
types of cancer. Our findings show that the proposed computational method can be used
to effectively achieve notable insights into the poorly understood molecular mechanisms
of miRNA-mediated interactions and dissect their functional roles in cancer in an effort to
pave the way for miRNA-based therapeutics in clinical settings.
1.2 MicroRNA/TF-mediated Networks in
Autism Spectrum Disorders
As our second research problem, we look into the role of LIN28-regulated miRNAs
and their interaction networks in Autism Spectrum Disorders (ASDs). In doing so, we are
going to utilize the miRNA-mediated Type III loops and also FFLs we introduced in our
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first research work. The reason miRNAs could potentially play a crucial role in ASDs is
because, it is known that the regulation of gene expression at the level of translation is a
critical factor in the neuronal response to several stimuli, including synaptic activity [60]
and neurotrophins [130], among others. Although many such stimuli enhance the overall
synthesis of cellular proteins, their responses demonstrate selection of specific mRNAs
for enhanced translation. One of the well-studied examples of such stimuli is the brain-
derived neurotrophic factor (BDNF), which is broadly expressed in the mammalian brain,
and critically contributes to modifications of synaptic growth and function.
The effects of BDNF on protein synthesis selectively targets a minority of expressed
mRNAs (an estimated 4% or less of expressed mRNAs which undergo enhanced
translation [130]). In [59], it was experimentally determined that the function of miRNA
biogenesis pathways plays a pivotal role in BDNF-mediated regulation of translation.
In particular, it is reported that BDNF induces widespread changes in miRNA biogen-
esis by rapidly elevating the miRNA processing enzype, DICER, which increases mature
miRNA levels. Moreover, BDNF induces LIN28a, which is a protein that prevents the pro-
cessing of certain miRNAs, and as a result, causes the loss of the corresponding mature
miRNAs and a consequent upregulation in translation of their target mRNAs. In this way,
it was shown that target specificity of BDNF-induced translation is achieved by a two-part
mechanism, i.e. the combined action of BDNF on DICER and LIN28a protein [59]. This
dual mechanism, depicted in Fig. 1.1, results in genome-wide control of translation speci-




Figure 1.1: The dual mechanism of BDNF inducing both positive (left path) and negative
(right path) regulation of miRNA biogenesis through DICER and LIN28a proteins. In one
mechanism (on the left), BDNF induces the phosphorylation of TRBP, which leads to the
elevation of DICER levels. Elevated DICER levels could invoke mature miRNA biogene-
sis, and with elevated levels of miRNAs, additional mRNAs could be targeted for repression
(shown at the bottom of the left path). In the second mechanism, with BDNF exposure, it
is experimentally observed that a rapid and transcription-independent increase in LIN28a
levels takes place. In addition, LIN28a recognizes a functionally confirmed “GGAG” se-
quence motif on the terminal loop of certain pre-miRNAs. This causes the uridylation of
the molecule, indicated by (UUU) on the right path, and as a result, it suppresses processing
of the targeted pre-miRNA to the mature miRNA. Adopted from [59].
Although it is possible that alternative mechanisms could coexist with the one discussed
above, the experimental results obtained in [59] strongly suggest that dual control by BDNF
of the miRNA biogenesis pathway by means of LIN28a and DICER plays a crucial role in




In this combined computational-experimental research work, our goal was to validate
the biological hypothesis that pathological regulation of LIN28-regulated miRNAs and
their network of interactions may lead to a selective overabundance of growth-promoting
synaptic proteins. We constructed these networks of interactions by identifying the Type
III loops and FFLs we introduced in our first research work. The results we obtained in this
way could account for synaptic and cognitive functions in FXS, and could help us infer the
miRNA-mediated systemic insights governing this dysregulation.
1.3 Modeling Synthetic Protein-Protein
Interaction Networks in Living Cells
The former two research problems were examples of statistical network inference in
systems biology. In our third research work, our goal was to model the dynamics of a
protein-protein interaction network in living cells, as an instance of the second broad cat-
egory of research in systems biology. For this purpose, we developed a combined compu-
tational method by utilizing certain biochemical reaction modeling techniques. Our col-
laborators at the School of Medicine planned to synthetically develop and characterize a
biomaterial, which was produced by this protein-protein interaction network, and which
would act as a molecular sieve to control the passage of biomolecules in living cells. And
we wanted to computationally model the formation of this biomolecular sieve, termed a
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hydrogel, and characterize its properties that were relevant to the experimental work.
Specifically, we investigate a novel strategy for generating intracellular hydrogels, termed
iPOLYMER for intracellular Production Of Ligand-Yielded Multivalent EnhanceRs. This
particular design not only circumvents invasive approaches, such as microinjection, but
also enables hydrogel formation inside living cells in a rapidly inducible manner.
To overcome difficulties in evaluating gel formation in situ, we first developed a compu-
tational model of iPOLYMER to assess the effects of various parameters on gel formation
and its properties. This presented us and our experimental collaborators with a deeper
understanding of the problem of gel synthesis, which guided the experimental design and
provided further validation of the experimental findings and conclusions. Our collaborators
succeeded in observing punctate polymer aggregates rapidly induced in living cell by prac-
ticing iPOLYMER, and examined their biophysical characteristics including the turnover
rate and molecular sieving effects. They additionally reconstituted the gel formation in vitro
using purified proteins, and described its characteristics as a molecular sieve. Isolation of
the gel in vitro also confirmed the identity of the material as a hydrogel that retains water
inside. Moreover, the strong potential of iPOLYMER was demonstrated by synthesizing
biologically functional entities, such as a size-dependent diffusion barrier and a nucleation
platform for RNA molecules.
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1.4 Contributions of the Dissertation
Here, we would like to note that the three research problems we address in this disser-
tation, involve two main instances of the two broad areas of research in systems biology
(one from each), i.e., i) statistical inference of biological interaction networks, and ii) the
dynamic modeling of such networks. In our first research work, we propose IntegraMiR,
an integrative computational method to reliably predict miRNA-target interactions from
mRNA/miRNA expression data, utilize certain molecular structures identified to be statis-
tically over-represented in gene regulatory networks (FFLs and Type III loops), sequence-
based miRNA-target predictions obtained from a set of reliable algorithms, known infor-
mation about mRNA and miRNA targets of TFs available in existing databases, available
molecular subtyping information, and state-of-the-art statistical techniques to appropriately
constrain the underlying analysis.
By comparison, the methods proposed in this specific research area by other groups,
that are reviewed in [17, 174], each suffer from a combination of these issues: i) They are
constrained to a specific motif, ii) They do not discriminate between coherent and inco-
herent FFLs, which is required for a systems-level understanding of transcriptome changes
in disease, iii) The standard statistical tests used to identify differentially expressed genes
between two conditions in a typical gene expression profiling study, as adopted by previous
methods [17, 174], become fundamentally flawed in the presence of unaccounted sources of
variability (due to biological and experimental factors among others) [15, 86, 87]. Molec-
ular subtyping information is a critical example of such sources of variability, iv) The pre-
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diction problem is defined on all edges of a given motif, and this substantially lowers the
accuracy of the predicted miRNA-target interactions, and will make the predictions highly
unreliable to be utilized by experimental biologists. Our proposed integrative method, In-
tegraMiR, addresses all the above issues and is specifically designed to achieve reliable
predicted miRNA-target interactions with a systems perspective, that can readily be used
by experimental biologists to guide their experimental procedures in a systematic way.
In our second research work, as an application of our previous work on miRNA/TF
loop and network identification, we utilize the IntegraMiR paradigm and exploit additional
publicly available databases and datasets to infer miRNA-mediated regulatory networks in
Autism Spectrum Disorders, that were of interest to our experimental collaborators at the
School of Medicine. In particular, we use certain databases and datasets that list the genes
and proteins that are relevant in the context of Fragile X Syndrome, a disease in the category
of ASDs, and also provide the expression levels of these genes and proteins in the disease
state. In addition, our experimental collaborators provided a set of experimental data they
obtained in their lab which could serve to validate part of our computational predictions
and results, and help them make informed decisions on which set of genes and proteins
they could focus as the most likely players in the disease state.
In this way, for this second research work, we were able to construct predicted miRNA-
mediated networks using the IntegraMiR paradigm, and perform an additional level of
computational analysis that allowed us to validate the relevance of certain miRNAs in the
disease. Specifically, we performed gene set enrichment analysis on the predicted targets
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of miRNAs of interest and validated at the computational level (in addition to the subse-
quent supporting experimental results) that the miRNAs our collaborators focused on in
the experimental work could indeed contribute to the disease state. Combining an integra-
tive framework similar to IntegraMiR with this additional gene set enrichment analysis to
validate the relevance of the miRNAs of interest is a unique procedure and is essentially
utilizing all the major sources of information available to us to take into account a given
experimental setting to tailor the results for that specific setting.
In our third research problem, we developed a physical computational model for three-
component multivalent-multivalent molecular interactions that led to a rigorous method for
computationally implementing iPOLYMER. Our approach was based on a realistic kinetic
Monte Carlo simulation algorithm that produced sufficiently accurate approximations of
stochastic reaction-diffusion dynamics. A directly related method has recently been pro-
posed in [89]. Although, at a first glance, this method seems to be similar to ours, there are
some major and important differences. The method proposed in [89] and other recent meth-
ods discussed in Chapter 4 each suffer from a combination of the following major issues:
i) The method cannot be directly related to any physical model (such as the Doi model)
for multivalent binding/unbinding interactions in continuous time/space. ii) It is not clear
whether the method converges to a continuous time/space model as the time-step size and
the voxel volume decrease towards zero. As a consequence, the method in [89] leads to
an ad hoc algorithm that cannot be directly related to a physical model for multivalent
molecular binding. This deficiency can seriously compromise the utility and accuracy of
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this method in an experimental setting. iii) They cannot provide a graphical representation
of molecular aggregates. As a consequence, such methods cannot be used to study sieving
properties of molecular aggregates, e.g., by means of computing Pore Size Distributions
(PSDs).
Our proposed computational method models three-component multivalent-multivalent
molecular interactions and provides a rigorous discretization of the well-known continuous
time/space Doi model for systems that involve reactions among different types of molecules
as well as molecular diffusions. In an effort to guarantee that the resulting discretization
converges to the Doi model, as the voxel volume approaches zero, our method provides
appropriate formulas for the probability rates of the underlying binding/unbinding reactions
as well as for the probability rates of molecular diffusion. Moreover, the proposed method
treats time as a continuous variable and results in a realistic kinetic Monte Carlo simulation
algorithm that is expected to produce sufficiently accurate approximations of stochastic
reaction-diffusion dynamics. In addition, our model considers reactions among the binding
sites of the underlying reactant molecules and can thereby construct a graph representing
each molecule of interest, and allow for further investigation of the sieving properties of
molecular aggregates.
In the end, we would like to note that the findings from all three research problems
we tackled here present strong computational evidence that proves to be highly valuable
to experimental biologists in providing reliable predictions and meaningful insights which









MicroRNAs (miRNAs) are small non-coding ribonucleic acids (RNAs) that extensively
regulate gene expression in metazoan animals, plants and protozoa. Approximately 22
nucleotides in length, miRNAs usually repress gene expression by binding to sequences
with partial complementarity on target messenger RNA (mRNA) transcripts. In mammals,
miRNAs are thought to control the activity of more than 60% of all protein-coding genes
and extensively participate in the regulation of many cellular functions [37, 114].
With few exceptions, metazoan miRNAs base-pair with their targets imperfectly, fol-
lowing a set of rules that have been formulated by employing experimental and bioinformatics-
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based analyses [8]. This limited complementarity makes the task of computationally iden-
tifying miRNA targets very challenging and usually leads to large numbers of, mostly false,
potential targets.
Earlier computational tools have mainly focused on dissecting individual miRNA-target
interactions by relying on sequence-based identification of miRNA-target binding sites
or on mRNA/miRNA expression data analysis [51, 126, 160]. Alternative methods use
miRNA host genes as proxies for measuring the expression of embedded miRNAs [44]
or employ an information-theoretic approach to identify candidate mRNAs that modulate
miRNA activity by affecting the relationship between a miRNA and its target(s) [143]. On
the other hand, recent work considers co-expression analysis, by assuming that targets of a
given miRNA are co-expressed, at least in certain tissues or conditions [43].
Conventionally, many computational methods developed for miRNA-target prediction
rely on the assumption that there is an inverse correlation between the expression level of a
miRNA and that of its target [140]. However, it has been recently shown that both positive
and negative transcriptional co-regulation of a miRNA and its targets are prevalent in the
human and mouse genomes [133, 155]. In particular, two types of regulatory circuits (that
we will be discussing shortly) have been proposed for miRNA-mediated interactions, which
ascribe modulatory and/or reinforcing roles to miRNAs in their networks based on motifs,
such as feed-forward loops (FFLs) [3]. As a consequence, miRNA-target predictions solely
relying on an inverse correlation assumption are expected to be limited if the prediction
method does not appropriately incorporate the underlying FFL network structure.
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Based on the previous paradigm, several researchers have investigated the statistical
over-representation of network structures involving miRNA and TF co-regulation of mR-
NAs to identify enriched network motifs and/or assess their prevalence in different biolog-
ical contexts [19, 21, 88, 119, 141, 145, 154, 178]. Essentially, these methods compute
measures of coordinated gene co-regulation by miRNA and TF regulators. Other investi-
gators have considered regression methods or Bayesian models to quantify statistical asso-
ciations by determining changes in the expression level of a given mRNA explained by the
expression levels of TFs and miRNAs predicted to target the mRNA based on sequence in-
formation [83, 132, 176, 177]. Subsequently, they use the inferred relationships to delineate
significant network structures and motifs in a fashion similar to that employed in the afore-
mentioned methods. It is important to note however that the collective findings produced
by all these approaches provide further support for the importance of miRNA/TF-mediated
FFLs as prevailing network motifs across different biological contexts, reconfirming the
hypotheses originally proposed in [133, 155].
In addition to the above, disruptions in gene regulation (for instance, by genetic and
epigenetic alterations) believed to induce changes in normal cell function that lead to the
progression of pathological conditions, such as cancer, are disseminated through gene reg-
ulatory networks. As a consequence, effective treatment of many human diseases may
require a fundamental and systemic understanding of genomic regulators, such as miRNAs
and TFs, and their networks of interaction. However, systematically inferring molecular
interactions by experimental methods is both difficult and costly. Therefore, it is highly de-
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sired to develop “reliable” computational approaches capable of identifying such networks.
Network predictions can subsequently be used by an expert biologist to formulate novel hy-
potheses and effectively proceed with their experimental investigation and validation.
Recently, several new methods have been proposed for identifying coordinated miRNA/TF
interactions [17, 174]. However, for a given motif structure (e.g., an FFL), these methods
attempt to predict the underlying interactions (the three edges of an FFL) by utilizing lim-
ited biological information and a narrow set of computational tools. As a result, although
the methods are effective in providing insights into the prevalence of various motif in-
stances in gene regulatory networks, they may not produce reliable predictions from an
experimental perspective.
The performance of some of the previous methods has been recently tested in [17]. It
was observed that, although some methods were capable of achieving a reasonable success
rate in predicting instances of one type of interaction, they were less effective in predicting
instances of the other two types, with several algorithms having a success rate of close to
or less than 1% in predicting TF-mRNA and TF-miRNA interactions. This highlights the
critical fact that predicting pair-wise molecular interactions and constructing higher-order
instances of motifs using the predicted edges could translate to higher overall false-positive
rates. Since there is a wealth of information on how a TF binds its targets and on their
specific regulatory roles, we decided to consider only experimentally validated TF-mRNA
and TF-miRNA interactions under the FFL framework and shift focus on reliably predicting
the poorly understood miRNA-target interaction edge. We believe that, by appropriately
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constraining the underlying statistical analysis problem, we could potentially increase the
reliability of miRNA/TF-mediated gene regulatory loop predictions.
To further constrain the miRNA-target interaction prediction problem, we focus, in this
work, on certain three-node regulatory motifs. The first set of motifs that our method con-
siders are three-node FFLs that have recently attracted a great deal of attention among
systems and experimental biologists. These motifs are excellent models of coordinated
miRNA-mediated and transcriptional regulation, which have been hypothesized to be preva-
lent in the human and mouse genomes [155].
We consider two Type I FFL motifs, in which the miRNA and TF are the upstream
and downstream regulators, respectively, as well as four Type II FFL motifs, in which the
TF is now the upstream regulator, whereas the miRNA is the downstream regulator – see
Fig. 2.1. From a mechanistic perspective, these six FFLs are classified as being coherent or
incoherent. In the coherent case, the miRNA and TF regulators act in a coordinated fashion
to reinforce the regulation logic along two feed-forward paths. In Type I and Type II-B co-
herent FFLs, these paths simultaneously repress the expression of the targeted mRNA. The
resulting mechanism is used, for instance, to subdue leaky transcription of a gene by ensur-
ing that its expression stays at an inconsequential level. On the other hand, in a Type II-A
coherent FFL, the TF reinforces the transcription of the targeted mRNA by directly activat-
ing it as well as by inhibiting its repression by the targeting miRNA regulator.
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Figure 2.1: Three-node regulatory motifs considered by IntegraMiR. The Type I FFL con-
sists of triplets (miRNA, TF, mRNA) such that a miRNA simultaneously targets a mRNA
and its TF mRNA. The Type II FFL consists of triplets (miRNA, TF, mRNA) such that a TF
simultaneously regulates a miRNA and its target mRNA. Finally, the Type III loop consists
of triplets (miRNA, G-1, G-2) such that the miRNA simultaneously targets two transcripts
in a given KEGG pathway, one from each gene G-1 and G-2, whose corresponding proteins
could potentially interact with each other based on a pathway map provided in the KEGG
database. The labels on the edges of these motifs are defined in Table 2.1.
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In the incoherent FFLs, the miRNA and TF regulators act in a coordinated fashion
to fine-tune the expression of the targeted mRNA. More specifically, any deviation from
the steady-state concentration of the upstream regulator (i.e., the miRNA in Type I and
the TF in Type II-A and Type II-B FFLs) would drive the targeted mRNA, as well as the
downstream regulator, away from their steady-state levels in the same direction. In this way,
the downstream regulator can balance the expression of the targeted mRNA, compensating
fluctuations in the expression level of the upstream factor.
Certain cellular processes might be ultra-sensitive to the activity of a given transcript
in a specific biological context. In these situations, the “noise buffering” mechanism pro-
vided by incoherent FFLs helps maintain target protein homeostasis and ensures that an
uncoordinated drift from the steady-state level of the upstream regulator may not result in
an undesirable variation in the target protein level which can lead to pathological outcomes.
MiRNAs are particularly effective in this setting, owing to their rapid mechanism of action
at the post-transcriptional level, as opposed to transcriptional repressors, thus accelerating
noise buffering [155].
In addition to the coherent and incoherent FFLs, our method also takes into account the
basic Type III loop motif depicted in Fig. 2.1, in which a miRNA targets two gene tran-
scripts, G-1 and G-2, whose proteins could potentially interact with each other according
to a pathway map provided in the KEGG database (http://www.kegg.jp). The existence of
Type III loop motifs is supported by two key hypotheses: (i) miRNAs play major roles in
regulating signaling pathways due to their sharp dose-sensitive nature [9, 26, 62, 128, 173],
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and (ii) targets of single miRNAs are more connected (i.e., interact) at the protein level than
expected by chance [26, 57, 92, 156].
By comparison, the method proposed in [174] considers only Type II FFLs and does not
discriminate between coherent and incoherent FFLs, which is required for a systems-level
understanding of transcriptome changes in disease. Moreover, the standard statistical tests
used to identify differentially expressed genes between two conditions in a typical gene ex-
pression profiling study, as adopted by previous methods [17, 174], become fundamentally
flawed in the presence of unaccounted sources of variability (due to biological and exper-
imental factors among others) [15, 86, 87]. Molecular subtyping information is a critical
example of such sources of variability.
To reliably predict miRNA-target interactions from mRNA/miRNA expression data,
we propose an integrative method to collectively utilize the aforementioned molecular
structures identified to be statistically over-represented in gene regulatory networks (FFLs
and Type III loops), sequence-based miRNA-target predictions obtained from several algo-
rithms, known information about mRNA and miRNA targets of TFs available in existing
databases, available molecular subtyping information, and state-of-the-art statistical tech-
niques to appropriately constrain the underlying analysis. We discuss the proposed method
in detail in the next section.
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2.1 An Integrative MiRNA-mediated Network
Analysis Method
To address the previous issues in inferring miRNA-target interaction networks, in this
research work, we develop IntegraMiR, a novel integrative analysis method that can be
used to infer certain types of regulatory loops of deregulated miRNA/TF interactions which
appear at the transcriptional, post-transcriptional and signaling levels in a statistically over-
represented manner.
In the context of our first research problem, the proposed method assigns biological
roles to miRNAs by integrating five major sources of information together with state-of-
the-art statistical techniques to reliably infer specific types of miRNA-target interactions in
the context of regulatory loops. In particular, IntegraMiR utilizes:
(i) mRNA and miRNA expression data.
(ii) Sequence-based miRNA-target information obtained from different algorithms.
(iii) Known information about mRNA and miRNA targets of TFs available in existing
databases.
(iv) Certain three-node motifs in gene regulatory networks.
(v) Known molecular subtyping information available with gene expression data.
To do so, IntegraMiR identifies deregulated miRNAs, TFs and mRNAs by performing sta-
tistical analysis within a constrained framework that uses “prior” information comprising
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recently discovered motifs, available knowledge on miRNA/mRNA transcriptional regu-
lation, and known protein-level interactions on signaling pathways. To illustrate the ef-
fectiveness and potential of this method, we apply it on mRNA/miRNA expression data
from tumor and normal samples and identify several known and novel deregulated loops in
prostate cancer (PCa). This allows us to demonstrate instances of the results and findings
in a number of distinct biological settings, which are known to play crucial roles in PCa
and other types of cancer.
The flow-chart depicted in Fig. 2.2 provides a general description of the different steps
employed by IntegraMiR.The procedure uses mRNA and miRNA expression data obtained
from prostate tissue at two different biological conditions (normal vs. cancer). It more-
over employs results obtained by sequence-based miRNA target prediction algorithms and





The first step of IntegraMiR applies standard preprocessing techniques on the raw ex-
pression data (such as background correction, normalization, and data heterogeneity cor-
1Recently, ENCODE released information on TF binding sites based on ChIP-seq experiments for 161
TFs in 91 cell lines (http://genome.ucsc.edu/ENCODE). Unfortunately, this database does not provide the
regulation type (activation or repression) of a particular TF-target interaction, information that is critical
in our approach. For this reason, IntegraMiR uses TRANSFAC. However, once this information becomes
available through ENCODE or any other TF-target database, it can be readily utilized by IntegraMiR.
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Figure 2.2: General description of IntegraMiR. The method assigns biological roles to
miRNAs by integrating five major sources of information together with state-of-the-art
statistical techniques to reliably infer specific types of miRNA-target interactions in the
context of regulatory loops from mRNA and miRNA expression data.
rection) to improve data quality, followed by multiple hypothesis testing (MHT) and sur-
rogate variable analysis (SVA) to identify mRNAs and miRNAs that are differentially ex-
pressed between the two biological conditions, while correcting for biological variability
due to molecular subtyping, multiple testing and batch effects.
The second step implements additional statistical analysis using gene set enrichment
analysis (GSEA) to further evaluate the biological significance of certain mRNAs and
miRNAs that are not deemed to be differentially expressed by MHT. By employing the
molecular signatures database mSigDB of annotated gene sets for use with GSEA and the
experimentally verified miRNA target database miRTarBase, IntegraMiR constructs three
separate groups of gene sets and evaluates the statistical significance of each gene set en-
riched for deregulation in the available mRNA expression data. The first group consists of
gene sets in the mRNA data indexed by a TF mRNA that is not deemed to be differentially
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expressed by MHT and is determined by mSigDB to directly regulate each gene in the gene
set. The second group consists of gene sets in the mRNA data indexed by a miRNA that
is not deemed to be differentially expressed by MHT and is determined by miRTarBase to
target each gene in the gene set. The third group consists of gene sets in the mRNA data
indexed by a specific KEGG signaling pathway [69, 70] included in mSigDB. Finally, TFs
associated with statistically significant enriched gene sets are amended to the list of those
mRNAs deemed to be differentially expressed by MHT to generate a combined list of dif-
ferentially expressed mRNAs, and the same is done for miRNAs. We should note here
that mSigDB is widely used to obtain gene sets for GSEA analysis. On the other hand,
we employ MiRTarBase since this database has accumulated a relatively large number of
experimentally validated miRNA-target interactions.
In brief, GSEA determines whether a given set of genes shows statistically significant
concordant differences between two biological states [142]. The main reason IntegraMiR
applies GSEA after the initial hypothesis testing step is to improve detection of differen-
tially expressed TFs and miRNAs, which may be missed when single expression levels
show only moderate changes between the two biological conditions. As a matter of fact,
if a number of transcripts are known to participate in a common biological mechanism,
then even moderate changes in the expression levels of these transcripts may be statis-
tically significant due to the fact that known biological relationships between transcripts
may result in higher statistical power when detecting small variations in their expression
levels as compared to the case of single transcripts. Moreover, for certain TFs, TF mRNA
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expression cannot necessarily be used as a proxy of its activity at the protein level, due to
post-transcriptional and post-translational modifications of TFs [20, 85]. To address these
issues, IntegraMiR also considers the collective differential expression of genes, as op-
posed to several procedures followed by other related work discussed earlier that mainly
build their analyses on statistics obtained from single transcripts.
The third step of IntegraMiR uses the results obtained by MHT and GSEA, as well
as available biological knowledge and sequence-based miRNA target predictions, to iden-
tify known directly regulated targets of differentially expressed TFs and miRNAs and pre-
dicted targets for the miRNAs. By employing the eukaryotic TF database TRANSFAC
and the TF/miRNA regulation database TransmiR, IntegraMiR produces a list of differ-
entially expressed TFs together with their gene targets and the regulation type (activation
or repression) for each target gene. It also produces a list of differentially expressed TFs
together with their differentially expressed miRNA targets and the regulation type for each
target miRNA. Note that our choice for using TRANSFAC and TransmiR is based on the
fact that TRANSFAC reliably provides the crucial information of regulation type (activa-
tion/repression) of a transcription factor and its target gene(s), whereas TransmiR provides
the crucial information of the miRNA(s) being regulated by it. On the other hand, to iden-
tify mRNA targets of differentially expressed miRNAs, IntegraMiR employs miRecords
(http://mirecords.umn.edu/miRecords), an integrated sequence-based miRNA target pre-
diction tool, as well as miRTarBase, a database of experimentally validated miRNA tar-
gets. At this step, IntegraMiR produces a list of differentially expressed miRNAs with the
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corresponding sequence-based target predictions, amended with experimentally validated
mRNA targets from miRTarBase to help identify true-positive and false-negative predic-
tions by using available biological knowledge. In this respect, IntegraMiR incorporates a
predictive module (exploiting miRecords) and a non-predictive module (miRTarBase) to
accomplish this task.
The fourth step of IntegraMiR implements a technique, described in Section 2.2.7, to
construct deregulated loops of the types depicted in Fig. 2.1 using the results obtained from
the previous steps. IntegraMiR constructs the following three types of regulatory loops:
(i) An FFL comprising a miRNA which simultaneously targets a TF and a mRNA that
is directly regulated by the TF.
(ii) An FFL comprising a TF which directly regulates a miRNA and a mRNA that is
directly targeted by the miRNA.
(iii) A regulatory loop comprising a miRNA which simultaneously targets two different
genes in a given KEGG pathway whose proteins could potentially interact with each
other based on a pathway map provided in the KEGG database.
To rank the constructed regulatory loops in terms of their “significance,” IntegraMiR
applies a hypothesis testing procedure using Fisher’s method [40]. The procedure employs
Fisher’s summary test statistic, given by Eq. (2.2) in Section 2.2.8, to combine the MHT-
computed P values assigned to each node of the loop into one P value used as a ranking
score for the entire loop. This does not apply to Type III loops, since these loops involve
genes and not specific mRNA transcripts. Since the functional roles of regulatory loops are
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different, IntegraMiR groups these loops into five distinct categories: Type I coherent FFL,
Type I incoherent FFL, Type II coherent FFL, Type II incoherent FFL, and Type III loops
– see Figs. 2.1 and 2.2. To provide additional flexibility in interpreting the results, Inte-
graMiR sorts Type II FFLs into two distinct subgroups, Type II-A and Type II-B, although
this additional sorting may not be necessary. Within each group and subgroup, IntegraMiR
ranks the deregulated loops by increasing scores, with lower scores corresponding to higher
“significance,” and highlights those loops discovered to be deregulated in a manner consis-
tent with the underlying edge structure and the expression data, as determined by the rules
depicted in Fig. 2.3 (see also Section 2.2.9). It moreover marks miRNA targets depending
on whether these targets are predicted by the procedure or have been experimentally vali-
dated according to miRTarBase, or both. Note that “consistency” refers to the fact that the
expression patterns of the nodes of a deregulated loop are in agreement with its regulatory
edge structure. For example, a Type I coherent FFL is said to be consistently deregulated if
it comprises an upregulated miRNA and downregulated TF and mRNA, or a downregulated
miRNA and upregulated TF and mRNA; see Fig. 2.3.
To investigate the effectiveness of our proposed procedure, we apply IntegraMiR on
mRNA/miRNA expression data from prostate tumor and normal samples. In the follow-
ing, we discuss the details on the materials and techniques used in the development and
evaluation of IntegraMiR.
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2.2 Methods
2.2.1 Biological Samples
In this work, we use publicly available mRNA expression data obtained from a previ-
ously published study [13] involving normal and cancerous prostate tissue samples. The
normal samples were acquired during radical prostatectomy from non-suspect (normal) pe-
ripheral areas of the prostate of 48 different individuals diagnosed with low-risk tumors.
The cancerous samples were acquired from 47 patients diagnosed with high-risk tumors,
before administering any medical treatment. Detailed discussion on the materials and meth-
ods used to obtain and prepare these samples can be found in [13]. We also use publicly
available miRNA expression data from a previously published study [162] obtained from
histologically confirmed matched malignant and peripheral nonmalignant prostate tissue
samples extracted from 20 different patients with untreated prostate cancer (PCa). These
samples were prepared from prostatectomy specimens using methods detailed in [162].
2.2.2 Expression Profiling
In [13], the total RNA extracted from each normal and cancerous prostate tissue sample
was used to produce mRNA expression profiles for 17,324 human mRNAs. This was done
by mRNA microarray hybridization using the Affymetrix (Santa Clara, CA) GeneChip
Whole Transcript Sense Target Labeling Assay in conjunction with Affymetrix 1.0 Human
Exon ST microarrays. The MIAME-compliant mRNA microarray data can be found in the
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NCBI GEO database (www.ncbi.nlm.nih.gov/geo) with accession number GSE29079.
The tumor samples used to obtain the mRNA expression data were characterized by
their disease subtype, based on their TMPRSS2-ERG gene fusion status, through a number
of reliable assessments using ERG gene expression levels, nested RT-PCR, and quantitative
PCR measurements [13, 18]. These data have also been validated with respect to an earlier
study [150], which included matched miRNA expression data for a number of patients.
Seventeen tumor samples were defined as TMPRSS2-ERG fusion-positive and twenty sam-
ples were defined as fusion-negative. The remaining ten tumor samples that could not be
reliably categorized were labeled as unknown fusion status.
The miRNA profiling experiments performed in [162] used Affymetrix 1.0 GeneChip
miRNA microarrays, whose content is derived from the miRBase miRNA database v11.0
(www.mirbase.org). These experiments produced expression data for 847 human miRNAs
in matched normal and cancerous tissues. The data can be obtained from the NCBI GEO
database using accession number GSE23022.
We should note here that several miRNA profiling studies have been published in the
literature concerning PCa [4, 97, 111, 118, 153, 161]. However, results on deregulation
of particular miRNA genes have been highly inconsistent [129]. Seeking support for the
reliability of the miRNA expression data used in the present study, we should mention
that a major factor that possibly contributes to these inconsistencies is known to be varia-
tions in the miRNA expression data due, for example, to a different proportion of stromal
cells in tissue preparation. The previous miRNA microarray experiments are based on
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micro-dissected tissue samples that avoid the previous issue. In addition, miRNA in situ
hybridization experiments were run to evaluate the localization of miRNA-expressing cells
and ensure that miRNA expression in tumor samples is indeed cancer cell-associated [162].
Moreover, the results were partially validated with RT-PCR and compared with a previous
study on miRNA expression data from PCa tissue obtained by deep sequencing [147].
2.2.3 Data Preprocessing
IntegraMiR analyzes the raw mRNA and miRNA expression data using the statistical
computing environment R (www.cran.r-project.org). Both types of data are background-
corrected and normalized using quantile normalization [63]. In addition, the method em-
ploys the robust multi-array average (RMA) as a measure of mRNA and miRNA expression
levels [63].
2.2.4 Multiple Hypothesis Testing/Surrogate Variable
Analysis
Standard statistical tests used to identify differentially expressed genes between two
conditions in a typical gene expression profiling study (as adopted by previous methods,
e.g., see [17, 174]) become fundamentally flawed in the presence of unaccounted sources
of variability (due to biological and experimental factors among others) [15, 86, 87]. As
a consequence, many genes that are indeed differentially expressed in the data are not
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detected, whereas many others are falsely declared as positives [16, 86].
To address this problem and effectively exploit the molecular subtyping information in
the available mRNA expression data, IntegraMiR incorporates surrogate variable analysis
(SVA) [87], together with multiple hypothesis testing (MHT), to identify differentially ex-
pressed genes between two conditions. The method uses the Bioconductor
(www.bioconductor.org) package SVA (written in R) to perform SVA in order to take into
account biological variabilities and batch effects due to molecular subtypes categorized by
TMPRSS2-ERG gene fusion status in the tumor samples. This step has been shown to
improve biological accuracy and reproducibility in genome-wide expression studies and
enhances the quality of subsequent statistical analysis [86, 87].
IntegraMiR applies MHT to test for the null hypothesis H(i)0 : di = 0 against the alter-






with µ(t)i and µ
(n)
i being the mean expression levels of the i-th transcript (mRNA or miRNA)
in the tumorous and normal data, respectively. The Bioconductor package LIMMA (written
in R), which implements a moderated t-statistic [137], is used on each data set to separately
identify mRNAs and miRNAs that are differentially expressed between tumor and normal
samples. Then, IntegraMiR applies the Benjamini-Hochberg method, described in [10],
to control the false discovery rate (FDR) at 0.05. These steps produce two separate lists,
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LmRNA and LmiRNA, each containing 17,324 mRNAs and 847 miRNAs, with the corresponding
FDR-adjusted P (or simply FDR) values and the direction of deregulation (+1 for upreg-
ulation and −1 for downregulation), as determined by the sign of the moderated t-statistic
– see Table 2.1. The mRNAs and miRNAs with FDR ≤ 0.05 are considered as being
differentially expressed between tumor and normal samples.
2.2.5 Gene Set Enrichment Analysis
To further evaluate the statistical significance of certain mRNA and miRNA transcripts
deemed not to be differentially expressed by MHT, IntegraMiR uses LIMMA to perform
gene set enrichment analysis (GSEA), taking into account known biological knowledge
about these transcripts – see [142]. Specifically, by employing the molecular signatures
database mSigDB v3.1 (www.broadinstitute.org/gsea/msigdb), the method uses GSEA to
evaluate the significance of non-differentially expressed TFs in LmRNA (MHT-based FDR >
0.05) for which the target gene sets can be obtained from mSigDB. IntegraMiR forms
gene sets indexed by these TFs, with the elements of each gene set being those mRNAs
in LmRNA whose expressions are directly regulated by the indexing TF, as determined by
mSigDB. It then uses GSEA to evaluate the statistical significance of each gene set to
be enriched for deregulation, by using the default Wilcoxon rank-sum test. To adjust for
multiple testing, IntegraMiR uses again the Benjamini-Hochberg method to control the
FDR at 0.25 – see [142]. This step produces a list LGSTF of TFs with the corresponding
FDR values computed by MHT and GSEA – see Table 2.1. Only TFs with significantly
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Table 2.1: Lists of mRNAs, TFs, miRNAs, and their targets used to construct deregulated
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enriched gene sets (GSEA-based FDR ≤ 0.25) are included in this list. By combining lists
LmRNA and LGSTF , IntegraMiR finally forms a list L
DiffExp
mRNA of mRNAs deemed to be differentially
expressed by MHT or GSEA.
Likewise, IntegraMiR could use GSEA to further evaluate the statistical significance
of non-differentially expressed miRNAs in LmiRNA for which it is able to obtain their targets
from the experimentally verified database miRTarBase v3.5 (http://mirtarbase.mbc.nctu.edu.tw
– see [58]). Unfortunately, the limited number of experimentally validated miRNA targets
available in miRTarBase is a restricting factor in constructing appropriate and sufficiently
large gene sets in order to reduce the resulting bias (e.g., due to small gene set size or exper-
imental predilection – see [164] for a discussion on this issue). Due to bias and relatively
small gene set sizes, GSEA produces an appreciable number of significantly enriched gene
sets for miRNAs that are not detected to be differentially expressed by MHT (FDR> 0.05),
a majority of which are expected to be false positives. A possible way to remedy this situa-
tion is to improve the statistical power of GSEA by constructing sufficiently large gene sets
of miRNA targets that have been validated to be important in PCa by at least one reliable
experimental procedure (see [164] for a discussion). For this reason, IntegraMiR limits this
step to a list LDeepSeqmiRNA of 33 miRNAs that have been deemed to be significantly deregulated
in PCa tissue using deep sequencing analysis [147]. Only gene sets having a minimum of
eight elements are considered, as suggested in [134]. We should note here that it is not
necessary to deal with this problem in the previous (and subsequent) application of GSEA,
since all gene sets considered include a large and rather diverse number of elements in both
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cases.
To proceed, IntegraMiR uses miRTarBase to form gene sets indexed by miRNAs inLDeepSeqmiRNA ,
with MHT-based FDR values > 0.05 and with the elements of each gene set being the
mRNA targets in LmRNA of the indexing miRNA, as determined by miRTarBase. It then
uses GSEA to evaluate the statistical significance of a particular gene set enriched for an
inverse direction of deregulation with that of the miRNA. The reason IntegraMiR uses an
inverse relation is because many experiments used in the past to identify miRNA targets,
with their results recorded in miRTarbase, have traditionally focused on observing an in-
verse relation between the expression level of a miRNA and its experimentally validated
target(s). This step produces a list LGSmiRNA of experimentally validated (by deep sequencing
analysis) miRNAs with the corresponding FDR values computed by MHT and GSEA – see
Table 2.1. Only miRNAs with significantly enriched gene sets (GSEA-based FDR ≤ 0.25)
are included in this list. Finally, by combining lists LmiRNA and LGSmiRNA, IntegraMiR forms a
list LDiffExpmiRNA of miRNAs deemed to be differentially expressed by MHT or GSEA.
IntegraMiR also forms gene sets indexed by a specific KEGG signaling pathway in-
cluded in mSigDB. The elements of each gene set are those mRNAs in LmRNA determined
by mSigDB to be in the indexing pathway. The method then uses GSEA to evaluate the sta-
tistical significance of a particular gene set to be enriched for deregulation in the available
mRNA data. This step produces a listLGSKEGG of gene sets, together with the associated KEGG
signaling pathways and the corresponding GSEA-based FDR values – see Table 2.1. Only
KEGG signaling pathways with significantly enriched gene sets (FDR≤ 0.25) are included
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in the list.
We should point out here that mSigDB provides miRNA target gene sets as well. How-
ever, using GSEA to evaluate the statistical significance of these gene sets to be enriched
for deregulation produces poor results. We believe that this is due to the possibility that
many miRNA target gene sets provided by mSigDB are false positives. Therefore, GSEA
cannot produce meaningful statistical significance for these gene sets. As a consequence,
IntegraMiR applies GSEA only on experimentally validated miRNA target gene sets in or-
der to infer their statistical significance and complement the statistical analysis performed
by simply using the available miRNA expression data.
2.2.6 Target Identification
Since the goal of IntegraMiR is to delineate deregulated miRNA/TF-mediated gene
regulatory loops from evidence provided in available data, the method focuses on loops
containing differentially expressed miRNAs and TFs (based on their individual expression
levels – via MHT analysis – or through their target interactions – via GSEA analysis). Note
however that the target mRNAs associated with the loops of interest may not necessarily
be differentially expressed. This is due to the fact that differential expression of a TF may
not imply differential expression of the targeting mRNA (a TF may produce insignificant
regulation of transcription), whereas miRNA targeting may result in direct translational
repression without affecting mRNA abundance. Moreover, simultaneous differential ex-
pression of the miRNA and TF nodes of an incoherent Type I or Type II FFL may result
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in no deregulation of the associated mRNA since, in this case, downregulation (upregula-
tion) of mRNA abundance by miRNA targeting may be counterbalanced by upregulation
(downregulation) of transcription.
By following the previous rules, and for each differentially expressed TF in LDiffExpmRNA , In-
tegraMiR uses information available in TRANSFAC v7.0 (public)
(www.gene-regulation.com/pub/databases.html – see [170]) to identify the directly regu-
lated genes inLmRNA as well as to determine the regulation type (activation or repression). To
access this information and provide the input to IntegraMiR, we first obtained for each TF
its TRANSFAC-compatible annotation using the automated sequence annotation pipeline
(ASAP) system [76, 139]. This process yields a list LmRNATF containing differentially ex-
pressed TFs in LDiffExpmRNA , their gene targets in LmRNA, and the regulation type (activation or
repression) for each target gene – see Table 2.1. TFs not predicted to target any mRNAs in
LmRNA are not included in the list.
Likewise, IntegraMiR uses TransmiR v1.2 (http://202.38.126.151/hmdd/mirna/tf – see
[163]) to identify differentially expressed TFs in LDiffExpmRNA that directly regulate the transcrip-
tion of miRNAs in LDiffExpmiRNA . This produces a list L
miRNA
TF containing TFs from L
DiffExp
mRNA , their
corresponding transcriptional miRNA targets in LDiffExpmiRNA , and the regulation type (activation
or repression) for each targeted miRNA – see Table 2.1. TFs not predicted to target any
miRNAs in LDiffExpmiRNA are not included in the list.
Finally, for each miRNA in LDiffExpmiRNA , IntegraMiR performs sequence-based target predic-
tion using miRecords (http://mirecords.umn.edu/miRecords – see [171]) with the filtering
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parameter set equal to 2. As a consequence, targets for each miRNA are predicted by at
least two (out of eleven) different sequence-based target prediction algorithms incorporated
in miRecords. Moreover, for each differentially expressed miRNA with experimentally val-
idated target information in miRTarBase, we identified those mRNA targets not predicted
by miRecords. This produced a list LmRNAmiRNA of differentially expressed miRNAs in L
DiffExp
miRNA
with the corresponding sequence-based target predictions in LmRNA amended with (exper-
imentally validated) targets from miRTarBase – see Table 2.1. miRNAs not predicted to
target any mRNAs in LmRNA are not included in this list.
The reason we decided to use predictions by at least two different algorithms was to
strike a balance between the number of false-positive and false-negative predictions. By
setting the filtering parameter equal to 1, we obtain a large number of predictions (most of
which are presumably false-positives) whereas by setting the filtering parameter equal to 3,
we obtain a very small number of predictions (which presumably indicates a large number
of false-negatives for the prediction). Note finally that miRecords provides a database for
experimentally validated miRNA targets as well, but we decided to use miRTarBase in-
stead, since the latter database is up-to-date, unlike the former which dates back to Novem-
ber 2010.
2.2.7 Construction of Regulatory Loops
IntegraMiR constructs Type I FFLs by first identifying (TF, mRNA) pairs using the
list LmRNATF . It then forms triplets (miRNA, TF, mRNA), such that a miRNA simultaneously
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targets the TF and the mRNA, as determined by the list LmRNAmiRNA – see Fig. 2.1. Likewise,
IntegraMiR constructs Type II FFLs by first identifying (TF, miRNA) pairs from the list
LmiRNATF . It then forms triplets (miRNA, TF, mRNA), such that the mRNA is directly regulated
by the TF and is simultaneously targeted by the miRNA, as determined by the lists LmRNATF
and LmRNAmiRNA, respectively. The method finally delineates all miRNA-target interactions in the
four deregulated KEGG pathways under consideration (TGF-β Signaling, WNT Signaling,
Prostate Cancer, and Adherens Junction) by first looking into the gene sets associated with
each pathway (obtained from the KEGG database), by filtering out the genes that are not
expressed in the data, and by identifying the targets of each miRNA as determined by the
listLmRNAmiRNA. In addition, IntegraMiR constructs Type III loops by taking gene pairs (G-1, G-2)
such that their corresponding proteins could potentially interact with each other according
to the pathway map provided by KEGG database. It then highlights triplets (miRNA, G-
1, G-2) such that the miRNA is predicted to target at least one transcript from each gene,
as determined by the list LmRNAmiRNA. We carried out this step to identify, as an example, Type
III loops in the KEGG Prostate Cancer Pathway for certain miRNAs.
Each edge depicted in Fig. 2.1 connecting a miRNA with its target is naturally repress-
ing. The list LmRNATF provides the regulation type (activation or repression) for each edge
connecting a TF with a mRNA whereas the list LmiRNATF provides the regulation type (activa-
tion or repression) for each edge connecting a TF with a miRNA.
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2.2.8 Significance Ranking of FFLs
For each constructed FFL, IntegraMiR calculates its statistical significance by employ-
ing the following procedure. First, by using the lists LDiffExpmRNA , L
DiffExp
miRNA , and LmRNA, it associates
with each node of the FFL a binary value (±1), which indicates the direction of deregu-
lation of the node. Moreover, it assigns the MHT-based FDR value corresponding to the
particular transcript (TF, mRNA, or miRNA) represented by the node, which quantifies
the significance of the transcript’s deregulation. To evaluate the statistical significance of
each FFL, IntegraMiR first assumes that the FFL is not deregulated if each one of its nodes
(1, 2, 3) is not deregulated. It then constructs a hypothesis testing procedure to test for the
null hypothesisH0 : di = 0, for every i, where i = 1, 2, 3, against the alternative hypothesis
HA : di 6= 0, for at least one i, where i = 1, 2, 3, with di given by Eq. (2.1), with µ(t)i and
µ
(n)
i being the mean expression levels of the transcript (TF, mRNA, or miRNA) assigned
at node i of the FFL in the tumorous and normal data, respectively. To do so, IntegraMiR
uses Fisher’s method [40, 169] based on the summary test statistic
T = −2 ln(p1p2p3) , (2.2)
where p1, p2, and p3 are the P values obtained by MHT for nodes 1, 2, and 3, respec-
tively. Under the null hypothesis, each (non-adjusted) P value obtained by MHT will have
a uniform distribution between 0 and 1. Assuming that these values are obtained from in-
dependent statistical tests, the statistic T follows a chi-square distribution with six degrees
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of freedom, from which a combined value is obtained that is used to score each FFL.
We should note that these statistical tests depend on each other in general. It turns out
that Fisher’s method may result in a combined P value that will be smaller than the P
value which could be obtained if dependencies among the statistical tests used could be
appropriately taken into account. For this reason, we regard Fisher’s method as producing
a score for each FFL and not a formal P value [5]. As a consequence, we expect that
IntegraMiR will produce a larger set of deregulated FFLs than a hypothesis testing method
that properly considers the underlying dependence of the individual tests. In the absence
of any prior information however, accounting for these dependencies is a difficult task [14,
77], which we cannot satisfactorily address in this dissertation.
2.2.9 Consistent Regulatory Loops
Since the functional roles of the FFLs considered in this dissertation are different, In-
tegraMiR groups them into five distinct categories: Type I coherent, Type I incoherent,
Type II coherent, Type II incoherent, and Type III – see Fig. 2.1. In addition, the method
sorts Type II FFLs into two distinct subgroups, Type II-A and Type II-B, and marks as
“consistent” those loops discovered to be deregulated in a manner compatible with the un-
derlying edge structure. To do so, note that molecular species joined by an activating edge
are expected to exhibit correlated deregulation whereas species joined by a repressing edge
are expected to exhibit anti-correlated deregulation. Taking this fact into account, Inte-
graMiR marks deregulated loops as being consistent by using the rules depicted in Fig. 2.3.
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Figure 2.3: Consistency of deregulated loops. A deregulated loop is deemed to be consis-
tent if the expression pattern of its nodes are in agreement with its regulatory edge structure.
Any deregulated loop that does not satisfy this property is said to be inconsistent.
For example, a deregulated Type I coherent FFL is said to be consistent if it comprises an
upregulated miRNA node and downregulated TF and mRNA nodes, or a downregulated
miRNA node and upregulated TF and mRNA nodes. A deregulated FFL that does not
follow these rules is said to be inconsistent.
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2.2.10 Extracting Regulatory Loops
The results obtained by IntegraMiR are tabulated in the Supplementary Tables S5-S10
of [1] and contain a large number of deregulated Type I and Type II FFLs. To identify
deregulated FFLs for specific miRNAs, TFs, or genes, we must search these results and
extract those FFLs that contain the molecular species of interest. Moreover, identifying
deregulated Type III loops for specific pairs of genes, requires construction of such loops
from the results tabulated in Supplementary Table S11 of [1]. Extracting regulatory loops
from the results can be done automatically.
2.3 Results
2.3.1 Identification of Extensive Transcriptional,
Post-transcriptional and Signaling Deregulation
in PCa
To investigate the effectiveness of IntegraMiR in delineating miRNA-mediated regu-
latory loops, we use mRNA microarray expression data, obtained from 48 normal and 47
prostate tumor tissue samples (NCBI GEO database, accession number GSE29079), as
well as miRNA microarray expression data obtained from matched normal and cancer-
ous tissue samples, extracted from 20 individuals (NCBI GEO database, accession number
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GSE23022). For more information about this data, we refer the reader to Sections 2.2.1
and 2.2.2. After data preprocessing, IntegraMiR incorporates Surrogate Variable Analysis
(SVA) [87], together with MHT, to identify differentially expressed genes between the two
conditions. It has been shown that SVA increases the biological accuracy and reproducibil-
ity of analyses in genome-wide expression studies [86, 87]. IntegraMiR employs SVA to
take into account biological variabilities due to molecular subtypes categorized by the sta-
tus of TMPRSS2-ERG gene fusion, which has been identified in about half of all PCa cases
and is a critical early event in the development and progression of this disease [29, 79, 152].
IntegraMiR first performs MHT, using a moderated t-statistic [137], to separately iden-
tify mRNAs and miRNAs that are differentially expressed between tumor and normal sam-
ples. This analysis identifies extensive transcriptional deregulation in the tumor tissue sam-
ples: 7,934 genes (out of 17,324) are found to be differentially expressed based on their
statistical significance, with 164 of these genes being overexpressed by a fold change ≥ 2
or repressed by a fold change≤ 0.5 – see Supplementary Tables S1 and S2 in [1]. The gene
list we provide in Supplementary Table S2 contains important genes, such as TARP, MYC,
SNAI2 (SLUG), WIF1 and ERG among others, which have been previously characterized
in PCa.
Analysis of the corresponding miRNA expression data by MHT results in 18 (out of
847) differentially expressed human miRNAs, which we list in Table 2.2 (first 18 miR-
NAs) – see also the Supplementary Table S3 in [1]. Recently, deep sequencing analysis of
miRNA expression profiles identified 33 miRNAs as being differentially expressed in PCa,
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with miR-375, miR-200c, miR-143 and miR-145 exhibiting the most pronounced deregu-
lation [147]. We compared the IntegraMiR results to the ones obtained by deep sequencing.
Of the 18 miRNAs identified by IntegraMiR, 7 miRNAs (miR-200c, miR-20a, miR-375,
miR-106a, let-7a, miR-21, and miR-106b) have been confirmed to be upregulated by deep
sequencing analysis, whereas 2 miRNAs (miR-221 and miR-145) have been confirmed to
be downregulated. The remaining 9 miRNAs identified by MHT were not detected by deep
sequencing.
During the second step of IntegraMiR, application of GSEA on gene sets of TF targets
obtained from mSigDB discovers 37 significantly deregulated TFs, which are not detected
by the initial MHT step based on single gene analysis. A list these TFs can be found in
Supplementary Table S4 of [1]. Interestingly, several of these TFs (e.g., NKX3-1, SMAD1,
SMAD3, SRF, ETV4 and ELK1) are known to play important roles in PCa, as well as in
other types of cancer.
Likewise, application of GSEA on gene sets of experimentally validated (by deep se-
quencing analysis) miRNA targets obtained from miRTarBase identifies 5 significantly
downregulated miRNAs, which are not detected by MHT. We list these miRNAs in Ta-
ble 2.2 (last 5 miRNAs). In both cases, and for each TF or miRNA, GSEA is performed
based on the availability of gene sets in the data.
Finally, application of GSEA identifies 30 significantly deregulated signaling pathways,
among the 186 KEGG signaling pathways available in mSigDB. We list the results in Ta-
ble 2.3. Among other pathways, the list contains the TGF-β and WNT Signaling pathways,
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Table 2.2: Differentially expressed miRNAs identified by IntegraMiR.
Rank miRNA1 dir2 FDR FDR
(MHT) (GSEA)
1 miR-222 ↓ 6.58E-4 n/a
2 miR-200c ↑ 1.32E-3 n/a
3 miR-221 ↓ 1.34E-3 n/a
4 miR-20a ↑ 1.70E-3 n/a
5 miR-20b ↑ 2.55E-3 n/a
6 miR-182 ↑ 3.52E-3 n/a
7 miR-375 ↑ 3.63E-3 n/a
8 miR-17 ↑ 4.12E-3 n/a
9 miR-93 ↑ 7.64E-3 n/a
10 miR-145 ↓ 9.58E-3 n/a
11 miR-106a ↑ 1.04E-2 n/a
12 miR-141 ↑ 2.05E-2 n/a
13 mir-720 ↑ 2.27E-2 n/a
14 let-7a ↑ 2.83E-2 n/a
15 miR-214 ↓ 2.85E-2 n/a
16 miR-200b ↑ 2.95E-2 n/a
17 miR-21 ↑ 2.95E-2 n/a
18 miR-106b ↑ 4.66E-2 n/a
19 miR-125b ↓ 3.15E-1 9.02E-4
20 miR-143 ↓ 7.45E-1 1.06E-1
21 miR-29a ↓ 8.62E-1 1.06E-1
22 miR-24 ↓ 8.79E-1 1.06E-1
23 miR-199a ↓ 9.96E-1 1.06E-1
1Highlighted miRNAs have been confirmed by deep sequencing analysis.
2Direction of deregulation.
which have been implicated in PCa initiation and progression. Naturally, the results also
include the Prostate Cancer and Adherens Junction pathways. The last pathway regulates
intercellular adhesion that plays an important role in epithelial-to-mesenchymal transition
(EMT), considered to be an important step in tumor progression [117, 172]. In the fol-
lowing, we limit our results and discussions to miRNA-target interactions associated with
these four pathways.
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Table 2.3: Significantly deregulated KEGG signaling pathways identified by IntegraMiR.
KEGG Signaling Pathway1 FDR (GSEA)
DILATED CARDIOMYOPATHY 6.67E-4
ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY ARVC 6.67E-4
REGULATION OF ACTIN CYTOSKELETON 8.34E-4
HYPERTROPHIC CARDIOMYOPATHY HCM 8.34E-4
TGF BETA SIGNALING PATHWAY 3.68E-3
CALCIUM SIGNALING PATHWAY 4.09E-3
FOCAL ADHESION 8.16E-3
ECM RECEPTOR INTERACTION 8.16E-3
WNT SIGNALING PATHWAY 8.77E-3
MAPK SIGNALING PATHWAY 1.40E-2
PROPANOATE METABOLISM 1.55E-2
VALINE LEUCINE AND ISOLEUCINE DEGRADATION 1.76E-2
PHOSPHATIDYLINOSITOL SIGNALING SYSTEM 1.76E-2
FC GAMMA R MEDIATED PHAGOCYTOSIS 4.02E-2
PATHWAYS IN CANCER 4.36E-2
VASCULAR SMOOTH MUSCLE CONTRACTION 4.36E-2
AXON GUIDANCE 8.86E-2
UBIQUITIN MEDIATED PROTEOLYSIS 1.00E-1
MELANOGENESIS 1.00E-1
PROSTATE CANCER 1.00E-1
ONE CARBON POOL BY FOLATE 1.20E-1
INOSITOL PHOSPHATE METABOLISM 1.49E-1
VASOPRESSIN REGULATED WATER REABSORPTION 1.68E-1
ADHERENS JUNCTION 1.71E-1
LONG TERM POTENTIATION 1.71E-1
PURINE METABOLISM 1.71E-1
GLYCINE SERINE AND THREONINE METABOLISM 1.72E-1
GAP JUNCTION 1.92E-1
ARGININE AND PROLINE METABOLISM 2.32E-1
MELANOMA 2.50E-1
1Highlighted pathways used by IntegraMiR to construct Type III loops.
Lastly, and during the third and fourth steps, IntegraMiR constructs deregulated reg-
ulatory loops, sorts them into the seven groups depicted in Fig. 2.1 and ranks the Type I
and Type II FFLs within each group using the scores computed by Fisher’s summary test
statistic. IntegraMiR predicts a large number of deregulated Type I and Type II FFLs,
which can be found in Supplementary Tables S5-S10 of [1] (see also Fig. 2.4A): 2,104
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Type I coherent, 649 Type I incoherent, 154 Type II-A coherent, 690 Type II-A incoherent,
486 Type II-B coherent, and 111 Type II-B incoherent. Moreover, the method predicts a
large number of deregulated miRNA-target interactions that could potentially form Type III
loops, which can be found in Supplementary Table S11 of [1]: 904 miRNA-mRNA pairs in
the TGF-β Signaling Pathway, 1,611 miRNA-mRNA pairs in the WNT Signaling Pathway,
1,025 miRNA-mRNA pairs in the Prostate Cancer Pathway, and 896 miRNA-mRNA pairs
in the Adherens Junction Pathway.
2.3.2 Discovery of Appreciable FFL-based
Transcriptome Deregulation
To gain insight into the occurrence of deregulated Type I and Type II FFLs, we depict in
Fig. 2.4A the fractions of deregulated FFL subtypes (among all deregulated FFLs predicted
by IntegraMiR) grouped in terms of consistent and inconsistent deregulation (as defined in
Section 2.2.9 and illustrated in Fig. 2.3) based on expression data. The results suggest that
certain FFL subtypes contribute to a larger portion of the observed net FFL deregulation
than other subtypes. Interestingly, consistent FFL deregulation accounts for about 35% of
net FFL deregulation. This type of deregulation is important since its functional charac-
teristics are corroborated by the available expression data, which provides a first level of
evidence of their significance. For this reason, an experimentalist may want to first consider
this type of FFL deregulation for validation. Among the consistently deregulated FFLs, the
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Figure 2.4: Predicted FFL-based transcriptome deregulation in PCa. (A) Distribution of
the fraction of deregulated FFL subtypes grouped in terms of consistent and inconsistent
deregulation based on expression data. (B) Percentages of transcriptome change due to
significantly upregulated (in green) and downregulated (in red) miRNAs. (C) Cumulative
percentages of transcriptome change due to significantly upregulated (in green) and down-
regulated (in red) miRNAs. (D) Venn diagram depicting the number of mRNA targets of
six significantly upregulated miRNAs, miR-17 and miR-20a (from the miR-17/92 cluster),
miR-106b and miR-93 (from the miR-106b/25 cluster), and miR-106a and miR-20b (from
the miR-106a/363 cluster), which belong to the same family. (E) Venn diagram depict-
ing the number of mRNA targets of three significantly downregulated tumor suppressor
miRNAs, miR-24, miR-29a, and miR-145, which do not belong to one family.
Type II-A incoherent FFLs account for about 14% of net FFL deregulation, followed by
Type I coherent FFLs, which account for 10%. On the other hand, Type I-A incoherent and
Type II-B coherent FFLs each account for about 5% of net FFL deregulation, whereas, the
two remaining subtypes, Type II-A coherent and Type II-B incoherent, account for less than
1%. It is striking however that 40% of FFL deregulation is attributed to inconsistent dereg-
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ulation of Type I coherent FFLs. Inconsistent FFL deregulation suggests that the implied
molecular interactions between the three nodes (miRNA, TF, mRNA) of a particular FFL
may not be used to explain biological function on its own, based on the transcript levels of
the nodes in the expression data. In this case, further investigation of underlying biological
mechanisms that could affect the three FFL nodes is needed, including other FFLs sharing
a node with the particular FFL under consideration.
To explain the previous result, note that we expect in the coherent case to observe
a relatively smaller number of consistently than inconsistently deregulated FFLs since,
for a coherent FFL to be consistently deregulated, the abundance of the three associated
molecular species (miRNA, TF, and mRNA) must satisfy the rules depicted in Fig. 2.3 (see
also Section 2.2.9). The required conditions however may not be observed in the data, since
the abundance of a molecular species may be influenced by several FFLs or by factors other
than FFL regulation. Clearly, the results depicted in Fig. 2.4A corroborate this remark. On
the other hand, IntegraMiR predicts that Type I coherent FFL deregulation accounts for
an appreciable portion (50%) of net FFL deregulation which, together with the previous
remark, explains the high percentage (40%) of net FFL deregulation due to inconsistently
deregulated Type I coherent FFLs.
By examining the constituent interactions that form deregulated FFLs, we determined,
for each significantly deregulated miRNA, the percentage of transcriptome deregulation
attributed to that miRNA. The results are depicted in Fig. 2.4B, ranked in terms of de-
creasing percentages of consistent deregulation. We call a miRNA-target interaction to be
53
CHAPTER 2. MIRNA/TF-MEDIATED NETWORKS IN PROSTATE CANCER
consistent, if the miRNA and the associated mRNA target exhibit anti-correlated deregu-
lation in the data. Note that miR-106a is responsible for the most consistent (1.88%) and
the most inconsistent (3.45%) transcriptome deregulation, whereas miR-720 has negligible
transcriptome changes associated with it. Finally, the cumulative distributions depicted in
Fig. 2.4C reveal that 6.35% of transcriptome changes between normal and cancer samples
are due to FFLs with significantly deregulated miRNA nodes, with 5.34% of the changes
being accounted for by consistently deregulated miRNA-target interactions.
2.3.3 Consonancy with MiRNA Family
Co-targeting Hypothesis
Among the top miRNAs depicted in Fig. 2.4B are members of three miRNA clus-
ters that have been investigated in other types of cancers as well [104]: miR-17/92 on
human chromosome 13 (with genomic locus 13q31.3) and its two cluster paralogs, miR-
106a/363 on chromosome X (Xq26.2) and miR-106b/25 on chromosome 7 (7q22.1). Mem-
bers of these clusters have been established to play essential roles in the normal develop-
ment of heart, lungs, and the immune system and are involved in tumor formation with
oncogenic roles [102, 115, 159]. More importantly, miR-17 and miR-20a (from the miR-
17/92 cluster), miR-106a and miR-20b (from the miR-106a/363 cluster), as well as miR-
106b and miR-93 (from the miR-106b/25 cluster) belong to the same family of miRNAs
(i.e., miRNAs with identical seed regions) and are deemed to be significantly upregulated
54
CHAPTER 2. MIRNA/TF-MEDIATED NETWORKS IN PROSTATE CANCER
by IntegraMiR. Note however that individual miRNAs on the same cluster could exhibit
varied levels of expression and, for some miRNAs, no expression at all in certain cell
lines [52, 136]. Along these lines, several miRNAs in the miR-17/92 cluster and its two
paralogs (in particular, miR-18a, miR-19a, miR-19b-1 and miR-92a-1 from the miR-17/92
cluster, miR-18b, miR-19b-2, miR-92a-2 and miR-363 from the miR-106b/25 cluster, as
well as miR-25 from the miR-106a/363 cluster) are not identified as being differentially
expressed based on the expression data we used in this study.
Recent work suggests that members of the same family of miRNAs tend to target com-
mon transcripts due to their shared seed sequences [156]. The results obtained by Inte-
graMiR corroborate this hypothesis. In Fig. 2.4D, we use a Venn diagram to depict the
numbers of mRNA targets predicted by IntegraMiR for the previous six miRNAs (obtained
from miRNA-target interactions among all FFLs in our results – see Supplementary Tables
S5-S10 in [1]). Clearly, a high level of overlap exists among the three target sets. In par-
ticular, our results predict that all six miRNAs target a set of 128 different mRNAs. This
finding has also been observed by using an alternative method and different data sets [43],
suggesting that cooperation among the six deregulated miRNAs may be present in other
cancer types as well.
On the other hand, the top three miRNAs miR-24, miR-29a, and miR-145 in Fig. 2.4B
which were found by IntegraMiR to be significantly downregulated, do not belong to
one family and are not known to reside on a common cluster according to the miRBase
(www.mirbase.org) database. The results depicted in Fig. 2.4E show that, in this case, the
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amount of overlap is less pronounced than the one depicted in Fig. 2.4D. It is important to
note that these three miRNAs have been hypothesized to possess tumor suppressor roles:
miR-24 has recently been shown to suppress expression of two crucial cell cycle control
genes, E2F2 and MYC [81], low levels of miR-29a have been attributed to the methylation
of its promoter region in PCa [90], and miR-145 is hypothesized to play roles in several
types of cancer [125].
2.3.4 Discovery of Appreciable FFL-based
MiRNA-TF Co-regulation
We now focus our attention on FFL-based miRNA-TF co-regulation. In Fig. 2.5A, we
depict the numbers of coherent and incoherent deregulated FFLs predicted by IntegraMiR
for each type of miRNA-TF interaction whereas, in Fig. 2.5B, we depict the percentages of
consistently and inconsistently deregulated miRNA-TF interactions under each category.
The results suggest that, in PCa, both coherent and incoherent FFLs are deregulated, al-
though the total coherent FFLs outnumber the incoherent ones, an observation that is espe-
cially true when the miRNA represses the TF (Type I). Moreover, the most prevalent FFL
deregulation involves repression of the TF by the miRNA (Type I coherent and incoher-
ent), followed by FFL deregulation that involves activation of the miRNA by the TF (Type
II-A incoherent and Type II-B coherent). On the other hand, deregulation of FFLs that
involve repression of the miRNA by the TF (Type II-A coherent and Type II-B incoherent)
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Figure 2.5: Predicted FFL-based miRNA-TF co-regulation. (A) Numbers of coherent and
incoherent deregulated FFLs for each type of miRNA-TF interaction. (B) Percentages of
consistently and inconsistently deregulated FFLs under each miRNA-TF interaction type
depicted in (A).
is not substantial. Note also that consistent deregulation of FFLs that involve activation of
the miRNA by the TF (Type II-A incoherent and Type II-B coherent) is appreciably more
prevalent than inconsistent deregulation whereas the opposite is true for the case of FFLs
in which the TF represses the miRNA.
All miRNA-TF pairs associated with the deregulated FFLs predicted by IntegraMiR
(obtained from miRNA-TF interactions among all the FFLs in our results) are listed in
Supplementary Table S12 of [1], categorized by their interaction type. As a notable ex-
ample, the six miRNAs considered in Fig. 2.4D appear in the list as being consistently
deregulated together with the MYC oncogene, which acts as their transcriptional activator.
We investigated how many of the 128 common mRNAs targeted by these six miRNAs were
predicted to form FFLs with MYC. IntegraMiR predicts 79 of the 128 mRNAs to be under
the regulatory control of MYC, divided into two sets, with 33 mRNAs being in the first
set and 46 mRNAs in the second. All six miRNAs interact with the first set of mRNAs in
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Type II-B coherent FFL configuration and with the second set in Type II-B incoherent FFL
configuration. Among these mRNAs, APP from the first set and E2F1 from the second set
have experimentally validated interactions with these miRNAs according to miRTarBase.
2.3.5 Discovery of Bona Fide MiRNA-mediated
Regulatory Networks
To demonstrate the significance of the results obtained by IntegraMiR from a mech-
anistic point of view, we focus on two biological settings known to play crucial roles in
PCa and other types of cancer. This will help us explain the functional roles of regulatory
modules and illustrate how one can use these modules to build an integrated network model
for a specific biological setting or molecular species of interest.
2.3.5.1 TP53 miRNA-mediated apoptotic network
We first consider the miR-125 family of miRNAs, which is highly conserved throughout
diverse species from nematodes to humans. Members of this family, such as miR-125a,
miR-125b, and miR-125b-2, have been validated to be downregulated, exhibiting disease-
suppressing properties in many conditions as well as disease-promoting functions [146].
It turns out that miR-125b is identified by IntegraMiR to be significantly downregulated
– see Table 2.2. It has been recently suggested that miR-125b is an important component
of a TP53 (p53) tumor-suppressor network whereas significant negative correlation has
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Figure 2.6: TP53 miRNA-mediated network model for apoptosis. IntegraMiR identifies
two deregulated FFLs in PCa that model regulatory interactions among miR-125b, TP53
(p53), and BBC3 (PUMA). (A) Type I coherent and Type II-A coherent FFLs. (B) TP53
miRNA-mediated network model for apoptosis obtained by combining the two FFLs in (A).
been reported between miR-125b and TP53 [11, 78]. Moreover, it has been shown that
the p53-upregulated modulator of apoptosis BBC3 (PUMA) and NOXA are direct targets in
p53-mediated apoptosis localized to mitochondria [112].
To investigate systemic relations among these molecules of interest, we identified all
deregulated FFLs predicted by IntegraMiR that contain miR-125b, TP53 (p53), BBC3
(PUMA) and NOXA. To focus our discussion on highly relevant FFLs, we consider only
FFLs with nodes comprised of one of the four species of interest. We could not find FFLs
that contain NOXA. However, we found one Type I coherent FFL and one Type II-A co-
herent FFL comprised of the other three species – see Fig. 2.6A. Both FFLs are deemed by
IntegraMiR to be deregulated in the prostate expression data.
The Type I coherent FFL suggests that miR-125b represses BBC3 while it reinforces
this repression by targeting its transcriptional activator TP53. The Type II-A coherent FFL
suggests that TP53 induces the transcription of BBC3 while it reinforces this induction by
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repressing miR-125b, an inhibitor of BBC3.
From a systemic point of view, if the Type I coherent FFL is functional in a specific
condition in which miR-125b is significantly upregulated, we would expect the expressions
of both TP53 and BBC3 to be repressed. As a consequence, miR-125b would assume an
anti-apoptotic role in this setting. A similar argument can be made when miR-125b is
significantly downregulated. As for the Type II-A coherent FFL, if TP53 is upregulated
and active as a TF, we would expect miR-125b to be downregulated. As a consequence,
BBC3 is expected to be significantly upregulated due to the concurrent upregulation of its
transcriptional inducer, TP53, and the repression of its inhibitor, miR-125b. It is noteworthy
that one cannot always expect to observe these exact relations in mRNA/miRNA expression
data. It turns out that both FFLs depicted in Fig. 2.6A are deregulated inconsistently based
on the expression data.
The previous steps provide a fundamental understanding of the underlying structure of
TP53 miRNA-mediated apoptotic network, which may not be directly attainable by look-
ing at individual molecular interactions. In particular, by combining the two FFLs depicted
in Fig. 2.6A, we obtain the simple network depicted in Fig. 2.6B. This network accentuates
the mutual inhibition between miR-125b and the pro-apoptotic interaction between TP53
and BBC3, which is in line with the earlier reported observation of significant negative cor-
relation between miR-125b and TP53 [11, 78]. The underlying double negative feedback
means that upregulation of miR-125b will inhibit TP53 which will derepress miR-125b,
a situation that can lead to the repression of BBC3. On the other hand, downregulation
60
CHAPTER 2. MIRNA/TF-MEDIATED NETWORKS IN PROSTATE CANCER
of miR-125b will derepress TP53 which will further repress miR-125b, a situation that
may lead to significant activation of BBC3 and thus apoptosis. Double negative feedback
loops are known to act as toggle switches that lead to different cell fates [2]. Interestingly,
both TP53 and BBC3 have been validated to be targets of miR-125b according to miRTar-
Base. Moreover, the Type I FFL discussed above has been recently reported in [135], thus
demonstrating the validity of the previous IntegraMiR predictions.
2.3.5.2 MYC-E2F1 miRNA-mediated cell proliferation network
It is well known that deregulated expression or malfunction of the transcription factor
MYC is one of the most common abnormalities in human cancers. Moreover, E2F1 is a
member of the E2F family of TFs which are critical regulators of cell cycle and apoptosis.
This TF regulates MYC and is transcriptionally targeted by MYC. Considering the fact that
the miR-17/92 cluster and its paralogs have recently been shown to be tightly linked to
the functions of MYC and E2F1 in the regulatory circuitry that controls cell proliferation
[104, 108, 109, 159], we decided to identify all miRNA regulators predicted by IntegraMiR
to interact with these critical TFs. This allowed us to delineate the regulatory network
depicted in Fig. 2.7, which we constructed from 18 distinct FFLs: 8 Type I coherent, 2
Type II-A coherent, and 8 Type II-A incoherent. A total of 9 miRNAs were predicted to
interact both with MYC and E2F1, with 8 of the miRNA-target interactions being identified
by the predictive module of IntegraMiR as being true-positives, 2 being identified as false-
negatives, and 3 being novel predictions that need to be experimentally validated.
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Figure 2.7: MYC-E2F1 miRNA-mediated network model for cell proliferation. A network
of proliferative and anti-proliferative miRNAs interacting with MYC and E2F1 predicted
by IntegraMiR. This network consists of 18 distinct FFLs: 8 Type I coherent, 2 Type II-
A coherent, and 8 Type II-A incoherent. Green edges depict true-positive miRNA-target
interactions identified by the predictive module of IntegraMiR, the brown edge predicts
a false-negative miRNA-target interaction, and the red edges depict novel miRNA-target
interactions.
From a mechanistic point of view, the negative feedback loops and incoherent FFLs
on the left-hand-side of Fig. 2.7 ensure a tightly controlled regulation of cell proliferation.
It has been argued in [102] that high levels of E2F proteins, especially E2F1, can induce
apoptosis, and the negative feedback with miR-17 and miR-20a may dampen E2F activity
following a physiologic proliferative signal, thereby promoting cell division rather than cel-
lular death. On the other hand, the double-negative feedback loops and coherent FFLs on
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the right-hand-side of Fig. 2.7 suggest anti-proliferative roles for the corresponding miR-
NAs, since these interactions repress MYC/E2F1 induced proliferation. As we mentioned
before in our discussion related to Fig. 2.4E, miR-24 and miR-29a exhibit tumor-suppressor
roles, which is compatible with the network depicted in Fig. 2.7. The miRNA let-7a has
also been given a tumor-suppressor role in PCa [35], as well as in lung and renal can-
cers [95, 110].
2.3.6 Tumor-suppressor Roles for MiR-24,
MiR-29a and MiR-145 in PCa
IntegraMiR identifies a large number of deregulated miRNA-target interactions in the
four pathways we consider in this dissertation: 906 interactions in the TFG-β Signal-
ing Pathway, 1,610 interactions in the WNT Signaling Pathway, 1,017 interactions in the
Prostate Cancer Pathway, and 895 interactions in the Adherens Junction Pathway – see
Supplementary Table S11 in [1]. These pairs can potentially be used to form Type III
regulatory loops.
To illustrate the functional scope and relevance of these interactions, we focus on the
top three miRNAs depicted in Fig. 2.4B found by IntegraMiR to be significantly downreg-
ulated. These are the tumor suppressor miRNAs miR-24, miR-29a, and miR-145 studied in
Fig. 2.4E. Using these miRNAs, we considered the deregulated miRNA-target interactions
predicted by IntegraMiR and identified, as an example, those interactions relevant to the
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KEGG Prostate Cancer Pathway. IntegraMiR predicts a considerable number of deregu-
lated interactions (45 for miR-24, 41 for miR-29a, and 40 for miR-145) with many com-
mon targets in this pathway. This may further be used to support the collaborative, tumor-
suppressor role of these miRNAs in PCa, despite the fact that their predicted, genome-wide
co-targeting features are relatively not much pronounced – see Fig. 2.4E.
By using Supplementary Table S11 in [1], we also identified the consistently deregu-
lated Type III regulatory loops associated with the three miRNAs, miR-24, miR-29a, and
miR-145, in the KEGG Prostate Cancer Pathway by excluding the missing pathway interac-
tions as well as interactions with indirect effects, as defined by the KEGG database [69, 70].
We depict the results in Fig. 2.8. From all predicted interactions, only the interaction be-
tween miR-145 and IGF1R, a product of the GFR gene, as well as the interaction between
miR-29a and PIK3R1, a product of the PI3K, are known (i.e., are true-positives). It turns
out that several Type III loops predicted by IntegraMiR encompass genes that have es-
tablished oncogenic roles, such as the genes in the PI3K-Akt backbone and the RAS and
RAF genes in the MAPK signaling section of the pathway. This observation thus provides
further support for the tumor-suppressor roles of these miRNAs in PCa.
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Figure 2.8: Predicted deregulated Type III regulatory loops in the Prostate Cancer Pathway.
Portion of the Prostate Cancer Pathway, adopted from the KEGG database, with the targets
of miR-24, miR-29a and miR-145 that participate in deregulated Type III loops being color-
coded. One example of a deregulated Type III loop is shown for each miRNA. All depicted
Type III loops are consistent, in the sense that the corresponding miRNA-target interactions
are anti-correlated according to the data.
2.3.7 A Novel Regulatory Circuit for
Epithelial-to-Mesenchymal Transition (EMT)
EMT is a complex gene expression program characterized by loss of cell adhesion
through repression of CDH1 (E-cadherin) and activation of genes associated with motility,
invasion and stemness [28]. EMT is activated during embryonic development and adult tis-
sue remodeling. In epithelium-derived tumors however, EMT seizes to promote metastasis
and gain of stem cell phenotypes [117]. Since modulation of CDH1 expression levels is
considered to be a major theme of epithelial plasticity, both in non-oncogenic and onco-
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genic EMT, we sought to construct and investigate an integrated circuit that controls EMT
in PCa based on IntegraMiR predictions.
A natural approach towards this goal is to first identify the most relevant molecular
species to build an initial network and subsequently expand this network with additional
species. Since our main interest here is to determine FFLs mainly involved in pathological
conditions related to EMT and since the most common biochemical change associated with
EMT is loss of CDH1 expression, we decided to focus on CDH1 repressors and their cor-
responding regulatory network. CDH1 transcriptional repressors, such as SNAI1 (SNAIL),
SNAI2 (SLUG), ZEB1, ZEB2 (SIP1), E12/E47, and TWIST have traditionally been impli-
cated in promoting EMT in various systems of embryonic development and tumor progres-
sion [28, 100]. Among these repressors, we found that SNAI2 and ZEB1 are associated
with FFLs predicted by IntegraMiR – see Supplementary Tables S5-S10 in [1]. It is impor-
tant to note that the TGF-β Signaling Pathway induces the transcription of SNAI2 (SLUG),
which in turn activates ZEB1 [103, 167]. Furthermore, the miR-200 family of miRNAs
(miR-200a, miR-200b, miR-200c, miR-141 and miR-429) has been shown to play a major
role in EMT [28, 48]. Among the family members, miR-200b, miR-200c and miR-141
have been identified by IntegraMiR to be significantly deregulated in PCa – see Table 2.2.
To delineate a basic network for EMT regulation, we first single out all deregulated
FFLs whose nodes comprise only entries among the molecular species we have identified:
miR-200b, miR-200c, miR-141, CDH1, SNAI2, and ZEB1. These FFLs are deemed to be
consistently deregulated by IntegraMiR. For miR-141, we discovered two loops whereas
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Figure 2.9: Predicted regulatory circuits controlling EMT. (A) An initial regulatory cir-
cuit, predicted by IntegraMiR, controlling EMT in PCa through regulation of CDH1 (E-
cadherin) transcriptional repressors. This network consists of 14 distinct FFLs: 2 Type I
coherent, 5 Type I incoherent, 2 Type II-A coherent, and 5 Type II-B incoherent. (B) The
five FFLs predicted to be (consistently) deregulated in PCa by IntegraMiR comprising
miR-200b, miR-200c, or miR-141, and GATA3 and TGFBR3. (C) The nine deregulated
miRNA-target interactions involving miR-200b, miR-200c, and miR-141 as well as the
TGFB ligands and receptors. (D) An extended integrated regulatory circuit, predicted by
IntegraMiR, controlling EMT through TGF-β signaling and regulation of CDH1 transcrip-
tional repressors. In these figures, green edges depict true-positive miRNA-target inter-
actions identified by the predictive module of IntegraMiR, brown edges represent false-
negative miRNA-target interactions, whereas red edges depict novel miRNA-target inter-
actions.
for miR-200b and miR-200c, we discovered six loops for each miRNA with identical types.
We then constructed the network depicted in Fig. 2.9A by combining these FFLs.
To extend this basic network, we regard the fact that TGF-β signaling induces the tran-
scription of SNAI2 and consider the recent discovery that SNAI2 and TGF-β signaling
interact in a positive feedback loop [30, 100]. We then hypothesized that we may observe
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a (mutually) inhibitory relation between members of the miR-200 family and upstream
factors in TGF-β signaling due to the fact that these miRNAs interact with SNAI2 in a mu-
tually inhibitory fashion, as predicted by the network depicted in Fig. 2.9A. To constrain
this investigation to a tractable number of transcripts, among the numerous transcripts
associated with TGF-β signaling, we focus on the very first elements of this pathway:
three TGFB isoforms (TGFB1, TGFB2, TGFB3) and three TGFB receptors (TGFBR1,
TGFBR2, TGFBR3).
We should note here that, among TGFB cell surface receptors, TGFBR3 has the most
abundant expression and it shows the highest affinity for binding TGFB2 ligand among all
three TGFB ligand isoforms. While TGFBR3 does not have a functional kinase domain
to activate TGF-β signaling, it helps TGFB ligands be presented to TGFBR2, which leads
to the association and phosphorylation of TGFBR1 and subsequent activation of TGF-β
signaling by phosphorylation of SMAD2 or SMAD3 proteins [36]. Reduced or loss of
TGFBR3 expression has been observed in many types of cancer, such as prostate, pancre-
atic, breast, renal, and lung cancer [25, 34, 39, 47, 157].
We identified all FFLs predicted to be deregulated by IntegraMiR (see Supplementary
Tables S5-S10 in [1]) comprising miR-200b, miR-200c, or miR-141, and one of the TGFB
ligand isoforms or one of the TGFB receptors. This produced the three Type I coherent
and the two Type II-A incoherent FFLs depicted in Fig. 2.9B all of which are deemed to
be consistently deregulated in the data. We also identified all deregulated miRNA-target
interactions for miR-200b, miR-200c, and miR-141 associated with the KEGG TGF-β
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Signalling Pathway (see Supplementary Table S11 in [1]), with the target being one of the
TGFB ligand isoforms or one of the TGFB receptors. We depict the results in Fig. 2.9C,
which shows that each of these miRNAs targets TGFB2, TGFBR1, and TGFBR2. Among
these interactions, only TGFB2 has been experimentally verified to be a target of miR-141
according to miRTarBase.
By incorporating the results depicted in Figs. 2.9A-C, we obtain the extended circuit
for EMT regulation depicted in Fig. 2.9D. To simplify presentation, we lump specific inter-
actions of the miRNAs with individual TGFB receptors in a single block. Interestingly, this
circuit predicts a mutually inhibitory relation between miR-200b, miR-200c and GATA3, a
recently discovered transcriptional activator for TGFBR3 [24]. Moreover, miR-200b, miR-
200c, and miR-141 are predicted to repress the upstream TGFB2 ligand and receptors in a
Type III regulatory loop. The resulting integrated regulatory circuit provides a hypothesis
for a novel and more comprehensive model for regulation of EMT at the transcriptional,
post-transcriptional and signaling levels, by means of miR-200 family members, TGF-β
signaling and the corresponding transcriptional program.
2.3.8 A Relatively Comprehensive Model for
PCa Development
To discern the effectiveness of the integrative analyses we carry out in this study, we
combined information from the results depicted in Fig. 2.7 and Fig. 2.8, as well as cur-
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rent knowledge of certain crucial genetic and epigenetic alterations in PCa (which we will
be discussing shortly), to delineate the model depicted in Fig. 2.10. This model encapsu-
lates some major sources of deregulation in PCa at the transcriptional, post-transcriptional,
signaling, and genetic/epigenetic levels, as opposed to models that only consider deregu-
lation at just one level, which may not be capable of capturing the overall behavior of the
underlying network. We use this model to discuss how genetic and epigenetic alterations
could propagate in cellular regulatory networks through circuits identified in this study and,
therefore, adversely affect gene regulation. These pieces of crucial information represent a
relatively comprehensive model for PCa development.
It has been demonstrated that chromosomal translocation involving TMPRSS2 (PSA-
regulated gene transmembrane protease, serine 2), an androgen receptor (AR)-regulated
gene, and a member of the ETS family of TFs (predominantly ERG) is present in about
half of all PCa cases [152]. This rearrangement in prostate cancer leads to androgenic
induction of ERG expression (see Fig. 2.10) and the critical outcomes associated with its
overexpression in PCa [151]. In particular, it has been suggested that ERG overexpres-
sion in PCa may contribute to the neoplastic process by activating MYC and by abrogat-
ing prostate epithelial differentiation [144]. Moreover, global analysis of copy-number
alterations (CNAs) in PCa has reported dramatic amplifications of oncogenes, such as
MYC (on 8q24.21) and AR (Xq12), deletions of tumor suppressor genes, such as PTEN
(10q23.31), RB1 (13q14.2), TP53 (17p31.1) and CDKN1B (due to the broader deletion of
the 12p13.31-p12.3 genomic region), and interstitial 21q22.2-3 deletion spanning ERG and
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Figure 2.10: Integrative miRNA-mediated model for PCa development. A snapshot of a
high-level integrative miRNA-mediated model for PCa development which encapsulates
major sources of deregulation at the transcriptional, post-transcriptional, and signaling lev-
els, coupled with genetic and epigenetic alterations.
TMPRSS2 [150]. Finally, based on the integration of CNA, transcriptome and mutation
data, it was found that PI3K, RAS/RAF and RB1 signaling were commonly altered in pri-
mary tumors and metastases [150]. Moreover, it was stated that the data provided strong
rationale for exploring the clinical activity of PI3K pathway inhibitors.
Interestingly, the findings depicted in Figs. 2.7 and 2.8 characterize miR-24, miR-29a,
and miR-145, which are identified by IntegraMiR to be significantly downregulated, as
inhibitors of the PI3K/AKT, RAS/RAF/ERK and RB1 signaling pathways through specific
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FFLs and Type III loops, as depicted in Fig. 2.10, and suggest tumor suppressor roles
for these miRNAs, coordinately cooperating with the tumor suppressors PTEN, CDKN1B
(p27) and RB1 (Rb).
As a notable example, the Rb tumor suppressor gene product in Rb signaling is known
to be a target of CDK2 (cyclin dependent kinase 2). When Rb is dephosphorylated, it
interacts with E2F transcription factors and, in this way, prevents transcription of genes
required for progression through the cell cycle. On the other hand, when Rb is phospho-
rylated by cell cycle dependent kinases, such as CDK2, it no longer interacts with E2F
and the cell cycle proceeds through the G1-S checkpoint. The results depicted in Fig. 2.10
identify miR-29a and miR-145 as potential inhibitors of the CDK2/Cyclin E complex and
E2F through FFLs and Type III regulatory loops and suggest that these miRNAs work in
concert with p27 and Rb tumor suppressors, preventing passage from the G1 to the S phase.
In addition to the previously discussed genetic alterations and their effect on gene reg-
ulation, recent studies have found that miRNAs are both regulated epigenetically and play
roles in epigenetic regulation of protein coding genes in different types of cancer, includ-
ing PCa [71, 90, 96]. A recently validated example, which is relevant to our discussion, is
miR-29a. It was discovered in [90] that the promoter region of miR-29a harbors numer-
ous CpG sites. Moreover, it was determined that the experimentally measured methylation
index of the miR-29a promoter was higher in the PCa cell group than in the prostate ep-
ithelial cell group, resulting in significant downregulation of miR-29a expression in PCa.
More interestingly, miR-29a has been shown to play tumor suppressor roles by reciprocally
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targeting DNA methyltransferases (DNMTs), which are key regulators of methylation of
CpG islands [71, 96, 120].
We summarize these findings in the model depicted in Fig. 2.10, in which the red edges
represent novel interactions predicted by IntegraMiR. In particular, edges emanating from
the three miRNAs that target the two signaling pathways at the bottom represent the novel
miRNA interactions depicted in Fig. 2.8. The resulting model suggests that upregulation
of the oncogene MYC could take place due to genetic amplification and/or by ERG through
TMPRSS2-ERG gene fusion. The upregulated MYC could then initiate a proliferative pro-
gram, for instance, through the depicted MYC-E2F interaction, as well as by inhibiting
the tumor suppressor miR-29a. In addition, other genetic and epigenetic alterations, for
instance hypermethylation of miR-29a or deletion of PTEN, p27 and Rb, could further
suppress the level of these tumor suppressor miRNAs and genes, leading to the activation
of PI3K/AKT, RAS/RAF/ERK and RB signaling, and a consequent uncontrolled cellular
growth.
It is important to emphasize at this point that miRNAs have attracted attention due to
their diagnostic as well as therapeutic potential. Inactivating oncogenic miRNAs or restor-
ing tumor suppressor miRNAs offers great prospects for cancer therapy [98, 99, 101, 107,
127]. As an important practical application, chromatin-modifying drugs, such as DNA
methylation inhibitors, can be used to reactivate hypermethylated tumor suppressor miR-
NAs. Two DNMT inhibitors, 5-azacytidine and 5-aza-2′-deoxycytidine, have indeed been
approved by the US Food and Drug Administration (FDA) for the treatment of myelodys-
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plastic syndromes and acute myeloid leukemia [122].
2.4 Discussion and Conclusions
Earlier computational tools have focused primarily on identifying pairwise miRNA-
target and TF-target interactions, either by relying on sequence-based analysis or expres-
sion data [8, 51, 126]. As a consequence, they may produce an excessively large number
of false-positive predictions making them inefficient for experimental follow-up.
More recently, two promising methods have been proposed to identify miRNA/TF in-
teractions [17, 174], which are based on the hypothesis that certain regulatory circuits,
defined as motifs [3], appear in a statistically over-represented manner in the human and
mouse genomes [155]. However, and for a given motif structure (e.g., an FFL), these meth-
ods attempt to predict all interactions (the three edges of an FFL) by utilizing a narrow set
of computational tools and limited biological information. Although the methods can be
employed to provide insights into the prevalence of various motif instances in gene reg-
ulatory networks, the user must keep in mind that the results may contain a rather large
number of possibly unreliable predictions for experimental validation due to the fact that
these methods do not effectively utilize certain known biological information to appropri-
ately constrain and systematically reduce the resulting predictions.
In this research work, we introduced IntegraMiR, a novel computational method for
inferring deregulated miRNA/TF-mediated regulatory loops and networks that appear in a
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statistically over-represented manner in gene regulatory networks. IntegraMiR addresses
the previous problems by appropriately constraining the statistical analysis of given
mRNA/miRNA expression data and sequence-based target identification methods using rel-
evant motif structures built by “prior” biological information readily available in existing
databases. The main strength of IntegraMiR originates from its capacity to fuse information
from multiple sources and incorporate several statistical techniques to exploit almost any
accessible aspect of available information in the expression data to identify integrated reg-
ulatory loops and networks at the transcriptional, post-transcriptional and signaling levels.
Therefore, IntegraMiR adds to the ongoing effort of developing effective computational
techniques for network identification by utilizing available experimental data and existing
biological knowledge in an effort to produce reliable predictions in a context-dependent
manner.
To appropriately constrain the problem of predicting miRNA-target interactions, Inte-
graMiR focuses on specific types of three-node regulatory motifs and, in particular, FFLs
that have attracted a great deal of attention in the literature. It is important to mention here
that, in contrast to earlier work, such as that in [174], by identifying instances of deregu-
lated FFL motifs and by using these motifs to construct interaction networks, IntegraMiR
can also provide instances of two types of deregulated two-node motifs: miRNA-TF nega-
tive and double-negative feedback loops – see Figs. 2.6B, 2.7, and 2.9D.
IntegraMiR identified a number of already validated and novel deregulated miRNA/TF-
mediated interactions. Although our interest was focused on certain types of regulatory
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loops deregulated in PCa, the basic method can be easily modified to handle any other type
of regulatory motif of interest and can be readily applied to other types of human disease,
provided that appropriate miRNA and mRNA expression data are available. The results
discussed in Section 2.3 demonstrate that IntegraMiR is a powerful computational tool for
miRNA/TF-mediated network prediction, which can effectively result in novel hypotheses
for further experimental study and validation. We should point out that the output results
produced by IntegraMiR can be used by interested investigators to formulate additional hy-
potheses for experimental validation, beyond the ones discussed in this dissertation, which
are expected to lead to additional novel findings.
IntegraMiR labels identified motifs into consistent and inconsistent loops, based on the
rules depicted in Fig. 2.3 (see also Section 2.2.9). This is an additional piece of informa-
tion that can be considered when evaluating the obtained results before carrying out exper-
imental validation, when one seeks evidence based on expression data. As an illustrative
example, we depict in Fig. 2.11 two loops considered in Section 2.3 – see Fig. 2.6A. These
are instances of a Type I coherent FFL, with the green edges representing true-positive pre-
dictions and the red edge representing a novel interaction. The FFL depicted in Fig. 2.11A
is identified by IntegraMiR to be consistently deregulated based on the data, whereas the
FFL depicted in Fig. 2.11B is identified to be deregulated inconsistently.
The consistency of the deregulated FFL depicted in Fig. 2.11A implies that there is
supporting evidence in the expression data to corroborate the intended reinforcing func-
tion modeled by this FFL. More specifically, when comparing tumor versus normal, the
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Figure 2.11: Examples of consistently and inconsistently deregulated FFLs identified
by IntegraMiR. (A) A consistently deregulated Type I coherent FFL. (B) An inconsis-
tently deregulated Type I coherent FFL. The green edges represent true-positive predic-
tions whereas the red edge represents a novel prediction. The black edges represent known
interactions.
observed significant upregulation of miR-200b leads to significant downregulation of the
transcription factor SNAI2 (SLUG) and to a consequent downregulation of ZEB1. On
the other hand, the inconsistency of the deregulated FFL depicted in Fig. 2.11B originates
from the fact that, although the upstream inhibitor miR-125b is found by IntegraMiR to
be significantly downregulated, and the opposite is true for the transcription factor TP53
(P53), the target gene BBC3 (PUMA) shows downregulation at the transcript level, which
is contrary to the expected function modeled by this FFL.
Although all three interactions in an FFL, such as the one depicted in Fig. 2.11B, may
have been experimentally validated individually, we may still not be able to observe con-
sistent deregulation among the FFL nodes at the transcript level. This situation may occur
due to a number of biological or technical factors. For example, the known miRNA-target
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interactions available in miRTarBase may experimentally have been validated in certain
cell type(s) and tissue(s) and may not take place in the context of interest (prostate tissue in
our case). On the other hand, microarray experiments may not be able to capture the effect
of translational repression by a miRNA (e.g., when this repression does not occur through
mRNA degradation) or the fact that the mRNA level of a TF may not serve as a proxy for
the corresponding protein-level activity. For example, in the case depicted in Fig. 2.11B,
although miR-125b is downregulated and the transcription factor TP53 transcript is upreg-
ulated based on the expression data, we may not have a high level of active TP53 protein in
the nucleus that sufficiently correlates with the abundance of TP53 mRNA transcripts. As
a result, the target BBC3 gene may not be transcribed in proportion to the level of the TP53
transcript. In addition to the above, each node in an FFL may not necessarily participate
only in that specific FFL and there can be numerous FFLs identified for certain nodes. This
means that, by focusing on just one FFL, we may not be able to capture the relevant overall
behavior. To do so, we may have to consider all collaborating FFLs in concert, which could
potentially provide a more accurate and comprehensive representation of gene regulation
for a specific gene of interest (we did this in several settings discussed in Section 2.3). Fi-
nally, alternate effects due to mechanisms other than FFL regulation, such as alterations at
the genetic and epigenetic levels, could give rise to behaviors and observations that cannot
be modeled by FFLs.
As we mentioned before, the two key hypotheses behind our interest in Type III loop
motifs are that miRNAs play major roles in regulating signaling pathways due to their
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GF GFR PI3K GFR PI3K
miR-29a miR-29a miR-24 miR-145
BA
Figure 2.12: Complex regulatory motifs can be constructed from results obtained by Inte-
graMiR. (A) SIM motif of GF, GFR, and PI3K genes targeted by miR-29a in the KEGG
prostate cancer pathway. (B) DOR motif of GFR and PI3K co-targeting by miR-29a, miR-
24, and miR-145 in the KEGG prostate cancer pathway.
sharp dose-sensitive nature, and that targets of single miRNAs are more connected (i.e.,
interact) at the protein level than expected by chance. IntegraMiR identifies closely related
miRNA targets on pathways deemed to be important in PCa and delineates certain miRNA-
mediated three-node regulatory loops in the KEGG Prostate Cancer Pathway. As an exam-
ple, we refer to the two consecutive Type III loops for miR-29a depicted in Fig. 2.12A,
which have been constructed from the results depicted in Fig. 2.8. The obtained mecha-
nism of a single miRNA regulating several closely related genes typically working together
to perform a common task represents a single-input module (SIM) motif [3]. SIMs can par-
tially explain how individual miRNAs could be potent regulators of pathway activity even
though the effect of the miRNA on any single gene target may be modest [6, 131, 156].
It has also been demonstrated in [156] that targeting of a set of genes by multiple miR-
NAs could produce effects that are much more dramatic than the modest effects exerted by
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individual miRNAs. A notable example identified by IntegraMiR in the KEGG Prostate
Cancer Pathway is the co-targeting of GFR and PI3K genes by miR-29a, miR-24 and
miR-145 depicted in Fig. 2.12B (which has been constructed from the results depicted
in Fig. 2.8). The resulting network structure represents a dense overlapping regulon (DOR)
motif [3] in which several input miRNAs co-regulate a set of output genes (known as a
regulon). Co-targeting in a DOR pattern presumably strengthens the notion that the miR-
NAs involved share similar regulatory roles. It is noteworthy that IntegraMiR can identify
numerous examples of miRNA co-targeting in the context of FFLs as well – see Fig. 2.7.
Clearly, the three-node loop motifs considered in this dissertation can serve as basic build-
ing blocks for identifying more complex regulatory motifs, such as SIMs and DORs [2, 26].
In principle, discoveries obtained by integrative computational approaches, similar to
IntegraMiR, can provide systemic insights into the molecular biology of miRNA-mediated
interactions and can, thereby, assign context-dependent biological functions to poorly un-






In Chapter 2, we looked into how certain gene regulatory loops can provide systemic in-
sights into the molecular biology of miRNA-mediated interactions and can, thereby, assign
context-dependent biological functions to poorly understood roles of miRNAs. Consistent
with the recent findings on miRNA networks, we argued that effective drug targeting and
successful disease treatments will eventually be realized through these molecular mecha-
nisms underlying physiological and pathological conditions of interest and that miRNAs
pose promising potential in this context.
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DISORDERS
In this chapter, we will investigate, as an application of our previous work on miRNA/TF
loop and network identification, the role of LIN28-regulated miRNAs and their networks
in Autism Spectrum Disorders (ASDs). Recent discoveries have provided experimental
evidence that miRNAs could also play a crucial role in the post-transcriptional regulation
of gene expression in neurons and diseases associated with neuronal growth and synaptic
function. These include autism spectrum disorders, as the category of our interest.
To this end, we will first provide the biological background of this research. Then, we
will propose a novel biological hypothesis whose validity we will investigate by combining
our computational research work together with the experimental work of our collaborators
(Dr. Mollie Meffert’s lab at the School of Medicine). Next, we will present a bioinformat-
ics analysis we carried out in order to assess the statistical significance of enrichment of
predicted targets of LIN28-regulated miRNAs in ASD-related genes. We performed this
analysis using publicly available datasets, which include gene expression levels in distinct
contexts of interest as well as computationally predicted miRNA targets. Our objective
was to provide evidence for guiding costly and time-consuming experiments for valida-
tion. We also used experimental data, provided by our collaborators, to validate part of our
computational analysis. At the end of this chapter, we will discuss the clinical utility and
translational impact of this research and provide further discussion and conclusions.
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3.1 Biological Background
It is well known that the regulation of gene expression at the level of translation is a
critical factor in the neuronal response to several stimuli, including synaptic activity [60]
and neurotrophins [130], among others. A well-studied example of such a stimulus is the
Brain-Derived Neurotrophic Factor (BDNF), which is broadly expressed in the mammalian
brain and critically contributes to modifications of synaptic growth and function. BDNF
selectively targets an estimated 4% or less of expressed mRNAs that undergo enhanced
translation [130], which we discuss in more detail later in this section. Moreover, it was ex-
perimentally determined in [59] that the function of the miRNA biogenesis pathway plays
a pivotal role in BDNF-mediated regulation of translation. Here, we will briefly review
an experimentally identified and validated mechanism that mediates target specificity in
BDNF-regulated translation. This review will lay the biological foundation of our research
work.
To investigate the role of miRNAs in BDNF translation specificity, it was examined
in [59] whether BDNF itself might affect the miRNA biogenesis pathway. By using miRNA
arrays, an overall pattern was observed toward higher miRNA abundance in BDNF-treated
versus mock-treated primary neurons, which indicates that BDNF might regulate a key
component of miRNA biogenesis, such as the DICER processing complex. It was indeed
validated in [59] that BDNF causes a distinct transcription-independent increase in DICER
levels in BDNF-stimulated neurons. As a matter of fact, it is known that BDNF binds
to TRKB receptors and this binding triggers growth- and survival-promoting pathways,
83
CHAPTER 3. MICRORNA-MEDIATED NETWORKS IN AUTISM SPECTRUM
DISORDERS
including the PI3K/AKT and MAPK/ERK signaling pathways. A previous research in
tumor cell lines reported that a component of the DICER complex, HIV-1 TAR RNA-
binding protein (TRBP), could undergo ERK-dependent phosphorylation and this could
lead to the stabilization and enhancement of DICER levels [113]. It was also verified in [59]
that BDNF rapidly causes the induction of phospho-ERK and a multi-banding pattern of
TRBP. This can explain the observed elevated levels of DICER, which could invoke mature
miRNA biogenesis. With elevated levels of miRNAs, additional mRNAs could be targeted
for repression.
It was also examined in [59] whether the miRNA biogenesis pathway could also be
regulated to positively select BDNF-upregulated targets in protein synthesis. Based on
miRNA array experiments, a small number of miRNAs were found to be decreased in
response to BDNF, including several members of the let-7 family of miRNAs.
In addition, it is known that miRNA biogenesis can be regulated at several steps by
trans-acting factors, such as the LIN28 RNA-binding proteins [55], which target let-7 fam-
ily members. Once LIN28 binds to the pre-miRNA molecule, it causes the uridylation
of the molecule. As a result, it suppresses processing of targeted pre-miRNA to mature
miRNA [55]. This could in fact present a mechanism to reduce specific mature miRNAs
even when the DICER level is elevated. Notably, it was experimentally observed in [59]
that, following BDNF exposure, a rapid and transcription-independent increase in LIN28a
takes place.
Previous research showed that the terminal loop of each of let-7, miR-107 and miR-143
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pre-miRNAs has a functionally confirmed “GGAG” sequence motif that is recognized by
LIN28 [50, 55]. By using individual qRT-PCR assays, it was observed that BDNF induces
a significant and reproducible decrease in the abundance of all tested members of the let-7
family, as well as miR-107 and miR-143, even though not all decreases were reproducibly
detected using less sensitive miRNA assays.
The previous results led to the following hypothesis: if LIN28 positively selects BDNF-
upregulated targets by binding to specific pre-miRNAs and decreasing their mature miR-
NAs, then a mRNA transcript that contains functional sites for a LIN28-downregulated
miRNA would be expected to show BDNF-enhanced translation. To test this hypoth-
esis, the existence of binding sites for LIN28-regulated miRNAs in the 3’UTR regions
of mRNA transcripts was examined in [59], known to undergo upregulation, downregu-
lation or no change in terms of the level of their translation. It was found that thirteen
representative BDNF-upregulated targets contain two or more binding sites for a LIN28-
regulated miRNA. However, BDNF-downregulated or unregulated targets did not contain
such sites [59]. To directly test the role of LIN28a in BDNF target mRNA selection, it
was experimentally validated in [59] that depletion of LIN28a, through RNAi or LIN28a
knockdown, prevented the enhanced translation of representative mRNA targets that are
normally upregulated by BDNF. Moreover, these targets, which are normally derepressed
and upregulated by BDNF, were observed to remain repressed in LIN28a-deficient neurons.
As a consequence of these results, a coordinated mechanism was established for genome-
wide control of translation specificity that involves BDNF-dependent positive and nega-
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tive regulation of the miRNA biogenesis pathway, which involves the combined action
of BDNF on DICER and LIN28a [59]. Although it is possible that alternative mecha-
nisms may coexist, the experimental results obtained in [59] strongly suggest that the dual
control of the miRNA biogenesis pathway by BDNF through LIN28a and DICER plays
a crucial role in selectively determining both upregulated and downregulated targets in
BDNF-mediated translation.
3.2 Biological Hypothesis
In [59], it was demonstrated that LIN28 was required for neurotrophin-induced trans-
lation of suites of genes that collectively contribute to synaptic growth and plasticity. In
particular, LIN28 selectively binds to and causes the degradation of the let-7 family of
miRNAs that suppress many pro-growth genes under basal conditions. This function of
one of the let-7 family members, i.e. let-7a, is consistently demonstrated in Fig. 2.7 of
Chapter 2 in the context of prostate cancer. It was discussed in that chapter that the let-
7a miRNA, being present in certain coherent Feed-Forward Loops, suppresses MYC-E2F1
genes that promote cell growth. As a result, our previous research work identified let-7a as
an anti-proliferative miRNA.
On the other hand, it was experimentally validated in [59] that the prevention of LIN28-
mediated downregulation of let-7 family of miRNAs can completely block neuronal growth
responses to BDNF. Congruent with this observation, the LIN28/let-7 axis has been recog-
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nized as a highly evolutionarily-conserved pathway that controls growth and development.
Interestingly, recent experimental investigation by our collaborators has revealed dysregu-
lation of the LIN28/let-7 axis in a mouse model of Fragile X Syndrome (FXS). FXS is an
autism spectrum disorder disease, and as such, it is the most commonly inherited form of
mental disability. It is caused by the expansion of CGG repeats in the promoter of FMR1,
which leads to the hypermethylation and transcriptional silencing of the FMR1 gene prod-
uct, the Fragile X mental retardation protein (FMRP). FMRP is essential for normal cog-
nitive development since it binds to a large number of mRNAs in neurons and regulates
targets in the hub of key signaling pathways.
The FMR1 knockout (KO) mouse model for FXS recapitulates many of the synaptic and
behavioral phenotypes found in FXS, including synaptic/neuronal overgrowth and cogni-
tive disorders. Using this model, and based on the previous biological facts and findings,
we plan in this research work to investigate the following novel biological hypothesis:
Dysregulation of LIN28-regulated miRNAs may lead, through their network of
interactions, to a selective overabundance of growth-promoting synaptic pro-
teins that could account for synaptic and cognitive functions in FXS.
3.3 Methods
To investigate the previous hypothesis, we focused on answering the following ques-
tions:
(i) Are predicted targets of LIN28-regulated miRNAs enriched in autism-related genes?
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(ii) Can we identify type III loops that comprise LIN28-regulated miRNAs and genes
that are directly related to and significantly upregulated in the disease state? Can we
construct a network of interactions of these miRNAs and genes? Among the pre-
dicted targets of LIN28-regulated miRNAs, which directly related and upregulated
genes will be in the predicted network? What is the structure of this network in terms
of coordinated functions of LIN28-regulated miRNAs?
(iii) Can the predicted LIN28-regulated miRNA-target interactions in the computation-
ally constructed networks be experimentally validated? Validation requires a series
of focused experiments that would provide supporting experimental evidence as to
whether the dysregulation of LIN28-regulated miRNAs is indeed contributing to the
dysregulation of growth-promoting synaptic proteins, and therefore contribute to the
disease state.
To answer the question in (i), we need to assess the statistical significance of enrichment
of predicted targets of LIN28-regulated miRNAs in ASD-related genes. To accomplish this
task, we perform two distinct sets of analyses based on independent studies and databases
in the context of ASDs. For this purpose, we use the R software package WGCNA to
perform the enrichment analysis based on the hypergeometric test [82].
The conceptual reasoning behind using the hypergeometric test is that, there is some
reference set of genes, and that these genes can be divided into two classes: those that
are interesting (autism-related for example), and those that are not. In addition, there are
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other important gene characteristics, such as a gene belonging to a particular category, for
example by being a predicted target of a given miRNA. Moreover, one would like to ask
whether there is an association between a gene being interesting and having a particular
property. In this case, the hypergeometric test quantifies the significance of enrichment of
genes having that particular property among those interesting genes by a P-value [82]. We
perform this test for gene sets representing available predicted targets of the let-7 family of
miRNAs (the 9 miRNAs let7a-g, let7i, as well as miR-98). We also perform this test for the
gene set representing predicted targets of miR-9, and we do the same for miR-107, as well
as for miR-143, three additional miRNAs known to be regulated by LIN28. In addition, we
perform the test for the gene set obtained by combining all genes predicted to be targeted
by the previous 12 LIN28-regulated miRNAs of interest. Finally, we perform the test for
miR-122, a liver-specific miRNA that is not regulated by LIN28, which we use as a control.
The reason we also use the combined set of genes is because, although miRNAs are
known to have subtle effects on protein levels of individual targets, given the multiplicity of
their targets and the concurrent downregulation of several of these targets, their cumulative
influence can significantly affect the outcomes controlled by cellular pathways. We looked
into several examples of this kind in the context of regulatory loops in Chapter 2 - see
Figs. 2.6-2.12. With this known fact, we expect to find that the predicted targets of a
specific miRNA may not be enriched in a particular set of genes related to a certain cellular
function. However, when we incorporate the targets of other miRNAs cooperating with
this miRNA for the same cellular function, we may find that the collective set is enriched
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in the gene set of interest, e.g. autism-related genes based on a specific study or database.
For each of the two autism-related enrichment analyses we perform here, we employ
three types of gene lists: i) a reference list of expressed genes, ii) lists comprised of genes
that are predicted to be miRNA targets as we discussed above, and iii) a test list of genes
that are associated with autism. Each analysis will focus on discovering enrichment of a
target gene set in the test gene list corresponding to the particular analysis.
We considered two reference gene lists that we deemed to be reliable and relevant to the
study. The reference list we used in our first analysis was obtained from a recent RNASeq
expression study at Johns Hopkins [49], which comprises 57 control and 47 autism sam-
ples. By following a practical approach to exclude genes that show negligible expression
levels, we included only those genes in the reference gene list that exhibit a normalized
and transformed read count value greater than 1 in at least 10% of the available samples.
This resulted in a reference list comprising 17,693 expressed genes, which we refer to as
REFLIST1.
On the other hand, we obtained the reference gene list we used in our second analysis
from the Brainspan database (www.brainspan.org), which comprises 525 samples associ-
ated with the hippocampus or the cortex of young and old individuals. We included in this
list only genes that exhibit an RPKM value greater than 1 in at least 10% of the samples.
This resulted in a list comprising 14,890 expressed genes, which we refer to as REFLIST2.
To construct the predicated gene lists, we extracted the sequence-based predicted tar-
gets of the 12 LIN28-regulated miRNAs of interest from the TargetScan database (v.7)
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(http://www.targetscan.org), and selected genes based on their 3UTR region and a seed
length of 7.
Finally, we constructed two test gene lists. For the first enrichment analysis, we consid-
ered a list of 749 differentially expressed genes in autism, obtained from [49]. As required
by the hypergeometric test, we matched these genes with the genes in REFLIST1, which
was also obtained from the same study. By doing so, we obtained 702 differentially ex-
pressed genes that formed our first test list, which we refer to as the HOPKINS list. For
the second analysis, we considered a list of 631 autism-associated genes, obtained from
the Simons Foundation Autism Research Initiative (SFARI) database (SFARI.org). We
then matched these genes with the genes in REFLIST2 and obtained 550 autism associated
genes that formed our second test list, which we refer to as the SFARI list.
Before proceeding with our first enrichment analysis, we visualize in Fig. 3.1 the overall
enrichment of predicted targets of the 12 LIN28-regulated miRNAs we consider in this
study versus non-targets in autism-related genes. Moreover, we depict in Fig. 3.2, the
number of autism-related genes in the HOPKINS list that are predicted to be targeted by a
miRNA of interest. These results indicate that there is some enrichment of predicted targets
of LIN28-regulated miRNAs in autism-related genes, although it is not clear whether this
enrichment is statistically significant. However, by performing statistical analysis using the
hypergeometric test, and by including miR-122 as control, we obtain the results depicted
in Table 3.1. All target sets, except the ones corresponding to let-7 and miR-122, show
statistically significant enrichment in autism-related genes (Bonferroni adjusted p-value
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Figure 3.1: (A) Proportion of genes predicted to be targeted by the LIN28-regulated miR-
NAs in the REFLIST1 gene list. G1: Predicted targets of LIN28-regulated miRNAs of
interest in REFLIST1. G2: Genes in REFLIST1 that are not predicted to be targeted by the
LIN28-regulated miRNAs. (B) Proportion of autism-related genes predicted to be targeted
by the LIN28-regulated miRNAs in the HOPKINS gene list. G3: Autism-related genes
in the HOPKINS list that are predicted to be targeted by the LIN28-regulated miRNAs.
G4: Autism-related genes in the HOPKINS list that are not predicted to be targeted by
the LIN28-regulated miRNAs. There are 17,693 genes in REFLIST1 and 702 genes in the
HOPKINS list.
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Figure 3.2: Number of autism-related genes (in descending order) in the HOPKINS list
predicted to be targeted by the miRNAs of interest. MiR-122 is used as a control in the
enrichment analysis.
< 0.05). Notably, Fig. 3.2 indicates that miR-122 is predicted to target a larger number
of autism-related genes than let-7. However, the significance of enrichment of its target
set is lower than that of let-7 according to Table 3.1. This reinforces our expectation that
the target set of a given miRNA that targets a large number of autism-related genes is not
necessarily enriched in these genes.
It is important to note here that, although the significance level of enrichment of the
predicted targets associated with let-7 is slightly above 0.05, there are 9 miRNAs in this
family. As we discussed in Chapter 2, miRNAs co-targeting a group of genes are expected
to have an appreciably larger effect on regulating their target set through their cumulative
influence, which is not captured by the hypergeometric test.
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Table 3.1: Statistical significance of enrichment of predicted targets of LIN28-regulated
miRNAs in autism-related genes based on the HOPKINS list, as determined by the hy-
pergeometric test. P-values have been adjusted for multiple testing using Bonferroni cor-
rection. The “pooled” gene set is formed by combining the predicted targets of all 12
LIN28-regulated miRNAs we consider in this study, whereas Let-7 indicates the gene set
of predicted targets of all 9 let-7 family miRNAs (including miR-98). The target set asso-
ciated with miR-122 was used as control.
Since the target gene sets corresponding to LIN28-regulated miRNAs have been found
to be significant, the previous results provide supporting computational evidence that LIN28-
regulated miRNAs could potentially be involved in the regulation of autism-related genes.
As a consequence, dysregulation of these miRNAs and their network of interactions could
be associated with this disease.
To seek further evidence for the role of LIN28-regulated miRNAs in autism, we per-
formed a second analysis based on publicly available gene sets. In particular, we investi-
gated enrichment of predicted targets of LIN28-regulated miRNAs in autism-related genes
using the Brainspan and SFARI databases. Notably, REFLIST2 includes 1,226 genes that
are not included in REFLIST1, a significant number of genes which is more than double
the number of genes in either one of the test lists. More importantly, however, 596 out of
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Figure 3.3: (A) Proportion of genes predicted to be targeted by the LIN28-regulated miR-
NAs in the REFLIST2 gene list. G1: Predicted targets of LIN28-regulated miRNAs of
interest in REFLIST2. G2: Genes in REFLIST2 that are not predicted to be targeted by the
LIN28-regulated miRNAs. (B) Proportion of autism-related genes predicted to be targeted
by the LIN28-regulated miRNAs in the SFARI gene list. G3: Autism-related genes in the
SFARI list that are predicted to be targeted by the LIN28-regulated miRNAs. G4: Autism-
related genes in the SFARI list that are not predicted to be targeted by the LIN28-regulated
miRNAs. There are 14,890 genes in REFLIST2 and 550 genes in the SFARI list.
the 631 autism-related genes obtained from SFARI are not among the 749 differentially-
expressed genes in autism obtained from [49], with the two sets having only 35 common
genes.
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Figure 3.4: Number of autism-related genes (in descending order) in the SFARI list pre-
dicted to be targeted by the miRNAs of interest. MiR-122 is used as a control in the
enrichment analysis.
Similar to what we did in the first analysis, we visualize in Fig. 3.3 and Fig. 3.4 the
overall enrichment of predicted targets of LIN28-regulated miRNAs versus non-targets in
autism-related genes using REFLIST2 and the SFARI list. The results are consistent with
the ones obtained using REFLIST1 and the HOPKINS list, suggesting again that there is
some enrichment of predicted targets of LIN28-regulated miRNAs in autism-related genes.
In terms of statistical significance, the results depicted in Table 3.2 show once more that the
gene sets corresponding to LIN28-regulated miRNAs are significantly enriched in autism-
related genes, although this now is not true for the target gene set corresponding to let-7
when the p-values are adjusted for multiple testing using Bonferroni correction. These
additional results are particularly encouraging, given the small overlap between the SFARI
and HOPKINS datasets, and provides further supporting evidence of our computational
findings.
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Table 3.2: Statistical significance of enrichment of predicted targets of LIN28-regulated
miRNAs in autism-related genes based on the SFARI list, as determined by the hyper-
geometric test. P-values have been adjusted for multiple testing using Bonferroni cor-
rection. The “pooled” gene set is formed by combining the predicted targets of all 12
LIN28-regulated miRNAs we consider in this study, whereas Let-7 indicates the gene set
of predicted targets of all 9 let-7 family miRNAs (including miR-98). The target set asso-
ciated with miR-122 was used as control.
3.4 Results
3.4.1 Predicted LIN28-regulated MiRNA-target
Interaction Networks in FXS
Given the results we obtained from our previous bioninformatics analysis, we sought to
examine whether we could identify predicted targets of LIN28-regulated miRNAs among
relevant genes reported in the literature to be upregulated in the disease state. By doing so,
we could provide answers to the second group of questions in Section 3.3.
We have mentioned before that, for the mouse model of FXS, the FMR1 knockout (KO)
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mouse serves as an appropriate and desirable animal model since it recapitulates many of
the synaptic and behavioral phenotypes found in FXS, including synaptic/neuronal over-
growth and cognitive disorders. Interestingly, in a very recent study with regards to FXS,
systematic protein expression measurements in neocortical synaptic fractions from FMR1
KO and wild-type (WT) mice have been reported [149]. These measurements revealed
upregulated proteins, which are associated with previously unidentified and known genes
involved in synapse formation, function, and brain development, as well as other genes
linked to mental disability and autism.
Therefore, and with our objective to investigate the effect of dysregulation of LIN28-
regulated miRNAs in the overabundance of genes involved in synapse formation and func-
tion, we decided to identify the predicted targets of LIN28-regulated miRNAs among cer-
tain highly relevant categories of genes. Specifically, we considered 6 representative pro-
tein complexes that have been identified in [149] to play key roles in pre- and post-synaptic
organization of signaling complexes, as well as in determining the structure and function
of nervous system development. These protein complexes were obtained by mapping the
genes associated with the dysregulated proteins to the CORUM database [124], which con-
tains curated data on 453 mouse protein complexes.
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Table 3.3: List of 17 genes whose products form 6 representative protein complexes that
have been identified to play key roles in pre- and post-synaptic organization of signaling
complexes, as well as in determining the structure and function of nervous system devel-
opment. Genes highlighted in red have been identified in this Dissertation to participate in
the LIN28-regulated miRNA-target interaction network depicted in Fig. 3.5.
Using the previous information, we identified the predicted targets of LIN28-regulated
miRNAs among the 17 genes listed in Table 3.3, whose products form the previously dis-
cussed complexes and whose protein levels were found to be significantly upregulated in
FMR1 KO versus WT samples. Based on our results, we constructed a predicted miRNA-
target interaction network that parallels the logic behind the Type-III loop construction in
Chapter 2, which we depict in Fig. 3.5. Notably, 9 out of 17 significantly upregulated
targets were found to be putative targets of at least one LIN28-regulated miRNA.
In addition to the above, 19 genes (see Table 3.4) were reported in [149] whose prod-
ucts: i) were found to be upregulated in KO versus WT samples, ii) existed in the gene-to-
cognition postsynaptic proteome (G2Cdb:PSP) database (http://www.genes2cognition.org)
listing the core set of synaptic proteins, iii) were among the 842 direct FMRP mRNA targets
identified by cross-linking immunoprecipitation and RAN-seq analyses in [27], iv) were in-
cluded among the autism-associated genes in the SFARI database. Note that FMRP is the
protein product of FMR1 gene, the silencing of which leads to the development of FXS.
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Figure 3.5: Predicted LIN28-regulated miRNA-target interactions using 17 selected up-
regulated genes, whose products form 6 representative protein complexes that play key
roles in the nervous system development and whose protein levels were found to be signif-
icantly upregulated in FMR1 KO versus WT samples. Let-7 represents the let-7 family of
9 miRNAs (including miR-98).
Intriguingly, we identified 14 out of these 19 genes to be predicted targets for at least one
of the LIN28-regulated miRNAs of interest and constructed the corresponding predicted
miRNA-target interaction network for these genes, which we depict in Fig. 3.6.
Together, these results provide strong evidence for our biological hypothesis discussed
in Section 3.2 (and the subsequent experimental work) that dysregulation of LIN28-regulated
miRNAs may lead to a selective overabundance of growth-promoting synaptic proteins that
could account for synaptic and cognitive functions in FXS.
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Figure 3.6: Predicted LIN28-regulated miRNA-target interactions using 19 core synaptic
genes in FXS associated with autism, which are known to be bound at the mRNA level by
FMRP and upregulated in FMR1 KO samples. Let-7 represents the let-7 family of miRNAs
(including miR-98).
Table 3.4: List of 19 genes whose products were found to be upregulated in KO versus WT
samples, existed in the gene-to-cognition postsynaptic proteome (G2Cdb:PSP) database
listing the core set of synaptic proteins, were among the 842 direct FMRP mRNA targets
identified by cross-linking immunoprecipitation and RAN-seq analysis, and were included
among the autism-associated genes in the SFARI database. Genes highlighted in red have
been identified in this Dissertation to participate in the LIN28-regulated miRNA-target
interaction network depicted in Fig. 3.6.
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3.4.2 Supporting Experimental Findings
Our collaborators have been working on utilizing the previous predicted miRNA-mediated
interaction networks with a goal to answer the third group of questions in Section 3.3 and
develop a biomarker for autism, as well as possible therapeutic strategies for this disease.
One of their initial steps was to investigate the expression levels of a subgroup of the miR-
NAs of interest (i.e., let-7a, let-7f, and miR-9), as well as the protein levels of LIN28a,
TRBP and DICER, which play crucial roles in the dual mechanism of regulation induced
by BDNF (see Fig. 1.1).
To this end, we constructed a predicted network of interactions among the LIN28-
regulated miRNAs, LIN28a, TRBP, and DICER, which we depict in Fig. 3.7. As we
discussed in the Introduction of this chapter, it is known that BDNF positively regulates
a group of genes through the LIN28a axis, which represses the 12 miRNAs of interest,
and negatively regulates other genes by inducing TRBP and DICER. This network, how-
ever, suggests that the 12 LIN28-regulated miRNAs mutually inhibit the dual regulation
mechanism induced by BDNF (see Fig. 1.1).
For the three miRNAs let-7a, let-7f, and miR-9, our collaborators obtained experimen-
tal measurements through qRT-PCR experiments. They also measured the protein levels
of the three genes LIN28a, TRBP, and DICER by western blot. For these six molecular
species, we used the Wilcoxon test to assess the statistical significance of the level of their
dysregulation in the disease state (FMRP knockdown) versus control, with the results de-
picted in Table 3.5.
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Figure 3.7: Predicted LIN28-regulated miRNA-target interactions in the context of Type-
III loops regulating DICER, TRBP and LIN28a.
It turns out that the experimental data obtained through FMRP knockdown experiments
are consistent with the predicted interactions for which data is available, see Fig. 3.7.
Specifically, an upregulation in LIN28a, TRBP, and DICER is consistent with the down-
regulation in the levels of miRNAs regulated by LIN28. These interactions consist of 7
Type-III loops with overlapping edges, listed in Table 3.6. To calculate a significance score
for each Type-III loop, we used Fisher’s method in the same way as we did in Chapter 2.
In this way, we obtain a systemic view on how these molecular species interact in the con-
text of the predicted network and this yields a holistic understanding of the dysregulated
network.
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Table 3.5: Dysregulation of molecular species in the induced disease state (FMRP knock-
down) versus control. Expression levels for miRNAs are obtained by qPCR and protein
levels are measured by western blot.
Table 3.6: Predicted dysregulated Type III loops in the induced disease state (FMRP
knockdown) versus control. The significance score has been calculated in the same way as
in Chapter 2.
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3.5 Discussion and Conclusions
In this collaborative research work, our goal was to investigate the biological hypothesis
stated in Section 3.2 and address the three groups of questions listed in Section 3.3.
For the purpose of enrichment analysis, we first considered two independent reference
gene sets that were relevant to the study and were deemed to be reliable. The first set
was obtained from a recent RNA-Seq study at Johns Hopkins [49], whereas the second
reference set was obtained from the Brainspan database, as we discussed in Section 3.3.
We then calculated the statistical significance of enrichment of the predicted targets of
miRNAs of interest using two slightly overlapping test gene lists: a list obtained from [49],
comprising genes that are differentially expressed in autism, and a list obtained from the
SFARI database, comprising autism-related genes.
Both of our analyses consistently demonstrated that the predicted targets of LIN28-
regulated miRNAs of interest collectively have statistically significant enrichment in autism-
related genes.
An interesting observation of our work is that the relative significance levels of enrich-
ment of predicted targets of miR-9, miR-107, and miR-143 is consistent between the two
analyses (see Tables 3.1 and 3.2) despite the fact that the test gene sets used in these two
analyses have small overlap. However, there is a difference between the relative numbers
of autism-related predicted targets of miR-9 and miR-107 (see Figs. 3.2 and 3.4).
In terms of the predicted interaction networks for LIN28-regulated miRNAs, we should
note that the experimental results are consistent with our computational results based on
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enrichment analyses. Altogether, these results provide a strong evidence for our biological
hypothesis. Moreover, subsequent experimental work may provide further evidence that
the dysregulation of LIN28-regulated miRNAs may lead to a selective overabundance of
growth-promoting synaptic proteins that could account for synaptic and cognitive functions
in ASDs.
In terms of translational impact, clinical relevance, and significance, it is noteworthy
that Fragile X Syndrome (FXS) represents the most common inherited form of mental
disability affecting 1 in 2500 births. FXS is also the leading inherited cause of autism
and other mental disabilities, whereas, diagnosis for these disabilities is made by clinical
evaluation. Reliance upon clinical evaluation means that autism in FXS patients is typically
not diagnosed until early school years and that gauging response to therapies for cognitive
impairments can suffer from subjective and potentially non-uniform measures of success.
The current lack of validated outcome measures hinders the progress of both research and
clinical trials, highlighting the value of investing in development of such a measure.
We would like to note here that our research has contributed to the discovery of a novel
biomarker based on LIN28-regulated miRNAs that is tested on an animal model. At the
current stage of development, our collaborators have identified dysregulation of LIN28
protein and the miRNAs regulated by it. This has been observed in both the brain and
peripheral blood of a specific mouse model that mimics the disease state. Extracellular
miRNAs have shown great potential as biomarkers in disease as they have been robustly
detected in plasma/serum of the blood and are generally highly stable. The very recent
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experimental findings indicate statistically significant results with regards to this biomarker
in the mouse models that mimicked the disease state as compared to age-matched control
mice.
From a therapeutic angle, current ongoing experiments are aimed at determining whether
drug treatment in the mouse model with disease state would objectively balance the dys-
regulated axis and lead to a normalization of the biomarker in the peripheral blood. A
subsequent important step would be moving into human FXS patient samples. From a
different therapeutic perspective, instead of using a drug to balance the dysregulated axis,
current gene-therapy-based experiments are aimed to directly restore the downregulated
miRNAs in the mouse model. This would then lead to a future work on developing a po-
tential therapy for human patients with FXS by targeting the dysregulated RNA binding
protein-miRNA axis. The significance for this miRNA-based biomarker includes its direct
use as a clinical outcome measure in FXS and other ASD clinical trials, and its possible




Interaction Networks in Living Cells
Introduction
In this chapter, our goal is to study biological interaction networks from a different
perspective than the one considered in Chapters 2 and 3, by focusing on their dynamic
behavior. Our research problem of interest here is to model the dynamics of a protein-
protein interaction network in living cells, as an instance of the second broad category of
research in systems biology.
Specifically, we investigate a novel strategy for generating intracellular hydrogels, termed
iPOLYMER for intracellular Production Of Ligand-Yielded Multivalent EnhanceRs. This
particular design, developed by our collaborators (Dr. Takanari Inoue’s lab at the School of
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Medicine), not only circumvents invasive approaches, such as microinjection, but also en-
ables hydrogel formation inside living cells in a rapidly inducible manner. In the following,
we briefly discuss the bioengineering background on hydrogels.
4.1 Bioengineering Background
A hydrogel is a cross-linked polymer network that is capable of absorbing water but
does not dissolve in it [56]. An outstanding feature of hydrogels as a material is that
their physico-chemical characteristics can be feasibly tuned over a wide range by chang-
ing relevant parameters, such as concentrations of polymers and cross-linkers or ambient
environments, including temperature and pH. In a biological context, these highly variable
properties enable biological hydrogel-like structures to serve versatile roles in living or-
ganisms, such as supporting and regulating functional entities [93] as well as lubricating
joints [80]. Recent works have found that biological hydrogel-like structures not only exist
in extracellular space, but also inside cells [61, 165]. These intracellular hydrogels serve
vital functions, such as forming diffusion barriers at the interface of subcellular compart-
ments or nucleating cellular activities [41]. One significant class of intracellular structure
that has been related to hydrogels is an RNA granule, which undergoes phase separation-
like behavior and dynamic structural rearrangements [12]. Many components of the granule
contain low complexity sequences, which actually form hydrogels when purified at higher
concentrations. While RNA granules are physiologically important [91], their structural
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organization and biological relevance remain uncharacterized. Development of synthetic
equivalents of the granules may become an alternative to facilitate our understanding of the
relationship between the structure and function of these intracellular hydrogel-like struc-
tures.
Synthetic hydrogels have long been of great interest in the field of biomedical engineer-
ing, primarily because their physical properties can be designed to achieve a desired objec-
tive; e.g., synthetic biomaterials to become a surrogate for damaged tissue [106]. In previ-
ous reports, the formation of those gels was successfully controlled in a stimuli-responsive
manner [105], providing a wide range of potential applications. Innovations in polymer and
protein science have already enabled the development of numerous synthetic hydrogels to
be used in clinical practice and bioengineering research [106]. However, the past research
has principally focused on extracellular applications, including the design of tissue engi-
neering scaffolds and drug delivery vehicles [73]. Until now, little has been achieved in an
effort to generate synthetic hydrogels inside cells, mainly due to the challenging nature of
inducing gel formation in intact, living cells. As such, researchers currently resort to either
a microinjection of acrylamide gels already formed outside cells [68], or to overexpres-
sion of building block molecules whose polymerization cannot be triggered [89]. These
reports used the hydrogel as a mechanical probe, described their dynamics in living cells,
or evaluated the effects of gel formation on cell survival. However, they have been less
successful in directly demonstrating synthetic hydrogels as being biologically functional
within living cells, primarily due to the lack of an experimental paradigm that is capable
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of forming gels in an inducible manner, with sufficiently fast kinetics to allow monitoring
functionality before and after induction.
Another difficulty in studying hydrogel formation inside the cell is the limited toolkits
available for gel evaluation. It is not often straightforward to claim the identity of an object
observed in the cell as being a gel, owing to limited physical access. Reconstitution of the
material in vitro is the most frequently adopted way to address this issue [41], although
the conditions adopted in vitro may not necessarily recapitulate the phenomena observed
in cells. Comprehensive understanding of the nature of induced hydrogels thus requires a
new paradigm, such as a computational model describing the gel formation process.
Given that this research work is a collaborative work, we first aimed to explore the
feasibility of iPOLYMER for rapid hydrogel-like network synthesis in silico, before our
collaborators proceeded with costly and highly time-consuming experimental procedures.
Therefore, we developed a physical model for three-component multivalent-multivalent
molecular interactions (Fig. 4.1), which led to a rigorous method for computationally im-
plementing iPOLYMER. We then performed kinetic Monte Carlo simulations based on this
model.
The proposed model employs a stochastic biochemical reaction system, which contains
three types of molecules, FKBP, FRB and rapamycin. These molecules interact according
to four reversible reactions (Fig. 4.1) and are subject to random diffusion. The binding
sites in FKBP and FRB are labeled as free or bound at each time point, along with the
information of binding partners. At a given time, the system may contain a mixture of
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FKBP, FRB, and rapamycin molecules, as well as aggregate molecules formed by the mu-
tual binding of these three basic molecules with other larger compound molecules. To
model iPOLYMER, we spatially discretize the well-known continuous-space Doi model of
stochastic reaction-diffusion [32, 33] and obtain a physically valid approximation based on
the reaction-diffusion master equation (RDME) [38, 53, 64, 66, 67]. This leads to a Markov
process model that describes the time evolution of the location of each basic or aggregate
molecule at a resolution of one voxel in the system. We simulate the resulting process by
a stochastic kinetic Monte Carlo algorithm. For our computational analysis, we model the
experimental system in a predefined volume of a subcellular size, discretize the system in
each spatial direction resulting in a given number of equally sized voxels that satisfy the
modeling assumptions and constraints, use experimentally verified kinetic rate values for
certain reactions, and plausible values for the kinetic rates of the remaining reactions. In
the following, we discuss the details of our methodology and the results and conclusions
we obtained from our analyses.
4.2 Model Construction and Simulation
4.2.1 Molecules and Reactions
We consider a biochemical reaction system of volume V that contains three types
of molecules: FKBP protein, denoted by an L molecule, FRB protein, denoted by a P
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Figure 4.1: The four reactions between molecules L (FKBP), P (FRB) andD (rapamycin),
as well as the corresponding reactions among their binding sites.
molecule, and the dimerizing agent rapamycin, denoted by a D molecule. Molecule D
comprises two binding sites: an L-binding site that allows D to bind with an L molecule
and a P -binding site that allows D to bind with a P molecule. We assume that a molecule
L comprises νL binding sites for D, whereas a molecule P comprises νP binding sites for
D. Molecules L and P can bind to each other only when their binding is mediated by
molecules D. There are two possibilities: either a molecule L binds on P through a free
P -binding site of a D molecule that is bound on L, or a molecule P binds on L through a
free L-binding site of a D molecule that is bound on P .
The previous molecules interact according to the four reactions depicted in Fig. 4.1,
which correspond to the following reactions among binding sites:1
1Note that Fig. 4.1 does not show the fact that molecules L and P comprise multiple binding sites for
molecules D. Moreover, it does not show the fact that each reactant molecule L, D, and P can be part of a
larger molecule (i.e., an aggregate).
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X11 +X12  X13 (binding/unbinding of a free site on L
with a free site on an unbound D) (4.1)
X21 +X22  X23 (binding/unbinding of a free site on L
with a free site on a bound D) (4.2)
X31 +X32  X33 (binding/unbinding of a free site on P
with a free site on an unbound D) (4.3)
X41 +X42  X43 (binding/unbinding of a free site on P
with a free site on a bound D) (4.4)
In these reactions, the Xmn’s denote sets of single and paired binding sites, where:
• X11 is the set of free D-binding sites on molecules L
• X12 is the set of free L-binding sites on unbound molecules D
• X13 is the set of bound pairs of binding sites between molecules L and D, in which
the P -binding site on the D molecule is free
• X21 = X11
• X22 is the set of free L-binding sites on molecules D bound on P
• X23 is the set of bound pairs of binding sites between molecules L and D, in which
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the P -binding site on the D molecule is bound
• X31 is the set of free P -binding sites on unbound molecules D
• X32 is the set of free D-binding sites on molecules P
• X33 is the set of bound pairs of binding sites between molecules P and D, in which
the L-binding site on the D molecule is free
• X41 is the set of free P -binding sites on molecules D bound on L
• X42 = X32
• X43 is the set of bound pairs of binding sites between molecules P and D, in which
the L-binding site on the D molecule is also bound
Note that the first subscript m in Xmn is used to denote the reaction, whereas the second
subscript n is used to denote the order of the “species” associated with each reaction (e.g.,
X11, X12 and X13 are the first, second, and third “species” associated with reaction 1).
The previous forward reactions are second-order, whereas the reverse reactions are first-
order. When a forward reaction is about to occur, the reactive components (i.e., the individ-
ual binding sites) are first identified. Upon occurrence of the reaction, these binding sites
are removed from the corresponding reactive components and the resulting bound pair of
binding sites is added to the product. On the other hand, when a reverse reaction is about
to occur, the reactive component (i.e., the individual bound pair of binding sites) is first
identified. Upon occurrence of the reaction, the pair of binding sites is removed from the
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reactive component and the resulting individual binding sites are added to the correspond-
ing products.
As a result of reactions (4.1)-(4.4), the system may contain a mixture of the three basic
molecules L, P , and D, as well as aggregate molecules resulting from their mutual bind-
ing. In addition, reactions (4.1)-(4.4) occur randomly, whereas molecules present in the
reaction system will randomly diffuse within the volume V . In the following, we develop
a stochastic reaction-diffusion computational model for these processes.
4.2.2 Available Models
Three reaction-diffusion physical models have been proposed in the literature to study
stochastic biochemical reactions in cellular systems. These are the Doi model, the Smolu-
chowski diffusion limited reaction model, and a model based on the reaction-diffusion
master equation (RDME) [66].
In the Doi model [32, 33], molecules are represented as points inside a three-dimensional
volume. First- and second-order reactions are assumed to occur with fixed probability rates
(probabilities per unit time). However, a second-order reaction occurs only when its two
reactants are separated by less than a specified “reaction radius” r. The product of a second-
order reaction of the formA+B → C is usually placed midway between the two reactants,
whereas the products of a reverse first-order reaction C → A + B are placed at a distance
that is not appreciably larger than r. Finally, diffusion of molecules is modeled by inde-
pendent Brownian motions.
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The Smoluchowski model [72] is similar to the Doi model. However, this model as-
sumes that second-order reactions may occur either instantaneously or when its two reac-
tants are separated exactly by the reaction radius r.
The RDME model can be interpreted as an extension of the non-spatial chemical master
equation model for stochastic chemical kinetics [42, 67, 158]. In this case, molecules are
represented as points inside a three-dimensional volume. The volume is partitioned by a
rectangular mesh into voxels and diffusion is modeled as a jump of a molecule from its
current voxel into one of its neighboring voxels. First- and second-order reactions occur
within a voxel with fixed probability rates and independently from the reactions in any
other voxel. Moreover, second-order reactions occur in a voxel under the assumption of
well-mixed reactants within the voxel. This is justified by assuming that the mesh spacing
is appreciably larger than the reaction radius and that the reactants become well-mixed at
an appreciably faster timescale than that of the occurrence of second-order reactions.
It turns out that the Doi model offers comparable accuracy to the Smoluchowski model [66,
94]. For this reason, we assume that the physical properties of the biological system at hand
can be modeled sufficiently well by the Doi model. Note that the Doi model is continuous in
space and cannot be used for computational analysis. To develop a computational approach
to our problem, we need to discretize this model. It turns out that the RDME model can
be interpreted as a formal discrete-space approximation of the Doi (or the Smoluchowski)
model [38, 53, 64, 66].
We should mention here that when the reaction system contains second-order reactions
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(which is true in our case), using the RDME model as an approximation to the Doi model
can be problematic. This is due to the fact that, in the limit, as the spacing of the three-
dimensional mesh approaches zero, second-order reactions are lost in the RDME model
(i.e., these reactions never occur) [53, 65]. The main reason for this problem is that, for
very small mesh spacings, the reactants within a voxel may not become well-mixed before
a reaction occurs. As a consequence, the error in approximating the Doi model by the
RDME model cannot be made arbitrarily small.
A variant of the RDME model, called convergent RDME (CRDME), has been pro-
posed in [66] to address the previous issue. This model promptly converges to the Doi
model in the limit as the mesh spacing tends to zero. Note however that the introduction
of the CRDME model in no way invalidates the use of the standard RDME model as an
approximation to the Doi model. The work presented in [66] provides choices for the ap-
propriate mesh spacing and the underlying parameters for which the RDME is considered
a physically valid approximation to the CRDME and Doi models.
4.2.3 RDME-based Approach
By following standard RDME modeling steps, we first employ a three-dimensional
rectangular mesh to partition the volume V of the biochemical reaction system at hand into
N3 equally-sized voxels. We consider a cubic volume V = [0, S] × [0, S] × [0, S], which
implies a uniform mesh spacing of s = S/N . In this case, the volume of each voxel is given
by V0 = s3. We assume that, within each voxel, molecules are well-mixed (i.e., uniformly
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distributed). As a consequence, the position of each molecule is known only to the scale of
one voxel. Note that molecules are considered to be points in the three-dimensional space
and are, therefore, dimensionless. This is not only true for the three basic molecules L, P
and D, but also for their forming aggregates.
We model diffusion as a first-order reaction that results in a jump of a molecule from
its current voxel to a non-diagonal nearest-neighbor voxel. In the following, we denote by
dij the probability rate of the reaction that models diffusion of a specific molecule within a
voxel i to a voxel j. We assume that every molecular species in voxel i is characterized by
the same probability rate of diffusion. We also assume that diffusion can be characterized
by the same probability rate irrespective of the particular voxel i and its nearest-neighbor
voxel j. To ensure that, when none of the reactions (4.1)-(4.4) occur, we can correctly
recover the diffusion of individual molecules in the limit as s→ 0, we must set [64, 67]
dij =

d/s2, if j is a non-diagonal nearest-neighbor of i
0, otherwise,
where d is the diffusion coefficient.
Note that, as aggregates start to form, the reaction system will contain a large number of
different types of molecules, which are expected to be characterized by different diffusion
coefficients. Using the Stokes-Einstein formula to calculate the values of these coefficients
is not possible, since this equation is valid for spherical particles [74], whereas the structure
of relatively small compound molecules are mainly tree-like. Therefore, obtaining reliable
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values for the diffusion coefficients of each individual compound molecule is an extremely
difficult problem. For this reason, it is not practical to assign different probability rates of
diffusion to each type of molecule in the system. However, the proposed procedure can be
modified to accommodate different rates if such rates become available.
Our previous choice for the probability rate of diffusion implies that our computational
model will take less time to reach steady state since, in reality, larger molecules would
diffuse more slowly than smaller molecules. Moreover, there are certain other factors that
contribute to the difference in time scale between our computational and experimental find-
ings, which we review in the Discussion section.
In the Doi model, the forward reactions (4.1)-(4.4) occur only if the associated reactants
are within the reaction radius r. Let λ+m, m = 1, 2, 3, 4, be the probability rates of these
reactions. Moreover, let λ−m, m = 1, 2, 3, 4, be the probability rates of the corresponding
reverse reactions. In the following, we assume that the mesh spacing s is appreciably larger
than the reaction radius r (i.e., we assume that s r). Intuitively speaking, this condition
guarantees the two main premises underlying the RDME model: most forward reactions
within a voxel will be between reactants within the same voxel whereas the products of
most reverse reactions will be placed within the same voxel.






and the probability rates κ+m and κ
−
m of the binding and unbinding reactions (4.1)-(4.4) to
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m, for m = 1, 2, 3, 4, (4.5)
then the RDME model may be interpreted as an asymptotic (as r/s→ 0) approximation of
the CRDME model (and thus of the Doi model). The error in approximation depends on
the values of r, λ and d. It turns out that, for a fixed ratio r/s, smaller values of r
√
λ/d
result in a better approximation of the CRDME and Doi models by the RDME model [66].
An important practical issue to consider here is choosing an appropriate value for the
mesh spacing s. On one hand, the previous results force us to take s r in order to use the
RDME model as a reasonable approximation to the CRDME model. On the other hand,
we must take s small enough so that s  S. This will ensure that discretization of the
continuous problem will be fine enough to guarantee sufficiently accurate approximation
of system behavior, both in terms of the binding/unbinding reactions within a voxel, as well
as in terms of molecular diffusion [65].
Recall now that a fundamental assumption associated with the RDME model is that
molecules within a voxel are well-mixed before one of the binding reactions (4.1)-(4.4)
occurs. To make sure that this is the case, we must assume that the timescale τd for the
reactants to become well-mixed due to diffusion is appreciably smaller than the timescale τr
of each of the binding reactions (4.1)-(4.4) to occur; i.e., we must have that τd  τr. As
we discussed previously, the probability rate of diffusion of a selected molecule is given
by d/s2. This implies that the timescale of diffusion will be approximately equal to s2/d;
i.e., τd ' s2/d [65, 67]. On the other hand, the probability rates of the binding reactions
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in a well-mixed voxel are given by Eq. (4.5). In this case, the timescale τr of the binding













Therefore, proper use of the RDME model requires that we employ a mesh spacing that
satisfies the following inequality













and s′′ = 3
√
V .
Note that the first-order unbinding reactions (4.1)-(4.4) do not restrict the mesh spacing
since they represent internal molecular events which do not require the molecules within a
voxel to be well-mixed.
Condition (4.6) underlies the required assumption that the molecules within a voxel are
well-mixed before any binding reaction occurs. It moreover leads to the assumption that
the binding/unbinding reactions within a voxel will occur independently from the reactions
within any other voxel. This is due to the fact that condition (4.6) implies that the vast
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majority of the reactants and products of the binding/unbinding reactions in a voxel will be
inside that voxel. Note also that the diffusion reactions within a given voxel are mutually
independent and independent from the binding/unbinding reactions within the voxel. More-
over, these reactions are independent from the diffusion and binding/unbinding reactions
within any other voxel. As a consequence, we can approximately partition the biochemi-
cal reaction system under consideration with volume V into V/s3 statistically independent
biochemical reaction subsystems of equal volume s3. Each subsystem comprises a number
of binding/unbinding reactions and a set of mutually independent diffusion reactions that
are also independent of the binding/unbinding reactions.
Let us now denote by ni(t) the total number of molecules within voxel i at time t.
By following the exact algorithm of Gillespie [45], the probability that the next diffusion
reaction will occur at time t+τ+dtwithin voxel i is governed by an exponential distribution
with rate parameter κdni(t), whereas the probability of a specific molecule to be diffused







Let us also denote by n+i,m(t) the total number of pairs of binding sites within voxel
i at time t, with each pair consisting of sites located on distinct molecules, which can
potentially react through the m-th binding reaction (4.1)-(4.4). Moreover, let n−i,m(t) be the
total number of pairs of bound sites within voxel i at time t that can potentially unbound
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through the m-th unbinding reaction (4.1)-(4.4). In this case, the probability that the next
binding/unbinding reaction will occur at time t + τ + dt within voxel i is governed by an











































When a diffusion reaction is about to occur at time t + τ + dt, the individual molecule to
be diffused is first identified by choosing it uniformly, with probability 1/ni(t), among all
possible molecules within voxel i. Subsequently, the direction of diffusion is identified by
choosing it uniformly among all possible directions with probability 1/6. Upon occurrence
of the reaction, the binding sites of the diffused molecule are relabeled to indicate their
jump from voxel i to the new voxel j.
On the other hand, when a binding reaction m is about to occur at time t + τ + dt,
the individual pair of binding sites are first identified by choosing them uniformly, with
probability 1/n+i,m(t), among all possible pairs of binding sites. Upon occurrence of the
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reaction, these binding sites are removed from the corresponding reactive components and
the resulting bound pair of binding sites is added to the corresponding product. On the other
hand, when an unbinding reaction m is about to occur at time t + τ + dt, the individual
bound pair of binding sites is first chosen uniformly, with probability 1/n−i,m(t), among all
possible bound pairs. Upon occurrence of the reaction, the pair of binding sites is removed
from the corresponding reactive component and the resulting individual binding sites are
added to the corresponding products for the given reaction.
4.2.4 Choosing Kinetic Values
The following kinetic rate values for reactions (4.1) & (4.4) have been experimentally
specified in [7]:
k+1 = 5.8× 106M−1sec−1
k−1 = 1.6× 10−3sec−1
k+4 = 1.7× 106M−1sec−1
k−4 = 1.9× 10−2sec−1.
Due to experimental difficulties however only values for the dissociation constants of reac-










3 ' 23× 10−6M .
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Since our model requires kinetic rates for all reactions, we can obtain plausible values
for the kinetic rates of reaction 2 by assuming that the rate of FKBP binding to an FRB-
rapamycin complex is α times faster than the rate of FKBP binding to a free rapamycin
molecule, whereas the rate of FKBP unbinding from an FRB-rapamycin complex is α



























As a consequence, we obtain
k+2 = 3.1× 108M−1sec−1
k−2 = 3.1× 10−5sec−1 .
Similarly, we can obtain plausible values for the kinetic rates of reaction 3 by assuming
that the rate of FRB binding to a free rapamycin molecule is α times slower than the rate of
FRB binding on an FKBP-rapamycin complex, whereas the rate of FRB unbinding from a
free rapamycin molecule is α times faster than the rate of FRB unbinding from an FKBP-
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As a consequence, we obtain
k+3 = 3.8× 104M−1sec−1
k−3 = 8.6× 10−1sec−1 .
Since our model utilizes probability rates, the previous values of the kinetic rates must
be translated to probability rates. This can be done by noting the following relationship




and κ− = k−, (4.7)
whereA = 6.022×1023 mol−1 is Avogadro’s number and V0 is the voxel volume measured
in litres. In this case, κ is measured in sec−1. As a consequence of Eqs. (4.5) & (4.7), we
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whereas, for the reverse reactions, we have that
λ− = k− sec−1.
By employing these formulas, we can use the previous values for the kinetic rates as inputs
to our model.
4.2.5 Simulation via Kinetic Monte Carlo
The previously discussed RDME-based approach leads to a stochastic Markovian pro-
cess that describes the time evolution of the location of each basic or aggregate molecule
within volume V at a resolution of one voxel. To simulate this process, we could use
standard kinetic Monte Carlo which leads to the following simulation algorithm:
Exact Simulation Algorithm
1. Specify values for the following parameters:
– V (system volume)
– s (mesh spacing)
– νL (valence number of L; i.e., number of binding sites on molecule L for D)
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– νP (valence number of P ; i.e., number of binding sites on molecule P for D)
– NL (initial number of L molecules)
– ND (initial number of D molecules)
– NP (initial number of P molecules)
– r (reaction radius)
– d (diffusion coefficient)
– λ+m, m = 1, 2, 3, 4 (physical probability rates of binding reactions)
– λ−m, m = 1, 2, 3, 4 (physical probability rates of unbinding reactions)
– tmax (simulation time).
2. Compute the probability rates κd = d/s2, κ+m = (4πr
3λ+m)/(3s
3), and κ−m = λ
−
m of
the RDME model, for m = 1, 2, 3, 4.
3. Initialize the molecular population by independently placing each molecule L in a
voxel, uniformly chosen from all possible voxels. Repeat this process for molecules
D and P . Set t = 0.
4. Choose a voxel i with probability s3/V uniformly among all possible voxels and
compute the total number ni(t) of molecules present in that voxel. Moreover, for
each m = 1, 2, 3, 4, compute the total number n+i,m(t) of pairs of binding sites, with
each pair consisting of sites located on distinct molecules, which can potentially react
through the m-th binding reaction (4.1)-(4.4), and compute the total number n−i,m(t)
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of pairs of bound sites that can potentially unbound through the m-th unbinding
reaction (4.1)-(4.4).
5. Determine the time of the next diffusion reaction within voxel i by drawing a sample
td from an exponential distribution with rate parameter κdni(t). In addition, deter-
mine the time of the next binding/unbinding reaction within voxel i by drawing a










6. If td ≤ tr, determine the direction of diffusion with uniform probability 1/6 over
all six possible directions as well as the particular molecule to be diffused with uni-
form probability 1/ni(t) among all possible molecules in voxel i. Move the selected
molecule from voxel i to the new voxel j and relabel the binding sites of the diffused
molecule to indicate their jump from voxel i to voxel j. If td < tr, set t = t+ td and
go to step 4.
7. Determine the binding/unbinding reaction to occur at time tr by drawing a sample





























, m = 1, 2, 3, 4
}
.
If the m-th binding reaction is drawn, identify the individual pair of binding sites
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to react by choosing them uniformly, with probability 1/n+i,m(t), among all possible
pairs of binding sites. If the m-th unbinding reaction is drawn, uniformly choose
the individual bound pair of sites to react, with probability 1/n−i,m(t), among all
possible bound pairs. Appropriately adjust the corresponding reactive and product
components to reflect the occurrence of the reaction. Set t = t+ tr and go to step 4.
8. Terminate the algorithm if t > tmax.
It turns out that exact spatial stochastic simulations can be costly. Essentially, this
is caused by the fact that refinement of the discretized spatial domain, together with the
relatively large number of molecules in the reaction system, give rise to a large number
of diffusive events between voxels. As a consequence, the stochastic simulation of the
reaction-diffusion system eventually becomes dominated by diffusive transfer events that
occur much more frequently than chemical reactions.
To address the previous issue, we utilize an approximation technique proposed in [121],
which is built on the multi-particle lattice gas automaton model presented in [22]. The per-
formance of this technique has been validated in [31] and leads to the following simulation
algorithm:
Approximate Simulation Algorithm
1. Specify values for the following parameters:
– V (system volume)
– s (mesh spacing)
131
CHAPTER 4. MODELING SYNTHETIC PROTEIN-PROTEIN INTERACTION
NETWORKS IN LIVING CELLS
– νL (valence number of L; i.e., number of binding sites on molecule L for D)
– νP (valence number of P ; i.e., number of binding sites on molecule P for D)
– NL (initial number of L molecules)
– ND (initial number of D molecules)
– NP (initial number of P molecules)
– r (reaction radius)
– d (diffusion coefficient)
– λ+m, m = 1, 2, 3, 4 (physical probability rates of binding reactions)
– λ−m, m = 1, 2, 3, 4 (physical probability rates of unbinding reactions)
– tmax (simulation time).
2. Compute the probability rates κ+m = (4πr
3λ+m)/(3s
3), and κ−m = λ
−
m of the RDME
model, for m = 1, 2, 3, 4.
3. Initialize the molecular population by independently placing each molecule L in a
voxel, uniformly chosen from all possible voxels. Repeat this process for molecules
D and P .




5. For each voxel i = 1, 2, . . . , N3 and for eachm = 1, 2, 3, 4, compute the total number
n+i,m(t) of pairs of binding sites that can potentially react through the m-th binding
reaction (4.1)-(4.4), with each pair consisting of sites located on distinct molecules.
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Moreover, compute the total number n−i,m(t) of pairs of bound sites that can poten-
tially unbound through the m-th unbinding reaction (4.1)-(4.4).
6. Determine the time t + τr of the next binding/unbinding reaction among all vox-












7. If t+ τr > tmax terminate the simulation.
8. Determine which binding/unbinding reaction will occur at time t + τr by drawing a

































, m = 1, 2, 3, 4, i = 1, 2, . . . , N3
}
.
If the (m, i)-th binding reaction (them-th binding reaction in voxel i) occurs, identify
the individual pair of binding sites to react, by choosing them uniformly with proba-
bility 1/n+i,m(t) among all possible pairs of binding sites. If the (m, i)-th unbinding
reaction (the m-th unbinding reaction in voxel i) occurs, identify the individual pair
of bound sites to react, by choosing them uniformly with probability 1/n−i,m(t) among
all possible bound pairs. Appropriately adjust the corresponding reactive and product
components to reflect the occurrence of the particular reaction.
9. Increment t by τr. If t < ndτd, go to Step 5.
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10. For voxels i = 1, 2, . . . , N3, diffuse each species in each voxel by determining the
direction of diffusion with uniform probability 1/6 over all six possible directions.
Move a selected molecule from voxel i to the new voxel j and relabel the binding
sites of the diffused molecule to indicate its jump from voxel i to voxel j.
11. Increment nd by 1 and set t = ndτd.
12. If t > tmax terminate the simulation. Otherwise, go to Step 5.
It is noteworthy to mention here that the reason why several distinct models have been
proposed in the literature to study stochastic and spatial effects in biochemical reaction sys-
tems (e.g., see [31, 46, 148]) is because no single model is currently capable of efficiently
coping with the broad range of spatial, temporal and concentration scales commonly found
in biochemical reaction networks. For this reason, models such as the one discussed in this
research, may represent a plausible approach that yields a compromise between computa-
tional efficiency as well as spatial and stochastic accuracy.
4.2.6 Size Distribution of Molecular Aggregates
To study the dynamic formation of molecular aggregates, we need to define the size
of a given molecule in the system at a given time. This will enable us to calculate and
track the size distribution of molecules in the system as a function of time. Moreover,
this information will allow us to study properties of molecular aggregation in terms of the
concentration and valence numbers of individual molecules initially present in the system.
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Understanding the evolutionary behavior of size distribution of molecules in the system
was important to our collaborators in their effort to design appropriate experiments for
hydrogel-like network synthesis.
Here, we define the size of a particular molecular aggregate to be the net number of
L and P molecules contained in the aggregate (as a consequence, individual L and P
molecules are characterized by unit size). We do not include D molecules in the definition
of an aggregate’s size since this can be misleading. To see why this is true, let us consider
two aggregates, one comprising 50 L and P molecules as well as 200 D molecules, and
the other 70 L and P molecules as well as 50 D molecules. If we include molecules
D in the definition of size, then the size of the first aggregate will be 250 whereas the
size of the second aggregate will be 120. However, the physical size of a D molecule is
negligible when compared to the physical size of an L or a P molecule (Fig. 4.2). As a
consequence, we expect that the size of the first aggregate will be smaller than that of the
second aggregate, since the former contains a smaller number of L and P molecules, which
are the dominant determinants of an aggregate’s size.
We can summarize the evolutionary nature of aggregate formation as a function of time
by employing the size distribution of molecular aggregates at different time points. We




, for σ = 1, 2, . . .,
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Figure 4.2: Physical sizes of L (FKBP) and P (FRB) molecules as well as of the LDP
(FKBP-rapamycin-FRB) complex.
where Nt(σ) is the number of aggregates with size σ at time t, Nt is the net number of
aggregates at time t, and E[·] denotes expectation.2 Unfortunately, we cannot calculate the
size distribution analytically. We can however estimate it computationally via Monte Carlo.
We can do this by employing K kinetic Monte Carlo simulation runs of the RDME-based













2Recall that aggregate formation is a random process.
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where N (k)t (σ) is the number of aggregates with size σ at time t, obtained from the k-th
simulation run.
4.3 RDME-based Simulation Results
To illustrate the potential of the previous RDME-based computational model, we now
provide a number of simulation results we obtained with our model. We use the following
choices for the parameter values:
S = 1µm, which corresponds to V = 10−15 l
s = 0.25µm, which corresponds to V0 = 1.5625× 10−17 l
νL = 1, 2, 3, 4, 5
νP = 1, 2, 3, 4, 5
NL = 200
NP = 200
ND = max{νL, νP} ×max{NL, NP}
r = 1nm
d = 10µm2sec−1
k+1 = 5.8× 106M−1sec−1
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k−1 = 1.6× 10−3sec−1
k+2 = 3.1× 108M−1sec−1
k−2 = 3.1× 10−5sec−1
k+3 = 3.8× 104M−1sec−1
k−3 = 8.6× 10−1sec−1
k+4 = 1.7× 106M−1sec−1
k−4 = 1.9× 10−2sec−1
tmax = 3sec
In order to guarantee that there are enough D molecules to bind all available L- and P -
binding sites, we set the initial number ofD molecules to be max{νL, νP}×max{NL, NP}.
Note that s′ = 0.05µm and s′′ = 1µm, in which case, s satisfies the inequalities in Eq. (4.6).
Kinetic Monte Carlo simulation of the previous RDME-based model using the Ap-
proximate Simulation Algorithm resulted in the accompanied Videos 1-5, corresponding to
νL = νP = 1, 2, 3, 4, 5. These videos depict samples of the dynamic behavior of aggregate
formation as a function of time over a 2-D planar projection of the 3-D volume V .3 Due to
lack of detailed information about the 3-D geometry of molecular aggregates, we represent
an aggregate as a sphere in 3-D, and thus as a disk in 2-D, whose diameter is proportional
to the aggregate’s size with proportionality constant 1.25× 10−3.
3With our values for V and s, the volume is partitioned into V/s3 = 64 voxels. As a consequence, its 2-D
planar projection is partitioned into 16 squares.
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Recall that the RDME-based model specifies the position of each molecule at a reso-
lution of one voxel. As a consequence, it is not possible to visually distinguish molecules
within a particular voxel and, therefore, within the square defined by the voxel’s 2-D planar
projection. To address this issue, and for the purpose of visualization, we arbitrarily shift
each molecule within a square uniformly over that square.
It is clear from the results visualized in Videos 1-5 that, at the beginning of each sim-
ulation, individual unbound molecules are scattered uniformly within the volume and thus
within the 2-D planar projection. As time proceeds however larger molecules (i.e., aggre-
gates comprising many L and P molecules) quickly emerge in the videos that correspond
to higher valence numbers, whereas a single large aggregate dominates the population at
the end of the simulation.
In Figs. 4.3-4.7, we depict log plots of estimated size distributions of aggregates, which
are formed at six equally-spaced time points between 0 and 3 sec, corresponding to valence
numbers νL = νP = 1, 2, 3, 4, 5. We obtained these distributions from Eq. (4.8) by em-
ploying K = 100 kinetic Monte Carlo simulation runs of the RDME-based model. These
distributions are binned into groups of 10 consecutive sizes. The results summarize the
dynamic formation of aggregates from smaller molecules and delineate the fact that, when
the valence numbers of the individual molecules are sufficiently high, complex aggregate
molecules appear in the course of time. Note that, at t = 0, the size distribution takes value
1 at size 1. This is a consequence of the fact that the reaction system contains only individ-
ual molecules. At later times, the size distribution spreads over larger sizes, reflecting the
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Figure 4.3: Estimated size distributions of molecular aggregates at different time points
when νL = νP = 1.
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Figure 4.4: Estimated size distributions of molecular aggregates at different time points
when νL = νP = 2.
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Figure 4.5: Estimated size distributions of molecular aggregates at different time points
when νL = νP = 3.
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Figure 4.6: Estimated size distributions of molecular aggregates at different time points
when νL = νP = 4.
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Figure 4.7: Estimated size distributions of molecular aggregates at different time points
when νL = νP = 5.
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formation of aggregates.
In Fig. 4.3, no formation of aggregates comprised of more than two basic molecules
L and P takes place (the reaction system contains only a mixture of L, P and LDP
molecules). Therefore, no formation of aggregates with size greater than 2 takes place
at valence number 1. On the other hand, Fig. 4.4 indicates that no formation of aggregates
with size greater than 50 is observed at valence number 2. This is expected, since a low
valence number limits the combinatorial binding of molecules and thus the size of the re-
sulting aggregates. However, as the valence number increases, more aggregates with larger
sizes gradually form, highlighting the crucial role of valency in the formation of complex
aggregates.
Of particular importance is the fact that, when νL = νP ≥ 3, the RDME-based model
evolves to a state characterized by the formation of a single large molecular aggregate at
steady state (t = 3sec), which may coexist with simpler molecules of appreciably smaller
sizes. This behavior demonstrates the feasibility of hydrogel-like network synthesis based
on the stochastic formation of FKBP-rapamycin-FRB complexes. Note also that, when
νL = νP ≥ 3, the size distribution evolves to a bimodal distribution, indicating the occur-
rence of a sol-gel phase transition.
For our biochemical system shown in Fig. 4.8a, simulation results for different valen-
cies of equivalent FKBP and FRB proteins are shown in Videos 1-5. The results indicate
that individual unbound molecules at the beginning of each simulation are scattered uni-
formly within the volume. For higher valencies of three or greater, quick formation of
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relatively large aggregates comprising many FKBP and FRB molecules occurred, while
only small aggregates were seen in valence number two, and none observed for valence
number one, as expected. Moreover, convergence to a stationary state was observed, char-
acterized by the formation of a single hydrogel-like aggregate that may coexist with simpler
and appreciably smaller molecules.
Further evidence of phase transition is demonstrated by the estimated probabilities of
iPOLYMER to produce aggregates of a threshold size of 100 or larger for different valence
numbers (Fig. 4.8b), as well as for different rapamycin concentrations (Fig. 4.8c). The
sharp increase in the probability values observed in Fig. 4.8b indicates that efficient poly-
merization can be achieved when the individual valence numbers of FKBP and FRB are at
least three, with the total valence number of FKBP and FRB molecules being at least six.
On the other hand, the sharp decrease in the probability values depicted in Fig. 4.8c indi-
cates that efficient polymerization requires a sufficient concentration of rapamycin. This
implies that, in addition to the valence numbers of FKBP and FRB, the concentration of
the dimerizing agent is expected to directly affect phase transition. Note that the base
number of rapamycin molecules is scaled to the common valency of FKBP and FRB. For
example, for the case of valency 1 for FKBP and FRB, we have five different systems
that are represented by five data points on the plot. The first system initially contains
40 rapamycin molecules, a number that is calculated by 40 (base number of rapamycin
molecules) multiplied with 1 (the valency of FKBP/FRB). The second system initially con-
tains 80 rapamycin molecules, a number that is calculated by 80 (base number of rapamycin
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Figure 4.8: In silico implementation of iPOLYMER demonstrates its feasibility for hydro-
gel network synthesis. (a) Four reversible reactions between monomeric FKBP, FRB and
rapamycin molecules modeled in our simulations. Each binding unit in the tandem repeats
of FKBP or FRB can undergo the four reactions in the presence of rapamycin. (b) Esti-
mated probabilities that iPOLYMER will produce aggregates of a threshold size of 100 or
larger for different valence numbers of the FKBP and FRB molecules. An aggregate of size
100 comprises 25% of the total number of FKBP and FRB molecules initially present in
the simulated system. (c) Estimated probabilities that iPOLYMER will produce aggregates
of a threshold size of 100 or larger for different valence numbers of the FKBP and the FRB
molecules, and different initial numbers of rapamycin molecules, determined by the base
number of rapamycin molecules multiplied by their valency.
molecules) multiplied with 1 (the valency of FKBP/FRB), and so on.
To validate our computational results we obtained thus far, our collaborators performed
experiments to evaluate iPOLYMER in living cells. Towards this end, they first generated
two series of engineered proteins in order to track their expression in cells (Fig. 4.9a,b): a
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yellow fluorescent protein (YFP) attached to N tandem repeats of an FKBP domain (de-
noted by YFN , N = 1,2,3,4,5), and a cyan fluorescent protein (CFP) attached to similar
tandem repeats of an FRB domain (CRM , M = 1,2,3,4,5). Then, they first co-expressed the
highest-valence number pair (YF5 and CR5), in COS-7 cells, in order to confirm diffuse
fluorescence, added rapamycin at a relatively high concentration (333 nM), and imaged
the fluorescence. Cells with high expression of both YF5 and CR5 peptides initially exhib-
ited diffuse fluorescence signals that rapidly turned into puncta upon rapamycin addition
(Fig. 4.10a), which steadily grew in size during prolonged rapamycin treatment. Finally,
they carried out the experiment by acquiring Förster resonance energy transfer (FRET)
measurements from CFP and YFP on the proteins, and observed increasing FRET values
in the cytosol within 5 minutes of rapamycin addition.
FRET is a mechanism for capturing energy transfer between two light-sensitive molecules
(i.e., chromophores) [54]. A donor chromophore, initially in its electronic excited state,
may transfer energy to an acceptor chromophore through nonradiative dipoledipole cou-
pling. FRET is extremely sensitive to small changes in distance since the efficiency of
this energy transfer is inversely proportional to the sixth power of the distance between
donor and acceptor. This makes FRET a powerful measuring technique for molecular in-
teractions and bindings. For monitoring complex formation between two molecules, one of
them is labeled by a donor and the other by an acceptor. In this way, the FRET efficiency
is measured and used to identify interactions between the labeled molecules.
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Figure 4.9: Schematic illustration of iPOLYMER. (a) Rapamycin induces rapid, stable and
specific binding between FKBP and FRB molecules. (b) YF5 and CR5 contain five repeats
of FKBP and FRB, respectively, spaced by 12 amino acid linker sequences. Mixing YF5
and CR5 (left) with rapamycin is expected to induce the formation of a hydrogel network
(right). YFN and CRM contain N -repeats of FKBP and M -repeats of FRB with the same
linkers, respectively.
In the experiment performed by our collaborators, a continuous FRET increase was
observed at the puncta that emerged at later time points (see Fig. 4.10a). This implies that
puncta formation was actually due to the binding between the two proteins induced by ra-
pamycin, further supported by lack of these phenomena when dimethylsulfoxide (DMSO)
was applied to the cells. DMSO is a solvent that has been shown to have no effect on a
wide range of protein-protein interactions in cells [123].
Our collaborators also experimentally explored the effect of the valence numbers on
the probability of puncta formation by testing all 25 different pairs of cytosolic proteins
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cytoYFN and cytoCRM , for N , M = 1,2,3,4,5, where cytoYFN and cytoCRM respectively
contain N -repeats of FKBP and M -repeats of FRB. It is noteworthy that cytoYFN and
cytoCRM essentially replicate our L and P molecules in the biochemical reaction system
we defined in Fig. 4.1, and equivalently in Fig. 4.8a.
At small total valence numbers (i.e., when N+M ≤ 5), less than 15% of cells formed
puncta (Fig. 4.10b and Fig. 4.10c). By contrast, the percentage of cells with puncta in-
creased rather dramatically at large total valence numbers. The similarity of the depen-
dency of aggregate formation on valence numbers in living cells (Fig. 4.10b) to that in
silico (Fig. 4.8b) strongly suggests that formation of puncta in situ is actually a result of
FKBP/FRB polymer networks having undergone a phase transition. We could thus ex-
perimentally observe the dependency of both puncta formation kinetics and efficiency on
valence number, which is in agreement with expectation drawn from our theoretical con-
siderations.
In addition to the results discussed above in terms of the dynamics of the biochemical
reaction system under consideration, since we now know that our computational model can
generate molecular aggregates under certain conditions, we can use the model to generate
graph representations corresponding to aggregates obtained by the RDME-based approach.
Next, we discuss how we can construct such representations and use them to gain further
insights into the sieving properties of molecular aggregates obtained in this work.
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Figure 4.10: iPOLYMER puncta formation in living cells. (a) Time-lapse imaging of
fluorescent puncta formation in COS-7 cells at indicated times relative to the addition of
rapamycin. Scale bars, 10µm. Punctate structures enriched with CFP, YFP, and FRET sig-
nals start to emerge within 5 min after rapamycin addition. (b) Frequency of iPOLYMER
puncta formation plotted against valence numbers in FKBP and FRB constructs. FN rep-
resents valence number of cytoYFN , whereas RM represents cytoCRM . (c) Probability of
iPOLYMER formation was plotted against the total valance number N +M . In order to
avoid bias, combinations of (N,M) with either N or M being one were excluded from the
data, except N=M=1. Note that the peptide with single valency should not lead to network
formation, confirmed by the rare puncta formation in (b).
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4.4 Molecular Aggregates as Sieves and their Ef-
fective Pore Sizes
Molecular aggregates, such as the ones produced in this work, are known to form a
selective three-dimensional gel-like sieve that interferes only slightly with the motion of
small molecules but appreciably slows down the motion of large molecules and blocks them
from passing through the sieve [93, 166]. To study the sieving properties of the aggregates
generated by our RDME-based model, we will need to construct graph representations of
these molecular aggregates. In the following, we discuss how we can construct these graphs
from the results obtained by the RDME-based algorithm.
4.4.1 Graph Representation of Molecular Aggregates
A graph is determined by its vertices and edges. To define the vertices of the graph
corresponding to a molecular aggregate generated by our computational model, we assign
a unique label to the binding sites associated with the aggregate as follows. We label each
unbound binding site on an L molecule as a Type I vertex. We also label each unbound
binding site on a P molecule as a Type II vertex. Finally, we label each L-binding site
that is bound to a P -binding site through a D molecule as a Type III vertex. We consider
an L-binding site as being “unbound” if it is not bound to a P -binding site through a D
molecule; i.e., if it is free or it is bound by a D molecule that is not bound to a P -binding
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site. Similarly, we consider a P -binding site as being “unbound” if it is not bound to an
L-binding site through a D molecule; i.e., if it is free or it is bound by a D molecule that is
not bound to an L-binding site. To define the edges of the graph, we link the binding sites
on L and P molecules that are physically linked to each other.
The reason for grouping vertices into Type I, Type II and Type III is that the actual
physical lengths of theL, P andDmolecules are different (Fig. 4.2). This becomes relevant
when calculating the pore sizes of molecular aggregates, which will become clear in the
next subsection. In Fig. 4.11, we illustrate our graph construction scheme by considering
two molecules L and two molecules P with the L molecules having a valency of 4 and the
P molecules having a valency of 3. In Fig. 4.11a, we depict a simple aggregate molecule
made up of these four molecules together with five D molecules. The corresponding graph
is depicted in Fig. 4.11b. This graph is represented by four Type I vertices, two Type II
vertices, and four Type III vertices as well, by a total of ten edges.
Early in the simulation, as well as in cells or in vitro, when the L, D and P molecules
start to interact and bind to each other, increasingly larger molecular aggregates are be-
ginning to form. In Fig. 4.12, we depict an example of a non-trivial graph corresponding
to such a molecular aggregate, which was computationally generated by our RDME-based
model at t = 1.5sec (a time that is close to the onset of phase transition). This aggregate
comprises a total of 40 L and P molecules with valency 5.
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Figure 4.11: (a) An example of a simple aggregate molecule made up of two L molecules
with valency 4, two P molecules with valency 3, and five D molecules. (b) The corre-
sponding graph representation consisting of four Type I vertices, two Type II vertices, four
Type III vertices, and ten edges.
4.4.2 Pore Size Distribution (PSD) and Effective Pore Size
(EPS)
Now that our model can generate the graph representations corresponding to the molec-
ular aggregates obtained by the RDME-based algorithm, to study the sieving property of a





, for σ > 0,
where Pt(σ) is the number of pores of size σ present in the aggregate, Pt is the net number
of pores, and E[·] denotes expectation. Unfortunately, we cannot calculate the PSD ana-
lytically. We can however approximate it computationally via Monte Carlo, provided that
154
CHAPTER 4. MODELING SYNTHETIC PROTEIN-PROTEIN INTERACTION
NETWORKS IN LIVING CELLS
Figure 4.12: Graph representation of a molecular aggregate obtained by an RDME-based
simulation at t = 1.5sec, which is close to the onset of phase transition. This aggregate
comprises a total of 40 L and P molecules with valencies νL = νP = 5.
we can appropriately compute Pt(σ). We can do this by kinetic Monte Carlo simulation
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where P (k)t (σ) is the number of pores of size σ in the k-th aggregate instance obtained at
time t.
An important use of the PSD is to determine which molecules can pass through a sieve
and which molecules will be blocked. Let us denote by πt(σ) the (expected) probability
that molecules of physical size σ pass through a sieve present at time t.4 In this case, the
(expected) probability that molecules of physical size σ are blocked by the sieve is given
























Let us now define the size σ∗t , given by
σ∗t = max
{
σ | π̂t(σ) ≥ 1/2
}
. (4.11)
This is the maximum size of a molecule that is expected to most likely pass through the
sieve. Moreover, molecules with sizes σ > σ∗t will most likely be blocked by the sieve. We
refer to σ∗t as the effective pore size (EPS) of the sieve that is formed at time t.
Although we can potentially compute the EPS from the pore size distribution (PSD)
4We represent a molecule by the smallest containing sphere and define its physical size to be the length of
the sphere’s diameter.
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of the molecular aggregate, we were unable to calculate the PSD or obtain the exact value
of the EPS for the biomolecular sieves we constructed in this work due to experimental
difficulties. However, our experimental collaborators were able to estimate an upper bound
of the EPS for our experimentally synthesized gels, either in cells or in vitro, through a
series of independent experiments that we discuss later in this chapter.
4.4.3 Estimation of PSD and EPS
In order to gain further insight into the sieving property of a gel, we now seek to estimate
the EPS of molecular aggregates that are computationally generated by the RDME-based
model. However, it is important to note that calculating PSDs for non-trivial dense aggre-
gates, which are the types of aggregates obtained at steady state in systems in which phase
transition takes place, is a computationally intractable problem. This is because calculating
PSDs would require identifying the “pores” on graphs that correspond to these aggregates,
which may comprise several hundreds or even thousands of vertices and edges. This in-
crease in graph size and/or density would dramatically affect the computational complexity
of the problem. On the other hand, due to the dense structure of the graphs, we can infer a
plausible range for the EPS values of dense molecular aggregates by utilizing experimental
measurements of the lengths of their vertices and edges, which could serve as a basis for
assessing the experimentally obtained EPS bounds. We perform this analysis in the next
section.
In addition, the problem of estimating the EPS value for a molecular aggregate formed
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at an early time is experimentally very challenging and we were not able to perform such
experiments either in cells or in vitro. Therefore, and in the context of a hypothetical
scenario and through a concluding computational analysis, we seek to calculate the PSDs
and EPSs for certain sets of molecular aggregates that are computationally generated before
the system reaches steady state. We expect such aggregates to have relatively less dense
graph structure with fewer vertices and edges than aggregates formed at a later time, which
will make the identification of pores on these graphs computationally manageable. We
carried out this analysis by employing a recently proposed graph-theoretic method [116],
by identifying all existing pores in each graph instance of an aggregate, by estimating
their sizes based on the actual physical length of the constituent molecules, as measured
experimentally, and eventually, by calculating the PSD and EPS values for the aggregate.
The following two types of analysis characterize a gel by its EPS value and provide further
insight into the development of biomolecular sieves.
4.4.3.1 Estimating Pore Sizes of Molecular Aggregates at Steady State
In this section, we discuss the problem of inferring plausible estimates for PSDs of
molecular aggregates at steady state. To do so, we first define pores as being one of two
types of cycles in the 3D graph associated with an aggregate: (i) triangles, and (ii) chord-
less cycles. A cycle is a set of edges over a closed walk, which consists of a sequence of
vertices starting and ending at the same vertex, with each two consecutive vertices in the
sequence adjacent to each other in the graph. No repetitions of vertices is allowed, other
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Figure 4.13: (a) ABCDEFA is a chordless cycle. (b) ABCDEFA is not a chordless cycle
due to the presence of chord AD connecting vertex A to vertex D. However, the cycles
ABCDA and ADEFA are chordless.
than the repetition of the starting and ending vertex. A triangle is a cycle of length three,
whereas a chord is an edge connecting two non-consecutive vertices on a cycle. A cycle is
said to be chordless if its length is at least four and has no chords (Fig. 4.13).
To estimate the size of a pore whose shape is polygon-like, we approximate the pore
with a circle whose perimeter is taken to be the same as the physical perimeter of the cy-
cle associated with the pore, and use the circle’s diameter to quantify the size of the pore.
We calculate the physical perimeter (girth) of a pore by adding the physical lengths corre-
sponding to each type of vertex in the corresponding cycle as well as the physical lengths
of its edges. According to Fig. 4.2, the physical length of a Type I vertex is 2.74 nm, of a
Type II vertex is 2.20 nm, and of a Type III vertex is 5.00 nm. Note that we do not include
“overhanging” D molecules (i.e., D molecules attached only to an L or a P molecule)
when specifying the physical lengths of Type I and Type II vertices. These molecules are
not part of the cycle and, therefore, are not relevant when calculating its physical perimeter.
On the other hand, the physical length of an edge linking two consecutive binding sites on
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an L or a P molecule has been experimentally determined to be equal to 6.00 nm. As a




(nI × 2.74 + nII × 2.20 + nIII × 5.00 + ne × 6.00) nm,
where nI is the number of Type I vertices in the cycle corresponding to the pore, nII is the
number of Type II vertices, nIII is the number of Type III vertices, and ne is the number of
edges.
As an example, the graph depicted in Fig. 4.11b consists of only one chordless cycle
corresponding to one pore. This cycle consists of nI = 3 Type I vertices, nII = 1 Type II




(3× 2.74 + 1× 2.20 + 4× 5.00 + 8× 6.00) nm = 24.97 nm.
This would suggest that molecules of size (diameter) no more than about 25 nm can pre-
sumably pass through the pore.
During a simulation, as well as in cells or in vitro, increasingly larger molecules start to
form and larger molecules also bind to each other and eventually form aggregates. As time
proceeds, free binding sites of L and P molecules on the aggregate are likely to bind to each
other. Thus, the aggregate will get denser with its pores becoming smaller. This is expected
to occur in the presence of, or even without, new L and P molecules being added to the
aggregate. In other words, the cross-linking density of the molecular aggregate, defined as
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the ratio of the number of L-D-P complexes to the aggregate size (i.e., the number of L
and P molecules on the aggregate), will presumably increase as a function of time.
At steady-state, the majority of the binding sites on the molecular aggregate will be
bound. This means that it is very likely for two L and P molecules located next to each
other to be bound. As a simple scenario, let us consider two adjacent L and P molecules
on the aggregate, each with valency 5 (as was the case with our in situ and in vitro sieving
experiments that determined the EPS). Given a sufficient number of availableD molecules,
the smallest pore that can be formed with the two L and P molecules corresponds to a
triangle, based on the definition of the pore and the experimental measurements for the
length of vertices and edges that was discussed earlier in this section. It turns out that, in
our problem, triangles (i.e., cycles of length three) are characterized by three possible sizes:
9.62 nm, 9.79 nm, or 10.51 nm.5 Since these values are very close to each other, we can
assign an average size of (9.62 nm + 9.79 nm + 10.51 nm)/3 = 9.97 nm, or about 10 nm,
to the pore size of any triangle on the graph of the aggregate. Moreover, the largest pore
that the two L and P molecules can form corresponds to a chordless octagon with a size
between 23.91 nm and 28.03 nm, an observation that is based on a similar analysis that
depends on how the octagon is connected with the aggregate.6 As one can imagine, the
5This is due to the fact that L and P molecules which form a triangle lead to a graph that has two Type III
vertices and a third vertex that can be Type I, Type II, or Type III. In this case, the perimeter of a triangle will
be equal to the sum of the lengths of the two Type III vertices (2 × 5.00 nm = 10.00 nm), of the length of
the third vertex (which is 2.74 nm if Type I, 2.20 nm, if Type II, or 5.00 nm, if Type III, and of the length
of the three edges (3 × 6.00 nm = 18.00 nm, since each edge is 6.00 nm long). Summing up the numbers
associated with the three possibilities and dividing by π results in sizes 9.62 nm, 9.79 nm, and 10.51 nm.
6As a matter of fact, L and P molecules forming a chordless octagon that is connected to an aggregate lead
to a graph that has at least three Type III vertices and at most eight Type III vertices. The octagon with three
Type III vertices, together with two Type I and three Type II vertices, is the smallest octagon, whereas the
octagon with eight Type III vertices is the largest octagon. In both cases, the length of the eight edges is given
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two L and P molecules can alternatively form pores corresponding to a chordless square,
pentagon, hexagon or heptagon with their pore sizes falling in the range between 9.97 nm
(for a triangle) and 28.03 nm (for a chordless octagon).
We can extend the previous analysis to the case of more than two L and P molecules. In
this case, the size of small pores will still fall within the range we obtained for the previous
simple case of just two L and P molecules, whereas more L and P molecules could poten-
tially form larger pores corresponding to polygons with more than eight edges. This would
be particularly relevant for the aggregates that form earlier, since we expect these aggre-
gates to have many unbound sites on their constituent L and P molecules, corresponding
to a much lower cross-linking density, and be associated with relatively larger pore sizes.
However, as we pointed out earlier in this section, an increasing number of binding sites on
a molecular aggregate will become bound as the system reaches steady state. As a result,
the aggregate will become increasingly denser, which would result in increasingly smaller
pore sizes. Presumably, when the valence number of the constituent L and P molecules is
5 (consistent with our in situ and in vitro sieving experiments that determine the EPS), the
sizes of these pores, and therefore the EPS value, will predominantly be within a range of
about 10-28 nm, corresponding to polygons with relatively fewer number of edges.
From a practical perspective, and due to the 3D structure of an aggregate, it is likely
that the spatial orientation of the molecules that form a dense aggregate could potentially
block the passage of molecules through the pores and lead to a smaller EPS value. Taken
by 8×6.00 nm = 48.00 nm, since each edge is 6.00 nm long. Summing up the numbers associated with each
of the two octagons and dividing by π results in sizes (2×2.74+3×2.20+3×5.00+8×6.00)/π = 23.91 nm
and (8× 5.00 + 8× 6.00)/π = 28.03 nm.
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together, the previous observations lead to the conclusion that the EPS values of dense
molecular aggregates which are experimentally observed at steady state will be smaller
than the computationally calculated EPS values, which are predicted to be within a range
of about 10-28 nm. It is finally important to note that the density of an aggregate directly
affects its EPS value and could be potentially influenced by: (i) the valence number of the
constituent L and P molecules, (ii) the initial concentrations of the L, P and D molecules,
and (iii) the experimental procedure used to obtain the aggregate. We will revisit these
practical issues in the context of our experimental results in the Discussion section.
4.4.3.2 Estimating Pore Sizes of Molecular Aggregates at Early-stages
As noted in the previous section, for an early forming aggregate (e.g., at a time close to
the onset of phase transition), its cross-linking density is expected to be much lower than
that of a comparably sized aggregate observed at steady state. We therefore expect that an
early-stage aggregate will be characterized by fewer and presumably larger pores and be
associated with a relatively less dense graph structure (Fig. 4.12) for an example). We now
seek to computationally characterize such an aggregate by its PSD and EPS in order to gain
further insight into the sizes of its pores and investigate how these sizes are affected by the
valence number of the constituent L and P molecules. To do so, we need to identify the
pores of a given molecular aggregate, which implies that we must find all chordless cycles
and triangles in the corresponding graph. We explain how we perform this analysis next.
To identify chordless cycles in a graph, we first need to compute the adjacency matrix
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of the graph. This is a matrix that summarizes which vertices are adjacent to which other
vertices in the graph. As a consequence, the adjacency matrix defines the graph. We can
compute the adjacency matrix of the graph corresponding to a molecular aggregate by
assigning unique labels to the vertices of the graph and by determining the connections
between vertices by tracking the occurrence of binding and unbinding reactions during our
kinetic Monte Carlo simulation.
The method we use to identify chordless cycles has been proposed by John Pfaltz [116].
In brief, for each vertex i of a graph, the method finds every chordless cycle starting from
that vertex using a depth-first approach [168]. It begins with a vertex j that is adjacent to i,
as determined by the adjacency matrix, and adds that vertex to a trial “cycle prefix,” which
stores all vertices that can potentially form a cycle. It subsequently identifies a vertex k
that is adjacent to j and adds it to the cycle prefix as well. It then recursively iterates this
process, with j taking the role of i and k taking the role of j, seeking to extend the cycle
prefix through a new vertex l adjacent to k. If the new vertex turns out to be the original
starting vertex, then a cycle has been found. If the new vertex is a different element of the
cycle prefix, a new cycle has been found that is not through the starting vertex. In either
case, the method checks to see if the cycle is chordless. If it is, then it stores the cycle
information (represented by the set of unique labels assigned to its vertices), backs up one
level in the recursion, tries some other vertex in the neighborhood of the last vertex in the
cycle prefix, and continues with a new cycle search.
It is noteworthy that, since the method seeks to find all chordless cycles through all
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vertices, the presence of tree-like structures in the graph would be detrimental to its perfor-
mance – see Fig. 4.12 for an example of tree-like structures in a graph. Tree-like structures
do not have any cycles in them. If they are not removed from the graph beforehand, the
algorithm will be searching for cycles on them in a futile manner, which will result in
a combinatorial increase of computational complexity. For this reason, the method first
reduces the graph to its “irreducible spine” consisting of only chordless cycles and then
proceeds with the cycle search [116].
Since our method finds only chordless cycles in a graph (whose length is at least four),
it does not identify “triangles” (cycles with length three). As a result, we need to find a way
to include the size of triangles when estimating the pore size distribution. In the previous
subsection, we calculated the average pore size corresponding to a triangle on the graph
of a molecular aggregate to be 9.97 nm. Unfortunately, identifying triangles individually
in large graphs, such as the ones obtained by our approach, is a computationally intensive
problem due to its combinatorial complexity. However, we can calculate the number nt
of all triangles in a given graph using a known result from graph theory [? ], and include
nt × 9.97 nm corresponding to all the triangular pores in our pore size calculation. It is
shown in [? ] that the number of all triangles in a graph is given by nt = trace[A3]/6,
where A is the adjacency matrix of the graph.
It turns out that using Pfaltz’s method to identify pores in the graphs corresponding to
aggregates with sizes above 40 (which are graphs obtained at times close to steady state)
is computationally intensive and not practical with our current computational capabilities.
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This is due to the fact such aggregates may produce graphs comprising several hundreds
or even thousands of vertices. This dramatically increases the complexity of cycle search,
making computation of the PSD intractable from a practical perspective.
To deal with this problem, we considered estimating the PSD of aggregates formed at
early times away from steady state. Unfortunately, for aggregates with low probability of
occurrence, Eq. (4.9) requires a large number of simulation runs, which can be compu-
tationally demanding. Note however that we expect molecular aggregates of comparable
sizes to be structurally similar. For this reason, we included in Eq. (4.9) all aggregates of
comparable sizes to the basic aggregate observed in a simulation run at time t, which ap-
preciably reduced the number of simulation runs needed for approximately computing the
PSD. We then focused on estimating the PSD of aggregates of sizes 30-40 formed at time
t = 1.5 sec. We did so by independently simulating our RDME-based model K = 2,000
times for three different valencies: νL = νP = 3, 4, 5. For each simulation run, we identified
all aggregates at time t = 1.5 sec with sizes 30-40 and computed the number P (k)t=1.5(σ) of
pores in these aggregates, for σ > 0. We then estimated the PSD using Eq. (4.9). The
results are depicted in Fig. 4.14. By using Eqs. (4.10) & (4.11), we also estimated the cor-
responding EPSs σ∗t=1.5. It turns out that σ
∗
t=1.5 ' 60 nm for valency 3, σ∗t=1.5 ' 80 nm for
valency 4, and σ∗t=1.5 ' 110 nm for valency 5.
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Figure 4.14: Estimated PSDs of molecular aggregates with comparable sizes of 30-40 nm,
observed by our in silico implementation of iPOLYMER at time t = 1.5sec (close to the
onset of phase transition). These distributions are binned into groups of 10 consecutive
pore sizes. Clearly, polymerization of L and P molecules with larger valence numbers
may result in early-stage aggregates with coarser sieving potential than molecular sieves
formed by molecules with smaller valencies.
We would like to note here that the PSD of a molecular aggregate changes with time as
aggregate formation evolves. It is reasonable to expect that, given a sufficient number of
rapamycin molecules, the EPS of the sieve formed by a molecular aggregate at an earlier
time will be larger than the EPS of the sieve formed by a molecular aggregate of comparable
size at a later time. This is due to the fact that, as time proceeds, free binding sites of FKBP
and FRB molecules that form the aggregate are likely to bind to each other, thus reducing
the size of the pores. In other words, we expect that the cross-linking density will increase
as a function of time, even without new FKBP and FRB molecules being added to the
aggregate. As a matter of fact, aggregates comprising FKBP and FRB molecules with
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a b
FKBP (valency 3)
FRB   (valency 3)
FKBP (valency 5)
FRB   (valency 5)
Figure 4.15: The aggregate in (a) is formed with FKBP and FRB molecules whose va-
lencies are smaller than the valencies of the FKBP and FRB molecules forming the aggre-
gate in (b). These aggregates have a relatively similar cross-linking pattern and identical
cross-linking density of 5/4, calculated by dividing the number (15) of FKBP-rapamycin-
FRB complexes per each compound molecule with the number (12) of the FKBP and FRB
molecules on each compound molecule. As a consequence, the aggregate in (a) is charac-
terized by smaller pores than the aggregate in (b).
smaller valence numbers are originally formed by smaller constituent molecules (a smaller
valence number corresponds to a smaller multivalent molecule in terms of its physical
size), and these aggregates are more likely to be characterized by smaller pores earlier in
their formation than aggregates comprising FKBP and FRB molecules with larger valence
numbers (Fig. 4.15). This explains why, in the case of early-stage aggregates, the PSD
depicted in Fig. 4.14 shifts to the right as the valence number of the constituent equivalent
FKBP and FRB molecules increases.
The previously described method for identifying chordless cycles in a graph has been
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implemented in a Unix platform using C++ by John Pfaltz [116]. It consists of two parts,
which correspond to two executable files, GR RED and CYCLE DIST that are provided
in [84].
The first executable file, GR RED, accepts as an input the “edge list” representation of
the graph, which lists all edges in the graph with their associated vertices. This list is ob-
tained from the adjacency matrix of a given graph and is produced, in the form of a text file,
by our MATLAB code that generates the graphs associated with the aggregates. GR RED
reduces a graph to its irreducible spine consisting of only chordless cycles. It also gener-
ates two output files, REDUCED and TRACE. The file REDUCED stores the information
for the reduced graph to be used as input to the second executable file CYCLE DIST. The
file TRACE stores certain information on the progress of the code, which comes in handy
when dealing with relatively large graphs. It is noteworthy that, for this type of graphs,
the computational time required by the algorithm might be in the order of several hours
to several days or even weeks, depending on the size and complexity of the graph. For
this reason, we strongly recommend use of a computing cluster. In our work, we used a
computing cluster consisting of 19 computing nodes, with each node being equipped with
24 processing cores and 128GB of memory (RAM).
The second executable file, CYCLE DIST, reads the output file REDUCED generated
by GR RED. It also uses the text file PARAMETERS to read the values of the physical
lengths (in nm) of the constituent L and P molecules and their valencies, together with
the physical length of the L-D-P complex and the physical distance between consecutive
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binding sites on L and P molecules. It then runs through the cycle search algorithm and
identifies the chordless cycles represented by the sets of their vertices. It outputs the file
CYCLE LENGTHS, which stores all cycle lengths (pore sizes) in nm, as well as the lengths
corresponding to triangles in the graph. This information is finally used to calculate the pore
size distribution of the graph.
4.5 Discussion and Conclusions
In this research work, we developed a physical model for three-component multivalent-
multivalent molecular interactions that led to a rigorous method for computationally im-
plementing iPOLYMER. Our approach was based on a realistic kinetic Monte Carlo simu-
lation algorithm that produced sufficiently accurate approximations of stochastic reaction-
diffusion dynamics.
We noticed that aggregate formation occurred faster in silico than in cells or in vitro
(See Figs. 4.5-4.7 and Fig. 4.10). We partially contributed this difference to the obser-
vation that our computational model does not take into account the fact that the rates of
diffusion decrease as the sizes of the aggregate molecules become larger. Moreover, our
model is based on the assumption that the rapamycin molecules are uniformly mixed with
the FKBP and FRB peptides at the start of the simulation and, therefore, the model does
not take into account the appreciable delay introduced initially by rapamycin diffusion into
cells. Finally, our computational analysis was based on a system volume of 1(µm)3, which
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is much smaller than the actual cellular volume of about 25(µm)3, resulting in faster con-
vergence to steady state. Despite these differences, however, the results obtained by com-
putational analysis provided valuable insights into the qualitative behavior of iPOLYMER,
which could not be easily obtained experimentally.
Our RDME-based model validated aggregate synthesis for sufficiently high valence
numbers of the constituent L and P molecules. In addition, the model captured the occur-
rence of phase transition, in the form of the size distribution evolving into a bimodal distri-
bution, which indicated coexistence of large aggregate molecules with simpler molecules
of appreciably smaller sizes (Figs. 4.5-4.7 and the accompanying Videos 3-5). It moreover
demonstrated the fact that phase transition depends on the valence numbers of the L and P
molecules and on the concentration of the dimerizing agent rapamycin (Fig. 4.9b,c). Our
in silico results provided strong supporting evidence to our experimental results associated
with hydrogel-like network synthesis (see Fig. 4.10a and our manuscript [84]), as well as
with the dependency of network synthesis on the valence number of the constituent L and
P molecules (Fig. 4.10b,c), and on the concentration of rapamycin (reported in [84]).
To investigate the sieving properties of molecular aggregates produced by iPOLYMER
in silico, we estimated the pore sizes on the graphs corresponding to molecular aggregates
generated by our RDME-based model. We did so for two different groups of non-trivial
aggregates: (i) dense aggregates observed at steady state, and (ii) early-stage aggregates
observed at a time close to the onset of phase transition. We considered these two groups
separately, since calculating PSDs for non-trivial dense graphs, such as the ones generated
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by our model at steady state, is computationally intractable.
Because of the previous unavoidable limitation of our model, we expect that the actual
EPS values of the sieves will be smaller than the ones we estimated for dense aggregates at
steady state and for early-stage aggregates obtained close to the onset of phase transition.
This is because the spatial orientation of molecules that form an aggregate will physically
block passage of molecules due to the dense structure of the aggregate (i.e., higher cross-
linking density) and the presence of molecules in front of the pores.
The in situ and in vitro experiments yielded dense aggregates, taking into account that
there were sufficient concentration levels of rapamycin in the system and the fact that the
aggregates were observed at steady state. For this case, our computational analysis pro-
duced an EPS value estimate within a range of 10-28 nm. We expect that, since our com-
putational model cannot consider the 3D spatial orientation of the constituent peptides on
the aggregate, the actual EPS value would be lower.
The corresponding experimental results regarding the pore sizes of aggregates produced
by our collaborators are discussed in our manuscript [84] in detail. In brief, from the in
vitro experimental results, the EPS value was estimated to be within a range of 4.3-6 nm,
based on the observation that fluorescent tracers (4.3 nm in diameter) did penetrate into
hydrogels almost freely, whereas Q-dots (6 nm in diameter) and fluorescent beads (20 nm
in diameter) did not. On the other hand, from the in situ experimental results, the EPS
value was estimated to be within a range of 16-70 nm. This is supported by the evidence
that mCherry-β-galactosidase, a tetramer complex with a rough diameter of 16 nm, passed
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through the gel, whereas there was no single event that mCherry-TGN38, an mCherry-
labeled vesicle with a varied size in the range 70-140 nm, could pass through the gel.
Notably, the experimental predictions are in line with our computational prediction, which
provided another level of validation of our results.
The estimated range of EPS values (4.3-6 nm) of the gel formed in vitro turned out to
be considerably smaller than the one obtained in situ (16-70 nm). Presumably, this is due
to the distinctly higher in vitro concentrations of the peptides and to the possibility that
our EPS estimates have been affected by the fact that the gels obtained from the in vitro
experiments were centrifuged in an effort to demonstrate their structural integrity and their
ability to hold water [84].
Regarding the effect of the valence number on the EPS value of a dense aggregate,
we should first note that we inferred the 10-28 nm range by assuming that the valence
number of the L and P molecules is 5. We argued, however, that the actual EPS value
could be smaller due to the spatial orientation of the constituent molecules, which cannot
be captured by our graphical representation of the aggregate. For the same reason, we also
expect that the actual EPS value will further decrease (but presumably not significantly) at
higher valence numbers, due to an increasing cross-linking density and, consequentially,
due to a more pronounced effect of the spatial orientation of the constituent molecules.
Our computational analysis, applied on early-stage aggregates, demonstrated a depen-
dency of the EPS value on valency and rapamycin concentration (Fig. 4.9b,c and Fig. 4.15),
although experiments could not be performed to validate this behavior. However, our col-
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laborators have experimentally demonstrated that the relative concentration of rapamycin to
the concentration of the L and P molecules could affect the density and even the formation
of aggregates (see Fig. 4.9c, and [84] for a more detailed discussion).
It is noteworthy that, in a recent paper [89], Li et al proposed an algorithm to simulate
stochastic two-component multivalent-multivalent interactions. The method involves the
association/dissosiation of two types of molecules (proteins) with the binding domains of
the first molecule type having affinity for the binding domains of the second molecule
type. Although, at a first glance, this method seems to be similar to our method, there
are some major and important differences. The most striking difference is that the Li et
al method cannot be directly related to any physical model (such as the Doi model) for
multivalent binding/unbinding interactions in continuous time/space. This method is based
on a uniform discretization of time and, similarly to our method, on a uniform discretization
of the three-dimensional space into voxels of equal volume. Formulas for the binding and
unbinding probabilities are determined by using simple probabilistic arguments, and the
same is true for molecular diffusion. It is not clear whether the method converges to a
continuous time/space model as the time-step size and the voxel volume decrease towards
zero. As a consequence, the Li et al method leads to an ad hoc algorithm that cannot be
directly related to a physical model for multivalent molecular binding. This deficiency can
seriously compromise the utility and accuracy of this method in an experimental setting.
On the other hand, our method models three-component multivalent-multivalent molec-
ular interactions and provides a rigorous discretization of the well-known continuous
174
CHAPTER 4. MODELING SYNTHETIC PROTEIN-PROTEIN INTERACTION
NETWORKS IN LIVING CELLS
time/space Doi model for systems that involve reactions among different types of molecules
as well as molecular diffusions. In an effort to guarantee that the resulting discretization
converges to the Doi model, as the voxel volume approaches zero, our method provides ap-
propriate formulas for the probability rates of the underlying binding/unbinding reactions
as well as for the probability rates of molecular diffusion. Moreover, the proposed method
treats time as a continuous variable and results in a realistic kinetic Monte Carlo simulation
algorithm that is expected to produce sufficiently accurate approximations of stochastic
reaction-diffusion dynamics.
Another fundamental disadvantage of the Li et al method is that it cannot provide a
graphical representation of molecular aggregates. As a consequence, this method cannot
be used to study sieving properties of molecular aggregates, e.g., by means of computing
PSDs. The reason for this deficiency is that the method does not consider reactions among
the binding sites of the underlying reactant molecules. Instead, it “coarsely” models aggre-
gate formation by simply simulating stochastic binding and unbinding reactions between
individual molecules using a rather ad hoc set of association and dissociation probabilities.
We should finally note that the technique developed in this dissertation is related to ki-
netic Monte Carlo methods for rule-based modeling of biochemical reaction systems [23,
138, 175]. Unlike conventional approaches that use population-based reactions to model
biochemical reaction systems, these methods are based on rules which identify the molecu-
lar components involved in a transformative reaction and determine how these components
change upon occurrence of a reaction under certain conditions. The main advantage of
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rule-based methods is an appreciable reduction in required memory and computational
cost when compared to conventional population-based approaches. This is particularly im-
portant for the problem at hand, since the number of distinct reactions that can occur may
explode due to the formation of an increasing number of molecular aggregates. Moreover,
rule-based approaches are capable of tracking the states of individual molecules while con-
ventional approaches usually track only populations of chemical species.
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Conclusion and Future Directions
The exquisite orchestration of molecular interactions in cells is essential for the normal
homeostatic regulation of multicellular organisms. Systematic delineation of networks of
such molecular interactions is a challenging task. Moreover, the identification of interaction
networks dysregulated in a particular disease may have profound effects on understanding
the molecular causes that lead to the disease and may dramatically influence the develop-
ment of effective strategies for pharmaceutical and therapeutic intervention.
In this research work, we introduced IntegraMiR, a novel computational method for
inferring dysregulated miRNA/TF-mediated regulatory loops and networks that appear in
a statistically over-represented manner in gene regulatory networks. IntegraMiR addresses
the problem of miRNA-target prediction by appropriately constraining the statistical analy-
sis of given mRNA/miRNA expression data and sequence-based target identification meth-
ods using relevant motif structures built by “prior” biological information readily available
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in existing databases. The main strength of IntegraMiR originates from its capacity to fuse
information from multiple sources and incorporate several statistical techniques to exploit
almost any accessible aspect of available information in the expression data to identify
integrated regulatory loops and networks at the transcriptional, post-transcriptional and
signaling levels. Therefore, IntegraMiR adds to the ongoing effort of developing effective
computational techniques for network inference by utilizing available experimental data
and existing biological knowledge in an effort to produce reliable predictions in a context-
dependent manner. With regards to the problem of network inference, we considered cer-
tain biological settings and relevant experimental data in the context of prostate cancer, as
well as of Autism Spectrum Disorders (ASDs). It is noteworthy that the potential future
directions we discuss in the following are relevant to the findings regarding both of these
biological contexts.
To appropriately constrain the problem of predicting miRNA-target interactions, Inte-
graMiR focuses on specific types of three-node regulatory motifs: FFLs and Type III loops,
both of which have attracted a great deal of attention in the literature. By identifying in-
stances of dysregulated FFL and Type III motifs, and by using these motifs to construct
interaction networks, IntegraMiR can also provide instances of two types of dysregulated
two-node motifs: miRNA-TF negative and double-negative feedback loops.
The two key hypotheses behind our interest in Type III loop motifs are that miRNAs
play major roles in regulating signaling pathways due to their sharp dose-sensitive nature,
and that targets of single miRNAs are more connected (i.e., interact) at the protein level
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than expected by chance. IntegraMiR identifies closely related miRNA targets on path-
ways deemed to be important in prostate cancer and delineates certain miRNA-mediated
three-node regulatory loops in the KEGG Prostate Cancer Pathway. Some of the result-
ing network structures obtained from Type III loops represent dense overlapping regulon
(DOR) motif [3] in which several input miRNAs co-regulate a set of output genes (known
as a regulon). Co-targeting in a DOR pattern presumably strengthens the notion that the
miRNAs involved share similar regulatory roles. The three-node loop motifs considered
in this work can serve as basic building blocks for identifying more complex regulatory
motifs, such as Single Input Modules (SIMs) and DORs [2, 26].
We should note that, in this work, we didn’t address the problem of systematically
constructing complex networks from the basic modules that are obtained by our procedure,
which can be an exciting future direction of our research. Although our algorithm is capable
of listing all three-node loops with nodes of interest, constructing a network from these
three-node basic modules is an independent problem that has its mathematical roots in
graph theory and graphical representations. Another potential future direction would be to
directly incorporate in the algorithm the identification of four- or higher-node motifs, such
as SIMs and DORs, in order to infer more complex network structures. However, one could
still consider the problem of constructing complex networks from such higher-level motifs
in such a scenario.
In principle, discoveries obtained by integrative computational approaches, similar to
IntegraMiR, can provide systemic insights into the molecular biology of miRNA-mediated
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interactions and can, thereby, assign context-dependent biological functions to poorly un-
derstood roles of miRNAs. With further advances in genomics research, the need for inte-
grative analysis approaches capable of utilizing information acquired from various sources
is becoming more evident than ever before. It is through these findings that researchers can
form hypotheses aimed at accurately dissecting context-dependent molecular mechanisms
underlying physiological and pathological conditions of interest. Through these types of
analyses, effective drug targeting and successful disease treatments will eventually be real-
ized. MiRNAs pose promising potential in this context.
IntegraMiR uses information from four databases, mSigDB, miRTarBase, TRANSFAC
and TransmiR. If new and more informative databases become available in the future, in-
formation relevant to the problem discussed in this dissertation can be easily incorporated
as part of the overall underlying strategy. For example, with the emergence and ever-
increasing accessibility of high-resolution transcriptome data, by means of chromatin im-
munoprecipitation with sequencing (ChIP-Seq) experiments, together with regulation in-
formation, IntegraMiR could efficiently exploit such large-scale transcription factor-target
information to obtain systems-level regulatory loops that could possibly account for much
higher percentages in transcriptome changes.
We should note that a relatively large number of TF-target interactions are not included
in the input to IntegraMiR owing to their unknown regulation type status in TRANSFAC
and TransmiR. On the other hand, the method proposed in [174] does not utilize informa-
tion on regulation type. As a result, although this method employs all available TF-target
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interactions/associations, it cannot be used to identify coherent/incoherent FFL subtypes,
which is the information required to derive a systems-level understanding of regulatory net-
works. However, by using all available TF-target interactions regardless of their regulation
type and by limiting analysis to Type II FFLs, it was found in [174] that more than 20%
of transcriptome changes could be attributed to these FFLs. This result demonstrates that
FFL-based analysis has the potential to explain a considerable percentage of transcriptome
changes. Once additional information about regulation type is made available through fu-
ture database updates, we expect that IntegraMiR will produce results that are capable of
explaining a higher percentage of transcriptome changes, with systemic insights similar to
the ones presented in this work, as opposed to the approach in [174].
In constructing FFLs, IntegraMiR considers loops comprising miRNA and TF nodes
that are both significantly dysregulated. The main reason for this choice is to focus primar-
ily on FFLs that exhibit significant levels of dysregulation at both regulator nodes, which
could play a major role in explaining observed transcriptome changes. This is mainly
because our confidence that an FFL contributes to transcriptome dysregulation in prostate
cancer will be diminished if the upstream regulator is differentially expressed but the down-
stream regulator is not (or vice versa). Note that IntegraMiR can be easily adjusted to
identify FFLs in which at least one regulator node is significantly dysregulated. It is impor-
tant however to understand that this adjustment, in combination with the high false-positive
rate of sequence-based miRNA-target predictions, can result in an excessive number of pre-
dicted FFLs and relatively higher false-positive rates. This is due to the fact that this simple
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modification allows a combinatorially larger number of potential nodes to be considered by
the method.
Finally, the ranking score obtained by employing Fisher’s method could be improved
by using methods proposed to combine dependent statistical tests [14, 77]. However, due to
lack of reliable between-node (and cross-platform) correlation estimation, accounting for
dependencies is not feasible. Therefore, IntegraMiR uses Fisher’s method to indicate the
significance for each FFL by a ranking score, rather than a P-value. Upon availability of
mRNA and miRNA expression data and techniques that could allow for reliable calculation
of correlations, a possible future direction would be to incorporate such information into
various aspects of the statistical analysis framework currently used by IntegraMiR to score
FFLs more accurately.
In our final research work on modeling the dynamics of biomolecular interaction net-
works, we developed a physical model for three-component multivalent-multivalent molec-
ular interactions that led to a rigorous method for computationally implementing iPOLY-
MER, a novel strategy developed by our collaborators at the School of Medicine to generate
intracellular hydrogels that can act as biomolecular sieves. Our approach was based on a
realistic kinetic Monte Carlo simulation algorithm that produced sufficiently accurate ap-
proximations of stochastic reaction-diffusion dynamics.
We should note here that several distinct models have been proposed in the literature
to study stochastic and spatial effects in biochemical reaction systems (e.g., see [31, 46,
148]) and this is because no single model is currently capable of efficiently coping with the
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broad range of spatial, temporal and concentration scales commonly found in biochemical
reaction networks. For this reason, models such as the one discussed in this research, may
represent a plausible approach that yields a compromise between computational efficiency
as well as spatial and stochastic accuracy.
Our RDME-based model validates aggregate synthesis for sufficiently high valence
numbers of the constituent L and P molecules. In addition, the model captures the occur-
rence of phase transition, in the form of the size distribution evolving into a bimodal distri-
bution, which indicates coexistence of large aggregate molecules with simpler molecules
of appreciably smaller sizes. It moreover demonstrates the fact that phase transition de-
pends on the valence numbers of the L and P molecules and on the concentration of the
dimerizing agent rapamycin. Our in silico results provided strong supporting evidence
to the experimental results on hydrogel-like network synthesis that were obtained by our
collaborators.
To investigate the sieving properties of molecular aggregates produced by iPOLYMER
in silico, we estimated the pore sizes on the graphs corresponding to molecular aggregates
generated by our RDME-based model. We did so for two different groups of non-trivial
aggregates: (i) dense aggregates observed at steady state, and (ii) early-stage aggregates
observed at a time close to the onset of phase transition. We considered these two groups
separately, since calculating PSDs for non-trivial dense graphs, such as the ones generated
by our model at steady state, is computationally intractable.
We therefore sought to infer a plausible estimate for the range of EPS values for these
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aggregates based on certain assumptions and constraints of the problem without having to
calculate the PSDs for such dense graphs. However, for early-stage aggregates, we were
able to directly calculate the PSDs and approximately determine the corresponding EPS
values. We considered molecular aggregates formed at a time close to the onset of phase
transition. We expected that these aggregates would have a relatively lower cross-linking
density, as compared to the ones obtained at steady state, and that the computationally
estimated PSD values could quantify their sieving properties reasonably well.
We conjecture that, when a group of molecular aggregates with comparable sizes is
characterized by a relatively high cross-linking density, the computationally estimated EPS
values may overestimate the actual EPS values. This is due to the fact that our computa-
tional EPS estimation depends entirely on the graph structure of a molecular aggregate and
the physical lengths of its constituent molecules, without taking into account the spatial
orientation of the graph nodes. This is true because our model does not consider the actual
distance between two nodes that are close but not adjacent to each other. It turns out that re-
alistic modeling of the spatial orientation of constituent molecules in a molecular aggregate
is an extremely challenging task, since it requires modeling of all dominant biochemical
and biophysical energies and forces which give rise to a specific spatial configuration of
molecules that form an aggregate.
A subsequent potential and at the same time challenging research problem would be
to look into other graph-theoretic approaches developed by applied mathematicians and
investigate their implementation feasibility to deal with large-scale dense graphs, such as
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the ones produced by our RDME-based algorithm, to more accurately estimate their PSDs
and consequently their corresponding EPS values.
In the end, we would like to note that the three specific research problems we tackled
here, categorized under the two broad modeling paradigms in systems biology (i.e., net-
work inference and modeling the dynamics of networks), have been identified as important
applied research problems by our collaborators at the Johns Hopkins School of Medicine.
The tools and techniques developed here have the potential to unravel the structure and
the dynamics of certain complex intracellular interactions at a systems level, and can be
generalized to many other biological settings. In this way, the findings from all three re-
search problems present strong computational evidence that proves to be highly valuable
to experimental biologists in providing reliable predictions and meaningful insights to help
them guide their applied research in an efficient and cost-effective manner.
185
Bibliography
[1] A. S. Afshar, J. Xu, and J. Goutsias. Integrative identification of deregulated
miRNA/TF-mediated gene regulatory loops and networks in prostate cancer. PloS
One, 9(6):e100806, 2014.
[2] U. Alon. An Introduction to Systems Biology. Design Principles of Biological Cir-
cuits. Chapman & Hall/CRC, Boca Raton, FL, 2006.
[3] U. Alon. Network motifs: theory and experimental approaches. Nat. Rev. Genet.,
8(6):450–461, 2007.
[4] S. Ambs, R. L. Prueitt, M. Yi, R. S. Hudson, T. M. Howe, F. Petrocca, T. A. Wal-
lace, C.-G. Liu, S. Volinia, G. A. Calin, H. G. Yfantis, R. M. Stephens, and C. M.
Croce. Genomic profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res., 68:6162–6170, 2008.
[5] S. Artmann, K. Jung, A. Bleckmann, and T. Beibarth. Detection of simultaneous




[6] D. Baek, J. Villén, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel. The impact
of microRNAs on protein output. Nature, 455(7209):64–71, 2008.
[7] L. A. Banaszynski, C. W. Liu, and T. J. Wandless. Characterization of the FKBP-
rapamycin-FRB ternary complex. J. Am. Chem. Soc., 127:4715–4721, 2005.
[8] D. P. Bartel. MicroRNAs: target recognition and regulatory functions. Cell,
136(2):215–233, 2009.
[9] L. E. Becker, Z. Lu, W. Chen, W. Xiong, M. Kong, and Y. Li. A systematic screen
reveals microRNA clusters that significantly regulate four major signaling pathways.
PLoS One, 7(11):e48474, 2012.
[10] Y. Benjamini and Y. Hochberg. Controlling the false discovery rate: a practical and
powerful approach to multiple testing. J. R. Statist. Soc. B., 57(1):289–300, 1995.
[11] L. Boldrup, P. J. Coates, M Wahlgren, G. Laurell, and K. Nylander. Subsite-based
alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the
oral cavity and correlation to important target proteins. J. Carcinog., 11:18, 2012.
[12] C. P. Brangwynne, T. J. Mitchison, and A. A. Hyman. Active liquid-like behavior
of nucleoli determines their size and shape in xenopus laevis oocytes. Proc. Natl.
Acad. Sci. USA, 108:4334–9, 2011.
[13] J. C. Brase, M. Johannes, H. Mannsperger, M. Fälth, J. Metzger, L. A. Kacprzyk,
T. Andrasiuk, S. Gade, M. Meister, H. Sirma, G. Sauter, R. Simon, T. Schlomm,
187
BIBLIOGRAPHY
T. Beibarth, U. Korf, R. Kuner, and H. Sültmann. TMPRSS2-ERG-specific tran-
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